WO2009040552A2 - Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof - Google Patents

Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof Download PDF

Info

Publication number
WO2009040552A2
WO2009040552A2 PCT/GB2008/003287 GB2008003287W WO2009040552A2 WO 2009040552 A2 WO2009040552 A2 WO 2009040552A2 GB 2008003287 W GB2008003287 W GB 2008003287W WO 2009040552 A2 WO2009040552 A2 WO 2009040552A2
Authority
WO
WIPO (PCT)
Prior art keywords
represent
formula
compound
optionally substituted
halo
Prior art date
Application number
PCT/GB2008/003287
Other languages
French (fr)
Other versions
WO2009040552A3 (en
Inventor
Paolo Pevarello
Ana María GARCÍA COLLAZO
Ana Belén GARCÍA GARCÍA
Original Assignee
Centro Nacional De Investigaciones Oncológicas (Cnio)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nacional De Investigaciones Oncológicas (Cnio) filed Critical Centro Nacional De Investigaciones Oncológicas (Cnio)
Priority to SI200831527T priority Critical patent/SI2193133T1/en
Priority to JP2010526362A priority patent/JP5410431B2/en
Priority to EP08806437.3A priority patent/EP2193133B1/en
Priority to PL08806437T priority patent/PL2193133T3/en
Priority to ES08806437.3T priority patent/ES2548768T3/en
Priority to US12/679,514 priority patent/US8563550B2/en
Priority to DK08806437.3T priority patent/DK2193133T3/en
Priority to CN200880118104.5A priority patent/CN101878219B/en
Publication of WO2009040552A2 publication Critical patent/WO2009040552A2/en
Publication of WO2009040552A3 publication Critical patent/WO2009040552A3/en
Priority to HRP20151128TT priority patent/HRP20151128T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to novel pharmaceutically-useful compounds, which compounds are useful as inhibitors of protein kinases (such as PI3Ks and the PIM family kinases).
  • the compounds are of potential utility in the treatment of diseases such as cancer.
  • the invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to synthetic routes for their production.
  • PKs protein kinases
  • a large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs.
  • the enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
  • PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders.
  • PIM-1 is the protooncogene activated by murine leucemia virus (Provirus Integration site for Moloney murine leucemia virus - MoMuLV) that induces T-cell lymphoma [Cuypers, H.T., et. al. Cell, 1984, 37, 141-150].
  • the expression of the protooncogene produces a non-transmembrane serine/threonine kinase of 313 residues, including a kinase domain consisting of 253 amino acid residues.
  • Two isoforms are known through alternative initiation (p44 and p33) [Saris, C.J.M. et al. EMBO J. 1991, 10, 655-664].
  • PIM-1, PIM-2 and PIM-3 phosphorylate protein substrates that are important in cancer neogenesis and progression.
  • PIM-1 phosphorylates inter alia p21 , Bad, c-myb, Cdc 25A and elF4B (see e.g. Quian, K. C. et al, J. Biol. Chem. 2005, 280(7), 6130-6137, and references cited therein).
  • PIM-2 and PIM-3 are respectively 58% and 69% identical to PIM-1 at the amino acid level.
  • PIM-1 is mainly expressed in thymus, testis, and cells of the hematopoietic system [Mikkers, H.; Nawijn, M.; Allen, J.; Brouwers, C;
  • PIM-1 expression is directly induced by STAT (Signal Transducers and Activators of Transcription) transcription factors, and PIM-1 expression is induced by many cytokine signalling pathways such as interleukins (IL), granulocyte-macrophage colony stimulating factor (GM-CSF), ⁇ - and ⁇ -interferon, erythropoietin, and prolactin [Wang, Z et al.. J. Vet. Sci. 2001 , 2, 167-179].
  • IL interleukins
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • erythropoietin erythropoietin
  • prolactin prolactin
  • gp130 a subunit common to receptors of the IL-6 cytokine family, activates the transcription factor STAT3 and can lead to the proliferation of hematopoietic cells [Hirano, T. et al. Oncogene 2000, 19, 2548-2556].
  • a kinase- active PIM-1 appears to be essential for the gp130-mediated STAT3 proliferation signal. In cooperation with the c-myc PIM-1 can promote STAT3-mediated cell cycle progression and antiapoptosis [Shirogane, T. et si., immunity, 1999, 11 , 709-719].
  • PIM-1 also appears to be necessary for IL-3-stimulated growth in bone marrow-derived mast cells [Domen, J. et al., Blood, 1993, 82, 1445-1452] and survival of FDCP1 cells after IL-3 withdrawal [Lilly, M. et al., Oncogene, 1999, 18, 4022-4031].
  • control of cell proliferation and survival by PIM-1 may be effected by means of its phosphorylation of the well-established cell cycle regulators cdc25
  • mice deficient for all three PIM genes showed an impaired response to hematopoietic growth factors and demonstrated that PIM proteins are required for efficient proliferation of peripheral T lymphocytes.
  • PIM function is required for efficient cell cycle induction of T cells in response to synergistic T-cell receptor and IL-2 signalling.
  • a large number of interaction partners and substrates of PIM-1 have been identified, suggesting a pivotal role for PIM-1 in cell cycle control, proliferation, as well as in cell survival.
  • chromosomal translocation of PIM-1 leads to overexpression of PIM-1 in diffuse large cell lymphoma.
  • a number of missense mutations in PIM-1 have been reported in lymphomas of the nervous system and AIDS-induced non-Hodgkins' lymphomas that probably affect PIM-1 kinase activity or stability [Pasqualucci, L. et al, Nature 2001, 412, 341-346; Montesinos-Rongen, M. et al., Blood 2004, 103, 1869-1875; Gaidano, G. et al., Blood 2003, 102, 1833-184].
  • the strong linkage between reported overexpression data and the occurrence of PIM-1 mutations in cancer suggests a dominant role of PIM-1 in tumorigenesis.
  • protein kinases have been described in the literature, in which the activity and/or elevated activity of such protein kinases have been implicated in diseases such as cancer, in a similar manner to PIM-1 , PIM-2 and PIM-3.
  • Such protein kinases include PI3-K, CDK-2, SRC and GSK-3.
  • International patent application WO 2004/111060 discloses various imidazothiadiazoles that may be useful in the treatment of neurodegenerative diseases and cancer. However, this document primarily relates to 6-aryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles, substituted in the 2-position with a sulfur (or oxidised derivative thereof) linker group. Further, international patent application WO 03/051890 also discloses various imidazothiadiazoles, which may be useful in the treatment of neurodegenerative diseases and cancer. However, this document primarily relates to 6-aryl substituted imidazo[2,1-bj-1 ,3,4- thiadiazoles, substituted in the 2-position with a sulfonamide group.
  • B represents -S-, -S(O)- or -SO 2 -;
  • Z represents a direct bond, -(CH 2 ) n -O-, -(CH 2 ) ⁇ -S-, -(CH 2 ) n -N(R a )-, -(CH 2 ) n1 -S(O)-, -(CH 2 ) H -SO 2 -, -(CH 2 ) n -NH-SO 2 -, -(CH 2 ) nr SO 2 -NH-, -(CH 2 ) n -N(R a )-CO-, -(CH 2 ) n -NH-CO-NH- or -(CH 2 ) n -CO-N(R 3 )-;
  • n represents, on each occasion when used herein, 0, 1 or 2;
  • n1 represents, on each occasion when used herein, 1 or 2;
  • M represents a direct bond or C 1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -OR b , -SR b or -N(R b ) 2 ;
  • R 1 represents hydrogen, halogen, -CN, -CO 2 H, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 1 ), C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 1 and B 2 , respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B 3 and B 4 , respectively);
  • X represents a direct bond, -(CH 2 ) m -O-, -(CH 2 ) m -S-, -(CH 2 ) m -N(R d )- , -S(O)-, -(CH 2 VSO 2 -, -(CH 2 ) m -NH-SO 2 -, -(CH 2 ) ⁇ SO 2 -NH-, -(CH 2 ) m -NH-CO-, -(CH 2 ) m -CO-N(R d )-, -(CH 2 ) m -NH-CO-NH- or C 1-8 alkylene optionally substituted by one or more substituents selected from A 2 ;
  • n 0, 1 or 2;
  • R 2 represents hydrogen, halo, -CO 2 H, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 3 ) or -T-Q;
  • T represents a direct bond or a C 1-3 alkylene linker group optionally substituted by one or more substituents selected from A 4 ;
  • Q represents C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 5 and B 6 , respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B 7 and B 8 , respectively);
  • a 1 , A 2 , A 3 and A 4 independently represent halo, -OR e , -S-C 1-4 alkyl, -N(R e ) 2 , -C(O) 2 R 6 , -C(O)N(R e ) 2 , -N(R e )-C(O)-R e , -C(O)R 6 , -CN, -SO 2 N(R 6 ) 2 and/or phenyl (optionally substituted by one or more halo and/or -OR 6 substituents);
  • R 3 represents hydrogen, halo, -R f , -OR f , -SR f , cyano or -N(R f ) 2 ;
  • R a , R b , R d , R e and R f represent independently, on each occasion when used herein, hydrogen, phenyl (optionally substituted by one or more halo or C 1-3 alkyl substituents) and/or C 1-4 alkyl optionally substituted with one or more substituents selected from halo, -OR h and -N(R h ) 2 ;
  • R h represents, on each occasion when used herein, hydrogen or C 1-3 alkyl optionally substituted by one or more halo atoms,
  • R 2 does not represent unsubstituted 1 ,2,4-triazol-3-yl when X represents -S- or -SO 2 -:
  • R 1 represents -CH 2 CH 3 and R 3 represents -CH 2 CH 3 or -CH 3 ;
  • R 2 does not represent 1 ,2,4-triazol-3-yl substituted in the 1-position by -C(O)N(CH 2 CH 3 ) 2 when X represents -SO 2 -:
  • R 1 represents -CH 2 CH 3
  • R 3 represents -CH 2 CH 3 or -CH 3 ,
  • R 1 represents -CH 3
  • R 3 represents -CH 2 CH 3 , -CH 3 or Cl
  • R 1 represents 4-methoxyphenyl
  • R 2 does not represent 4-chlorophenyl or unsubstituted phenyl
  • R 2 does not represent 4-fluoro-1-naphthyl when R 1 represents pentyl, butyl or isopropyl;
  • R 2 does not represent 3-chloro-4-fluoro-1-naphthyl when R 1 represents pentyl, methyl or ethyl;
  • R 2 does not represent 2-methyl-4-fluoro-1-naphthyl when R 1 represents trifluoromethyl
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • esters and amides such as those defined herein may be mentioned, as well as pharmaceutically acceptable solvates or salts.
  • esters and amides of the compounds of the invention are also included within the scope of the invention.
  • Pharmaceutically acceptable esters and amides of compounds of formula I may have an appropriate group, for example an acid group (e.g. when R 1 and/or R 2 represent -CO 2 H), converted to the appropriate ester or amide.
  • pharmaceutically acceptable esters (of carboxylic acids) that may be mentioned include optionally substituted C 1-6 alkyl, C 5-10 aryl and/or C 5-10 aryl-C 1 . 6 alkyl- esters.
  • amides of carboxylic acids
  • pharmaceutically acceptable amides include those of the formula -C(O)N(R 21 )R z2 , in which R z1 and R z2 independently represent optionally substituted C 1-6 alkyl, C 5-10 aryl, or C 5-10 aryl- C- I-6 alkylene-.
  • C 1-6 alkyl groups that may be mentioned in the context of such pharmaceutically acceptable esters and amides are not cyclic, e.g. linear and/or branched.
  • esters and amides of compounds of the invention include esters and amides of compounds of the invention in which R 1 and/or R 2 represent -CO 2 H.
  • R 1 and R 2 may each independently represent -CO 2 R X (wherein R x represents C 1-4 alkyl optionally substituted by one or more halo atoms or -OR h ) or -C(O)N(R h ) 2 , wherein, in each case, R h is as hereinbefore defined.
  • prodrug of a relevant compound of the invention includes any compound that, following oral or parenteral administration, is metabolised in vivo to form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)).
  • parenteral administration includes all forms of administration other than oral administration.
  • Prodrugs of compounds of the invention may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesising the parent compound with a prodrug substituent.
  • Prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfhydryl, carboxy or carbonyl group in a compound of the invention is bonded to any group that may be cleaved in vivo to regenerate thefree hydroxyl, amino, sulfhydryl, carboxy or carbonyl group, respectively.
  • prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs” p. 1-92, Elesevier, New York-Oxford (1985).
  • Compounds of the invention may contain double bonds and may thus exist as E (entadel) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e.
  • a 'chiral pool' method by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.
  • C 1-q alkyl, and C-i -q alkylene, groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number of carbon atoms, be branched-chain, saturated or unsaturated (so forming, for example, an alkenyl or alkynyl group).
  • C 3 .q cycloalkyl groups (where q is the upper limit of the range) that may be mentioned may be monocyclic or bicyclic alkyl groups, which cycloalkyl groups may further be bridged (so forming, for example, fused ring systems such as three fused cycloalkyl groups).
  • Such cycloalkyl groups may be saturated or unsaturated containing one or more double or triple bonds (forming for example a cycloalkenyl or cycloalkynyl group). Substituents may be attached at any point on the cycloalkyl group. Further, where there is a sufficient number (i.e. a minimum of four) such cycloalkyl groups may also be part cyclic.
  • halo when used herein, includes fluoro, chloro, bromo and iodo.
  • Heterocycloalkyl groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between five and ten. Such heterocycloalkyl groups may also be bridged. Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C 2-q heterocycloalkenyl (where q is the upper limit of the range) or a C 7-q heterocycloalkynyl group.
  • C 2-q heterocycloalkyl groups that may be mentioned include 7-azabicyclo[2.2.1]heptanyl, 6- azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2.1]-octanyl, 8-azabicyclo-
  • heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyl groups may also be in the N- or S- oxidised form.
  • Aryl groups that may be mentioned include C 6-10 aryl groups. Such groups may be monocyclic, bicyclic or tricyclic and have between 6 and 10 ring carbon atoms, in which at least one ring is aromatic.
  • C 6-10 aryl groups include phenyl, naphthyl and the like, such as 1 ,2,3,4-tetrahydronaphthyl. The point of attachment of aryl groups may be via any atom of the ring system. However, when aryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring.
  • heteroaryl when used herein refers to an aromatic group containing one or more heteroatom(s) (e.g. one to four heteroatoms) preferably selected from N, O and S.
  • Heteroaryl groups include those which have between 5 and 10 members and may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic (so forming, for example, a mono-, bi-, or tricyclic heteroaromatic group).
  • heteroaryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring.
  • Heteroaryl groups that may be mentioned include acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1 ,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiadiazolyl (including 2,1 ,3-benzothiadiazolyl), benzothiazolyl, benzoxadiazolyl (including 2,1 ,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1 ,4- benzoxazinyl), benzoxazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1 ,3-benzoselenadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1 ,
  • heteroaryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heteroaryl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heteroaryl groups may also be in the N- or S- oxidised form.
  • the heteroaryl group is monocyclic or bicyclic.
  • the heteroaryl may be consist of a five-, six- or seven-membered monocyclic ring (e.g. a monocyclic heteroaryl ring) fused with another a five-, six- or seven-membered ring (e.g. a monocyclic aryl or heteroaryl ring).
  • Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulphur.
  • Linker groups for example as defined by X and Z are specified with hyphens C'-"s) at the respective ends, depicting the points of attachment with the rest of the compound of formula I.
  • the first hyphen of the linking moiety is the point at which that moiety links to the requisite 5,5-bicycle of formula I (and the last hyphen depicts the linking point to -R 2 , in the case of the X linker group, or -M-R 1 , in the case of the Z linker group).
  • Z represents -(CH 2 ) n -N(R a )-, it is the -(CH 2 ) n - portion that is attached to the 5,5-bicycle of formula I.
  • R 8 to R f when employed herein, this will be understood by the skilled person to mean R a , R b , R d , R e and R f , inclusively.
  • B 1 to B 8 when employed herein, will be understood by the skilled person to mean B 1 , B 2 , B 3 , B 4 , B 5 , B 6 , B 7 and B 8 , inclusively.
  • provisos (a) to (p) above will become redundant.
  • preferred such compounds include those in which "when R 2 represents aryl, then it is a monocyclic aryl group", then in relation to such a preferred aspect of the invention, at least proviso (j) above will become redundant.
  • R a , R b , R d , R e and R f (e.g. R a , R b , R d and R f ) represent independently, on each occasion when used herein, hydrogen and/or C 1-4 alkyl optionally substituted with one or more substituents selected from halo and -OR h ; when Z represents -(CH 2 ) n -N(R a )-CO-, then R a represents hydrogen.
  • X preferably represents a direct bond, -(CH 2 ) m -O-, -(CH 2 ) m -S-, -(CH 2 ) m -N(R d )- -S(O)-, -(CH 2 WSO 2 -, -(CH 2 ) m -NH-SO 2 -, -(CH 2 VNH-CO-, -(CH 2 ) m -CO-N(R d )-, -(CH 2 ) m -NH-CO-NH- or C 1-8 alkylene optionally substituted by one or more substituents selected from A 2 ).
  • R 1 does not represent hydrogen or (e.g. when Z and M represent direct bonds) halo; and/or (ii) R 2 does not represent hydrogen or (e.g. when X represents a direct bond) halo.
  • R 1 represents -CN, -CO 2 H or, more preferably, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 1 ), C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 1 and B 2 , respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B 3 and B 4 , respectively);
  • R 2 represents -CO 2 H or, more preferably, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 3 ) or -T-Q;
  • T represents -CH 2 -, -(CH 2 ) 2 - or, preferably, a direct bond
  • R 2 preferably represents halo or, preferably, -CO 2 H or, more preferably, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 3 ) or C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 5 and B 6 , respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B 7 and B 8 , respectively)).
  • R 2 preferably represents halo or, preferably, -CO 2 H or, more preferably, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 3 ) or C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 5 and B 6 , respectively),
  • R 1 represents halogen, or, preferably, hydrogen, -CO 2 H, C 1-8 alkyl (optionally substituted by one or more substituents selected from A 1 ), C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 1 and B 2 , respectively), aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B 3 and B 4 , respectively); when Z represents -(CH 2 ) n -O-, then n represents 0; when Z represents -(CH 2 ) n -S-, then n represents 0;
  • R 3 represents hydrogen, halo, -R f or -OR f ;
  • Z represents -(CH 2 ) n -O-, -(CH 2 ) n -S-, -(CH 2 ) n -N(R a )-, -(CH 2 ) ⁇ 1 -S(O)-,
  • M represents C 1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -OR b , -SR b or N(R b ) 2 ; when X represents -(CH 2 ) m -O-, then m represents 0; when X represents -(CH 2 ) m -S-, then m represents 0; X is selected from -(CH 2 ) m -O-, -(CH 2 ) m -S-, -(CH 2 ) m -N(R d )-, -S(O)-, -(CH 2 ) m -SO 2 -,
  • X represents a single bond or C 1-3 alkylene (optionally substituted as defined herein); and/or R 2 represents optionally substituted aryl or heteroaryl.
  • preferred compounds of the invention include those in which:
  • R 1 preferably represents aryl, monocyclic heteroaryl or bicyclic heteroaryl; X represents a single bond; and/or
  • R 2 represents halo or, preferably, -CO 2 H or, more preferably, C 1-S alkyl, C 3-6 cycloalkyl or heterocycloalkyl, which latter three groups are optionally substituted as defined herein).
  • preferred compounds of the invention include those in which:
  • M represents a direct bond or C 1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -OR b , C 1-4 alkylthio or -N(R b ) 2 ;
  • R 1 represents C 3-6 cycloalkyl; and/or X represents a single bond.
  • Preferred C 1-8 alkyl groups that R 1 and R 2 may independently represent include optionally substituted C 1-6 alkyl, which alkyl group may be unsaturated, linear (for example, methyl, ethyl, n-propyl) or branched (e.g. branched C 1-5 alkyl, such as 1- methyl-isobutyl, 1-methyl-n-propyl or 2,2-dimethylpropyl).
  • C 1-4 alkyl which alkyl group may be cyclic, part-cyclic, unsaturated or, preferably, linear or branched (e.g. C 1-4 alkyl (such as ethyl, n-propyl, isopropyl, f-butyl or, preferably, n-butyl or methyl), all of which are optionally substituted with one or more substituents selected from -OR z1 , -N(R z4 )R z5 (so forming for example a -CH 2 -CH 2 -OH or -CH 2 -CH 2 -N(CH 3 ) 2 group) and, preferably, halo (e.g.
  • fluoro so forming, for example, fluoromethyl, difluoromethyl or, preferably, trifluoromethyl
  • aryl e.g. phenyl
  • aryl e.g. phenyl
  • R z1 to R z1 ° independently represent, on each occasion when used herein, H or C 1-4 alkyl (e.g.
  • halo e.g. fluoro
  • Preferred compounds of the invention include those in which: at least one of X and Z is other than a direct bond; B represents -S-; Z represents a direct bond, -O-, -S-, -(CH 2 ) n -N(R a )- or -(CH 2 ) n -N(H)-C(O)-; R a represents H; n represents 0;
  • R 1 represents C 1-6 alkyl, then it preferably represents methyl, ethyl, n-propyl or optionally branched C 1-5 alkyl such as 1-methyl-isobutyl, 1-methyl-n-propyl or 2,2-dimethylpropyl), which C 1-6 alkyl groups may be substituted by A 1 (e.g.
  • - OR e so forming, for example a hydroxyalkyl group, such as hydroxypropyl, 1- hydroxymethylisobutyl or 1-hydroxymethyl-n-propyl); when R 1 represents heterocycloalkyl, then such a group preferably represents a 5- or 6-membered heterocycloalkyl group containing one or two heteroatoms selected from nitrogen and/or oxygen, so forming for example a piperidinyl (e.g. 1-piperidinyl), morpholinyl (e.g. 4-morpholinyl), imidazolidinyl (e.g. 1- imidazolidinyl) or tetrahydropyranyl (e.g.
  • a piperidinyl e.g. 1-piperidinyl
  • morpholinyl e.g. 4-morpholinyl
  • imidazolidinyl e.g. 1- imidazolidinyl
  • tetrahydropyranyl e.g.
  • R 2 represents halo (e.g. iodo), C 1-6 (e.g. C 1-4 ) alkyl (e.g. methyl or ethyl) optionally substituted by A 3 , C 3-6 cycloalkyl (e.g. cyclohexyl), heterocycloalkyl (e.g. tetrahydropyranyl, such as 4-tetrahydropyranyl or morpholinyl, such as 4- morpholinyl) optionally substituted by B 6 , aryl (e.g. naphthyl or, preferably, phenyl) optionally substituted by B 7 , or, heteroaryl (e.g. pyrazolyl, such as 4- pyrazolyl, indolyl, such as 2- or 5-indolyl, pyridyl, such as 3-pyridyl) optionally substituted by B 8 ;
  • C 1-6 e.g. C 1-4 alkyl (e.g
  • a 1 to A 4 independently represent halo, -OR e , -CO 2 R e , -N(R e )-C(O)-R e or phenyl optionally substituted by -OR e ;
  • B 1 to B 8 independently represent -N(R e )-C(O)R e , preferably, -C(O)N(R e ) 2 , or, more preferably, halo (e.g. fluoro or chloro), -OR e , -C(O) 2 R 8 ,
  • R a , R b , R d , R e and R f independently represent hydrogen or C 1-3 alkyl (e.g. methyl) optionally substituted by one or more substituents selected from -N(R h ) 2 , -OR h and, preferably, halo (e.g. fluoro);
  • R h represents H or C 1-2 alkyl (e.g. ethyl or, preferably, methyl);
  • R 3 represents hydrogen, C 1-2 alkyl (e.g. methyl) or halo (e.g. fluoro).
  • X is direct bond, -O-, -CO-N(H)-, -NHSO 2 -
  • R 1 represents aryl (e.g. phenyl) optionally substituted as defined herein;
  • X represents -NH-;
  • (III) Z represents -O-, then preferably:
  • M represents a direct bond or C 1-3 alkylene as defined herein, R 1 represents -CO 2 H or an amide thereof (i.e. -C(O)N(R h ) 2 ), C 1-3 alkyl or aryl (e.g. phenyl), which latter two groups are optionally substituted as hereinbefore defined;
  • X represents -NH- or a direct bond;
  • Z represents a direct bond, then, preferably: M represents C 1-3 alkylene as defined herein (e.g. ethynylene); R 1 represents aryl as defined herein; R 2 represents halo (e.g. iodo), heterocycloalkyl, aryl or heteroaryl, all of which are as defined herein;
  • X represents -N(H)- or a direct bond.
  • R 2 groups that may be mentioned include those in which: when R 2 represents aryl, naphthyl (which group is preferably unsubstituted; e.g. unsubstituted 2-naphthyl) or, preferably, unsubstituted phenyl, (3- trifluoromethyl)phenyl, 3-cyanophenyl, 3-fluorophenyl, 3,5-difluorophenyl, 4- cyanophenyl, 4-trifluoromethylphenyl, 3-acetylphenyl, 3-aminophenyl, 4- aminophenyl, (3-chloro-4-fluoro)phenyl, 3-methanesulfonylphenyl, (4- trifluoromethoxy)phenyl, 4-hydroxyphenyl, (4-acrylic acid)phenyl, 4- carboxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl and 3-chloro-4- fluorophenyl; when R 2 represents
  • 2- or 3-thienyl or, preferably, pyrazolyl (such as 1-methyl-4-pyrazolyl), indolyl (such as 5-indolyl or 2-indolyl), 5- methoxy-3-pyridyl and 6-methoxy-3-pyridyl; when R 2 represents C 1-8 alkyl, C 3 . 6 cycloalkyl or heterocyclalkyl (e.g. a monocyclic 5- or 6-membered heterocycloalkyl group, containing one or two heteroatoms selected from nitrogen and/or oxygen), ethyl, cyclohexyl, carboxy-methyl and 4- morpholinyl.
  • pyrazolyl such as 1-methyl-4-pyrazolyl
  • indolyl such as 5-indolyl or 2-indolyl
  • 5- methoxy-3-pyridyl and 6-methoxy-3-pyridyl when R 2 represents C 1-8 alkyl, C 3 . 6 cycloalky
  • More preferred compounds of the invention include those in which: B 1 to B 7 substituents independently represent -N(H)-C(O)CH 3 , -N(CH 3 ) 2
  • a 1 represents halo or, more preferably, -OR e ;
  • a 3 represents -CO 2 R e , -N(R e )-C(O)-R e (e.g. -N(H)-C(O)-CH 3 ) or phenyl optionally substituted by -OR e ;
  • B 1 represents -OH;
  • B 3 represents -SO 2 NH 2 , fluoro, -OCH 3 , chloro, -C(O)CH 3 ;
  • B 4 represents methyl;
  • B 8 represents -CH 3 , -OCH 3 ;
  • R a represents hydrogen.
  • Z represents -(CH 2 ) n -O- or, preferably, a direct bond or -(CH 2 ) n -N(R a )-;
  • M represents a direct bond or C 1-2 alkylene, which is preferably unsubstituted
  • R 1 represents C 1-6 (e.g. C 1-4 ) alkyl (optionally substituted by one or more substituents selected from A 1 ) or, R 1 preferably represents C 3-6 (e.g. C 3-5 ) cycloalkyl (e.g. cyclopropyl) or aryl (e.g. phenyl), optionally substituted by one or more substituents selected from B 3 ;
  • X represents -(CH 2 ) m -N(R d )-, -(CH 2 ) m -C(O)-N(R d )-, C 1-2 alkylene, which is preferably unsubstituted (e.g. -CH 2 -), or, X more preferably represents a direct bond;
  • m represents 0 (e.g. when X represents -(CH 2 ) m -C(O)-N(R d )-) or 1 (e.g. when X represents -(CH 2 ) m -N(R d )-);
  • R d represents hydrogen or, preferably, C 1-2 alkyl (e.g. methyl) (e.g. when X represents -(CH 2 ) m -N(R d )- or -(CH 2 ) m -C(O)-N(R d )-);
  • R 2 represents hydrogen, preferably, halo (e.g. iodo) or, more preferably, -T-Q;
  • T represents unsubstituted C 1-2 alkylene (e.g. -CH 2 -CH 2 - or -CH 2 -) or, preferably, a direct bond;
  • T preferably represents a direct bond when X represents a direct bond
  • B 1 to B 8 independently represent -N(R e )-C(O)R e , preferably, -CN, -C(O)N(R e ) 2 , -OR e , -N(R e ) 2 , or, more preferably, halo (e.g. fluoro or chloro), -C(O)R 6 or C 1-2 alkyl (e.g. methyl) optionally substituted by -OR e ;
  • R h represents hydrogen (e.g. when appended to an oxygen atom, i.e. in the case of -OR h ) or C 1-2 alkyl such as methyl (e.g. when appended to a nitrogen atom, i.e. in the case of -N(R h ) 2 ).
  • B 3 represents halo (e.g. fluoro or chloro);
  • B 7 represents -N(R e )-C(O)R e (e.g. -N(H)-C(O)CH 3 ) or, preferably, halo (e.g. chloro or fluoro), -CN, -C(O)R e (e.g. -C(O)CH 3 ), -OR e (e.g. -OH, -OCH 3 Or -OCF 3 ),
  • -N(R e ) 2 e.g. -N(CH 3 ) 2
  • -C(O)N(R e ) 2 e.g. -C(O)N(H)-CH 2 CH 2 -N(CH 3 ) 2 or, preferably, C(O)N(CH 3 ) 2 or -C(O)N(H)-CH 2 CH 2 -OH
  • -N(R e ) 2 e.g. -N(CH 3 ) 2
  • -C(O)N(R e ) 2 e.g. -C(O)N(H)-CH 2 CH 2 -N(CH 3 ) 2 or, preferably, C(O)N(CH 3 ) 2 or -C(O)N(H)-CH 2 CH 2 -OH
  • B 8 represents -OR e (e.g. -OH, -OCF 3 or, preferably, -OCH 3 ).
  • Preferred Z groups include a direct bond, -N(H)-, -N(CH 3 )- and -O-.
  • Preferred "-M-R 1 " groups include: phenyl (e.g. unsubstituted phenyl, 4-fluorophenyl or 4-methoxyphenyl);
  • C 1-6 part cyclic alkyl e.g. cyclopropylmethyl
  • optionally substituted C 1-6 (e.g. C 1-2 ) alkyl such as ethyl (e.g. methoxyethyl or phenoxyethyl), isobutyl, methyl (for example, -M-R 1 represents methyl when Z represents -N(CH 3 )-) or methyl substituted by phenyl (e.g. benzyl, such as 3,4- dichlorobenzyl, 4-fluorobenzyl, 2-methylbenzyl4-methoxybenzyl, 4- dimethylaminobenzyl) or heteroaryl (e.g. thienyl, furanyl or pyridyl);
  • 5- or 6-membered heterocycloalkyl e.g. containing one or two heteroatoms, e.g. tetrahydropyranyl (e.g. 4-tetrahydropyranyl)); 5- or 6-membered heteroaryl, e.g. pyridyl, furanyl or thienyl; hydrogen (e.g. when Z represents -N(H)-).
  • Preferred "-X-R 2 " groups include: pyridyl (e.g. 3-pyridyl, 6-methoxypyrid-3-yl, 5-methoxy-3-pyridyl, 4-pyridyl); indolyl (e.g. 6-indolyl); phenyl (e.g. unsubstituted phenyl, 3-acetylphenyl (i.e. 3-(C(O)CH 3 )-phenyl), 4-
  • -CH 2 -N(H)-phenyl e.g. -CH 2 -N(H)-(3-acetylphenyl), -CH 2 -N(H)-(3,4- dimethoxyphenyl) and -CH 2 -N(H)-(3-chloro-4-fluorophenyl)
  • Particularly preferred compounds of the invention include those of the examples described hereinafter.
  • L 2 represents a suitable group such as -B(OH) 2 , -B(OR 1 ⁇ ) 2 or -Sn(R ⁇ ) 3 , in which each R ⁇ independently represents a C 1-6 alkyl group, or, in the case of -B(OR ⁇ ) 2 , the respective R ⁇ groups may be linked together to form a 4- to 6-membered cyclic group (such as a 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl group),
  • X a represents a direct bond
  • R 2a represents C 1-8 alkyl, C 3-6 cycloalkyl, aryl, heteroaryi or heterocycloalkyl, all of which are optionally substituted as hereinbefore defined
  • X b represents C 1-8 alkylene optionally substituted as hereinbefore defined in the definition of X, and R 2 is as hereinbefore defined.
  • This reaction may be performed, for example in the presence of a suitable catalyst system, e.g. a metal (or a salt or complex thereof) such as CuI, Pd/C, PdCl 2 , Pd(OAc) 2 , Pd(Ph 3 P) 2 Cl 2 , Pd(Ph 3 P) 4 (i.e.
  • a suitable catalyst system e.g. a metal (or a salt or complex thereof) such as CuI, Pd/C, PdCl 2 , Pd(OAc) 2 , Pd(Ph 3 P) 2 Cl 2 , Pd(Ph 3 P) 4 (i.e.
  • the reaction may also be carried out for example at room temperature or above (e.g. at a high temperature such as the reflux temperature of the solvent system).
  • the reaction may also be carried out under microwave irradiation reaction conditions, for example at elevated temperature (e.g. at above 100°C, such as at about 135 to 140°C).
  • Alternative L 2 groups that may be mentioned include alkali metal groups (e.g. lithium) and halo groups, which may be converted to a magnesium halide (i.e. a Grignard reagent), in which the magnesium may undergo a 'trans-metallation' reaction, thereby being exchanged with, for example, zinc.
  • a magnesium halide i.e. a Grignard reagent
  • X c represents -O-, -S- or -N(R d )-, and R 2 is as hereinbefore defined, for example optionally in the presence of an appropriate metal catalyst (or a salt or complex thereof) such as Cu, Cu(OAc) 2 , CuI (or Cul/diamine complex), copper tris(triphenyl-phosphine)bromide, Pd(OAc) 2 , Pd 2 (dba) 3 or NiCl 2 and an optional additive such as Ph 3 P, 2,2'-bis(diphenylphosphino)-1 ,1'-binaphthyl, xantphos, NaI or an appropriate crown ether such as 18-crown-6-benzene, in the presence of an appropriate base such as NaH, Et 3 N, pyridine, N.N-dimethylethylenediamine, Na 2 CO 3 , K 2 CO 3 , K 3 PO 4 , Cs 2 CO 3 , f-BuONa or
  • reaction may be carried out under microwave irradiation reaction conditions, for example a described in process step (i) above.
  • the reaction may be performed as described herein, under such microwave irradiation reaction conditions, but in the absence of other reagents such as catalyst, base and even solvent (i.e. the reaction mixture may contain only compound of formula Il and compound of formula IVA);
  • L 1 is as hereinbefore defined, and R 1a represents aryl, heteroaryl or, preferably, C 1-8 alkyl, C 3 - 6 cycloalkyl or heterocycloalkyl, all of which are optionally substituted as hereinbefore defined in respect of corresponding R 1 substituents, for example at around room temperature or above in the presence of a suitable base (e.g. pyridine, triethylamine, dimethylaminopyridine, diisopropylamine, sodium hydroxide, or mixtures thereof), an appropriate solvent (e.g.
  • a suitable base e.g. pyridine, triethylamine, dimethylaminopyridine, diisopropylamine, sodium hydroxide, or mixtures thereof
  • an appropriate solvent e.g.
  • Z a represents -O-, -S- or -N(R a )-, and R a , R 1 and M are as hereinbefore defined, under standard conditions, for example, such as those hereinbefore described in respect of process step (i) or (ii) above (preferably process step (ii) above);
  • compounds of formula I in which B, Z or X represents -S(O)- or -S(O) 2 may be prepared by oxidation of a corresponding compound of formula I in which B, Z or X represents -S-, under standard conditions, for example in the presence of a suitable oxidising agent, such as KMnO 4 or mef ⁇ -chloroperbenzoic acid (mCPBA), optionally in the presence of a suitable solvent;
  • a suitable oxidising agent such as KMnO 4 or mef ⁇ -chloroperbenzoic acid (mCPBA)
  • L 1 -Q 1 -M-R 1 X wherein L 1 is as hereinbefore defined and preferably represents chloro, Q 1 represents -S(O) 2 -, -C(O)- or -C(O)NH-, and M and R 1 are as hereinbefore defined, under standard reaction conditions, for example such as those hereinbefore described in respect of process step (iii) above.
  • M and R 1 are as hereinbefore defined, under standard reaction conditions, for example such as those hereinbefore described in respect of process step (iii) above.
  • X in the compound of formula I may also be prepared in a similar manner;
  • R 2b represents C 1-7 alkyl optionally substituted by one or more substituents selected from A 3 , and A 3 is as hereinbefore defined, under standard reaction conditions, for example in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride, optionally in the presence of a suitable solvent such as an alcohol (e.g. ethanol or methanol);
  • a suitable solvent such as an alcohol (e.g. ethanol or methanol);
  • R 2 is as hereinbefore defined, for example under conditions such as those described hereinbefore in respect of process step (viii) above; (x) for compounds of formula I in which X represents -CH 2 -N(R d )- and R 2 represents hydrogen or optionally substituted C 1 - ⁇ alkyl, provided that at least one of R 2 and R d is other than hydrogen (so forming a secondary or tertiary amine), or, for compounds of formula I in which -X-R 2 represents -CH 2 -heterocycloalkyl, in which the heterocycloalkyl group is attached to the relevant -CH 2 - moiety via a nitrogen atom of the heterocycloalkyl group (so forming a tertiary amino moiety; for example -CH 2 -[4-morpholinyl]), reaction of a compound of formula XIIIA,
  • X d represents -N(R d )- and R 2d represents hydrogen or C 1-8 alkyl (optionally substituted by one or more substituents selected from A 3 ), provided that at least one of R d and R 2d is other than hydrogen (so forming a secondary or tertiary amine), or with a compound of formula XIIIC,
  • R d and R 2 are as hereinbefore defined, under standard amide coupling reaction conditions, for example in the presence of a suitable coupling reagent (e.g. 1 ,1 '-carbonyldiimidazole, N./V-dicyclohexylcarbodiimide, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof) or N 1 N 1 - disuccinimidyl carbonate), optionally in the presence of a suitable base (e.g.
  • a suitable coupling reagent e.g. 1 ,1 '-carbonyldiimidazole, N./V-dicyclohexylcarbodiimide, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof) or N 1 N 1 - disuccinimidyl carbonate
  • a suitable base e.g.
  • the carboxylic acid group may be converted under standard conditions to the corresponding acyl chloride (e.g. in the presence of SOCl 2 or oxalyl chloride), which acyl chloride is then reacted with a compound of formula XIV, for example under similar conditions to those mentioned above;
  • R 2a -M 1 XV wherein M 1 represents an appropriate alkali metal group (e.g. sodium, potassium or, especially, lithium), a -Mg-halide or a zinc-based group (e.g. a zinc halide group) and R 2a is as hereinbefore defined, i.e.
  • M 1 represents an appropriate alkali metal group (e.g. sodium, potassium or, especially, lithium), a -Mg-halide or a zinc-based group (e.g. a zinc halide group) and R 2a is as hereinbefore defined, i.e.
  • R 2a represents C 1-8 alkyl (optionally substituted by one or more A 3 substituents), C 3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B 5 and B 6 , respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B 7 and B 8 , respectively), under appropriate reaction conditions, for example under an inert atmosphere, in the presence of a suitable anhydrous solvent (e.g. an anhydrous polar aprotic solvent such a tetrahydrofuran, diethyl ether and the like);
  • a suitable anhydrous solvent e.g. an anhydrous polar aprotic solvent such a tetrahydrofuran, diethyl ether and the like
  • Compounds of formula Ii in which L 1 represents halo may be prepared by reaction of a corresponding compound of formula XIIIA, with a source of halide ions, for instance an electrophile that provides a source of iodide ions includes iodine, diiodoethane, diiodotetrachloroethane or, preferably, W-iodosuccinimide, a source of bromide ions includes N-bromosuccinimide and bromine, and a source of chloride ions includes N-chlorosuccinimide, chlorine and iodine monochloride.
  • a source of halide ions for instance an electrophile that provides a source of iodide ions includes iodine, diiodoethane, diiodotetrachloroethane or, preferably, W-iodosuccinimide, a source of bromide ions includes N-
  • R 3 represents halo (and L 1 preferably represents halo) may be prepared from a corresponding compound of formula Il in which R 3 represents hydrogen, using the above-mentioned compounds that provide a source of halide ions, under standard reaction conditions.
  • Other compounds of formula Il may also be prepared under standard conditions, for instance such as those described herein.
  • L 1 represents a sulfonate group
  • reaction of a compound corresponding to a compound of formula Il but in which L 1 represents -OH with an appropriate sulfonyl halide under standard reaction conditions, such as in the presence of a base (e.g. as hereinbefore described in respect of preparation of compounds of formula I (process step (iii)).
  • Compounds of formula XII may be prepared by reaction of a corresponding compound of formula XIIIA, with dimethylformamide, under standard conditions, and optionally in the presence of POCI 3 (so forming for example, a Vilsmeir- Haack reagent), oxalyl chloride, phosgene or the like, in optionally in the presence of a further solvent other than DMF (e.g. dichloromethane).
  • R 3a represents hydrogen or C 1-4 alkyl optionally substituted by one or more halo atoms, under standard conditions known to those skilled in the art.
  • the compound of formula XVII may already be present in water, and hence, the reaction may be performed in the presence of water as a solvent, optionally in the presence of a further solvent, such as an alcohol (e.g. n-butanol), for example at room temperature or, preferably, elevated temperature such as at reflux.
  • a further solvent such as an alcohol (e.g. n-butanol)
  • DCC dicyclohexylcarbodiimide
  • EDCHCI 1-ethyl-3-(3- dimethyllaminopropyl)carbodiimide hydrochloride
  • hydrogen peroxide e.g. 50% H 2 O 2
  • M 1 represents a -Mg-halide, employing magnesium or a suitable reagent such as a mixture of C 1-6 alkyl-Mg-halide and ZnCl 2 or LiCI, under standard Qrignard conditions known to those skilled in the art (e.g. optionally in the presence of a catalyst (e.g. FeCI 3 ));
  • a catalyst e.g. FeCI 3
  • magnesium of the Grignard reagent or the lithium of the lithiated species may be exchanged to a different metal (i.e. a transmetallation reaction may be performed), for example to zinc (e.g. using ZnCl 2 ), so forming for example, the corresponding compound of formula XV in which M 1 represent a zinc-based group.
  • XXI (as well as some compounds of formula II, Vl, VIII 1 XII and XX) are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. Further, the skilled person will appreciate that where reactions to introduce the "-Z-M-R 1 " moiety of compounds of formula I is described, similar reactions may be performed to introduce the "-X-R 2 " moiety in compounds of formula I and vice versa. Further, processes to prepare compounds of formula I may be described in the literature, for example in:
  • the substituents Z, M, R 1 , X, R 2 and B in final compounds of the invention or relevant intermediates may be modified one or more times, after or during the processes described above by way of methods that are well known to those skilled in the art. Examples of such methods include substitutions, reductions, oxidations, alkylations, acylations, hydrolyses, esterifications, etherifications, halogenations or nitrations. Such reactions may result in the formation of a symmetric or asymmetric final compound of the invention or intermediate.
  • the precursor groups can be changed to a different such group, or to the groups defined in formula I 1 at any time during the reaction sequence.
  • carboxyester groups may be converted into carboxylic acid derivatives through basic or acidic hydrolysis conditions, widely known in the art.
  • amino derivatives of compounds of the invention may easily be converted into the corresponding carbamate, carboxamido or ureido derivatives.
  • Compounds of the invention may be isolated from their reaction mixtures using conventional techniques (e.g. recrystallisations).
  • inhibitor may refer to any measurable reduction and/or prevention of catalytic protein kinase (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1, PIM-2 and/or PIM-3) activity.
  • the reduction and/or prevention of protein kinase activity may be measured by comparing the protein kinase activity in a sample containing a compound of the invention and an equivalent sample of protein kinase (e.g.
  • the measurable change may be objective (e.g. measurable by some test or marker, for example in an in vitro or in vivo assay or test, such as one described hereinafter, or otherwise another suitable assay or test known to those skilled in the art) or subjective (e.g. the subject gives an indication of or feels an effect).
  • Compounds of the invention may be found to exhibit 50% inhibition of a protein kinase (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PlM family kinase such as PIM-1 , PIM-2 and/or PIM-3) at a concentration of 100 ⁇ M or below (for example at a concentration of below 50 ⁇ M, or even below 10 ⁇ M), when tested in an assay (or other test), for example as described hereinafter, or otherwise another suitable assay or test known to the skilled person.
  • a protein kinase e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PlM family kinase such as PIM-1 , PIM-2 and/or PIM-3
  • Compounds of the invention are thus expected to be useful in the treatment of a disorder in which a protein kinase (and particularly CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) is known to play a role and which are characterised by or associated with an overall elevated activity of that protein kinase (due to, for example, increased amount of the kinase or increased catalytic activity of the kinase).
  • a protein kinase and particularly CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3
  • the compounds of the invention may be useful in the treatment of cancer. More, specifically, the compounds of the inventiona may therefore be useful in the treatment of a variety of cancer including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate and skin, as well as squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and
  • protein kinases e.g. CDK-2, SRC, GSK-3 or, more particularly, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3
  • CDK-2, SRC, GSK-3 or, more particularly, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3 may also be implicated in the multiplication of viruses and parasites. They may also play a major role in the pathogenesis and development of neurodegenerative disorders.
  • compounds of the invention may also be useful in the treatment of viral conditions, parasitic conditions, as well as neurodegenerative disorders.
  • CDK-2 e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as
  • PIM-1, PIM-2 and/or PIM-3) is desired and/or required (e.g. cancer or another disease as mentioned herein), which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined but without the provisos, to a patient suffering from, or susceptible to, such a condition.
  • the term "effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated patient.
  • the effect may be objective (e.g. measurable by some test or marker) or subjective (e.g. the subject gives an indication of or feels an effect).
  • Compounds of the invention may be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form.
  • Compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.
  • the type of pharmaceutical formulation may be selected with due regard to the intended route of administration and standard pharmaceutical practice.
  • Such pharmaceutically acceptable carriers may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use.
  • Such formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice. Otherwise, the preparation of suitable formulations may be achieved non-inventively by the skilled person using routine techniques and/or in accordance with standard and/or accepted pharmaceutical practice.
  • a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without provisos (a), (c), (d), (e), (g) and Q) to (o), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • pharmaceutical formulations that may be mentioned include those in which the active ingredient is present in at least 1% (or at least 10%, at least 30% or at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e. the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1:99 (or at least 10:90, at least 30:70 or at least 50:50) by weight.
  • the amount of compound of the invention in the formulation will depend on the severity of the condition, and on the patient, to be treated, as well as the compound(s) which is/are employed, but may be determined non-inventively by the skilled person.
  • the invention further provides a process for the preparation of a pharmaceutical formulation, as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined but without provisos (a), (c), (d), (e), (g) and (j) to (o), or a pharmaceutically acceptable ester, amide, solvate or salt thereof with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • Compounds of the invention may also be combined with other therapeutic agents that are inhibitors of protein kinases (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3- K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) and/or useful in the treatment of a cancer and/or a proliferative disease.
  • Compounds of the invention may also be combined with other therapies.
  • a combination product comprising:
  • each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • Such combination products provide for the administration of a compound of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent).
  • kit of parts comprising components: (a) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos (for example without provisos (a), (c), (d), (e), (g) and (j) to (o)), in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
  • a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
  • the invention further provides a process for the preparation of a combination product as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined but without the provisos (for example, without provisos (a), (c), (d), (e), (g) and (j) to (o)), or a pharmaceutically acceptable ester, amide, solvate or salt thereof with the other therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
  • provisos for example, without provisos (a), (c), (d), (e), (g) and (j) to (o)
  • a pharmaceutically acceptable ester, amide, solvate or salt thereof with the other therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
  • the two components of the kit of parts may be: (i) provided as separate formulations (i.e. independently of one another), which are subsequently brought together for use in conjunction with each other in combination therapy; or
  • compounds of the invention may be administered at varying therapeutically effective doses to a patient in need thereof.
  • the dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable timeframe.
  • the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by inter alia the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the potency of the specific compound, the age, condition, body weight, sex and response of the patient to be treated, and the stage/severity of the disease.
  • Administration may be continuous or intermittent (e.g. by bolus injection).
  • the dosage may also be determined by the timing and frequency of administration.
  • the dosage can vary from about 0.01 mg to about 1000 mg per day of a compound of the invention.
  • the medical practitioner or other skilled person, will be able to determine routinely the actual dosage, which will be most suitable for an individual patient.
  • the above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • Compounds of the invention may have the advantage that they are effective inhibitors of protein kinases (such as CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3).
  • protein kinases such as CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3.
  • Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the above- stated indications or otherwise.
  • pharmacokinetic profile e.g. higher oral bioavailability and/or lower clearance
  • the biochemical assay to measure PIM-1 activity relies on the ADP Hunter assay kit (DiscoveRx Corp., Cat. # 90-0077), that determines the amount of ADP as direct product of the kinase enzyme activity.
  • the enzyme has been expressed and purified in-house as a recombinant human protein with a C-terminal histidine tag.
  • the protein is active and stable.
  • PIM-1 substrate peptide PIMtide (ARKRRRHPSGPPTA)
  • the enzyme has been expressed and purified in-house as a recombinant human protein with a N-terminal histidine tag.
  • the protein is active and stable.
  • PIM-1 substrate peptide PIMtide (ARKRRRHPSGPPTA) • Peptide concentration: 100 ⁇ M
  • Assays were performed in either 96 or 384-well plates.
  • the final outcome of the coupled reactions provided by the kit is the release of the fluorescent product Resorufin and has been measured with a multilabel HTS counter VICTOR V (PerkinElmer) using an excitation filter at 544 nm and an emission filter at 580 nm.
  • the crude mixture was purified by column chromatography (BiotageTM/Flash, silica) to give the desired product (e.g. (6-chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-isobutyl-amine).
  • desired product e.g. (6-chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-isobutyl-amine.
  • the title compound was obtained in 42% yield after purification by column chromatography (Biotage/Flash, silica, ethylacetate:dichloromethane 0.1 :9.9 to 3:7).
  • the title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a yellow solid in a 65% yield.
  • the title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 49% yield.
  • the title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isoiute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 33% yield.
  • the title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isoiute cartridge flash Si II, 5g, hexane:ethyl acetate) as a brownish solid in a 24% yield.
  • the title compound was obtained in 7% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1 :9.9 to 3:7) and by semi-preparative-HPLC (Gemini C18 (150 x 10 mm; 5um), Solvent A: water with 0.1% formic acid; Solvent B: acetonitrile with 0.1% formic acid. Gradient: 60% of A to 20% of B).
  • the title compound was obtained in 19% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1 :9.9 to 3:7).
  • the title compound was obtained in 37% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1:9.9 to 3:7).
  • the aqueous layer was extracted with dichloromethane (3 x) and the combined organic layers were washed with brine and dried over sodium sulfate.
  • the crude product was purified by flash chromatography (methanokdichlormethane, 0:10 to 2.5:7.5) to yield the required product (e.g. cyclopropylmethyl-(5-morpholin-4-ylmethyl-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl)-amine).
  • the mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 1 hour. On cooling, the mixture was diluted with dichloromethane (7 mL), adsorbed in silica and purified by column chromatography (BiotageTM/Flash, silica, methanol:dichloromethane 0.2:9.8 to
  • Example 18 4-[2-(4-Fluoro-phenylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenoI (4-Fluoro-phenyl)-(5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine (0.065 g, 0.18 mmol) was suspended in 1 ,4-dioxane (1 mL) at room temperature, and argon was bubbled into the mixture while tetrakis(triphenylphosphine)- palladium(0) (21 mg, 0.018 mmol), 4-hydroxyphenylboronic acid (21 mg, 0.21 mmol), cesium carbonate (118 mg, 0.36 mmol) and water (1 mL) were added.
  • the mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 30 minutes. On cooling, the mixture was diluted with dichloromethane (5 mL), adsorbed in silica and purified by column chromatography (BiotageTM/Flash, silica, methanokdichloromethane 0.4:9.6 to 1 :9) to give 4-[2-(4-fluoro-phenylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenol as a beige solid (21 mg, 36% yield).
  • the mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 30 minutes. On cooling, the mixture was diluted with dichloromethane (5 mL), adsorbed in silica and purified by column chromatography (BiotageTM/Flash, silica, methanoLdichloromethane 0.4:9.6 to 1.5:8.5). The product obtained was treated with diethylether (7 mL) and filtered to give N- ⁇ 4-[2-(4-fluoro-phenylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenyl ⁇ - acetamide as an off-white solid (10 mg, 15% yield).
  • the mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 1 hour. On cooling, the mixture was diluted with dichloromethane, adsorbed in silica and purified by column chromatography (BiotageTM/Flash, silica, methanokdichloromethane 0.2:9.8 to 2:8). The obtained residue was further purified by preparative HPLC to give ⁇ 5-[3- dimethylaminophenyl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl] ⁇ -(4-methoxyphenyl)- amine as a white solid (4 mg, 7% yield).
  • the reaction mixture was cooled to room temperature, diluted with water (30 mL) and extracted with chloroform (3 x 40 mL). The combined organic layers were washed with water (3 x 40 mL), dried over anhydrous sodium sulphate and concentrated.
  • the crude was purified by column chromatography (Biotage/flash, silica, methanol:dichloromethane 0:10 to 0.7:9.3), yielding a fraction containing the title compound and a byproduct.
  • the title compound was obtained in 34% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
  • the title compound was obtained in 34% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
  • the title compound was obtained in 26% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
  • the title compound was obtained in 26% yield after purification by column chromatography on flash silica gel (methanohdichloromethane, 0:10 to 0.5:9.5).
  • (22) 1-(3- ⁇ 2-[(Thiophen-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl ⁇ - phenyl)-ethanone; (23) [5-(3-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(tetrahydro-pyran-4- ylmethyl)-amine;
  • Example 35 The following examples are also prepared in accordance with the methods described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

There is provided compounds of formula (I), wherein Z, M, R1, X, R2, R3 and B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family kinase or PI3-K) is desired and/or required, and particularly in the treatment of cancer.

Description

IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS
Field of the Invention
This invention relates to novel pharmaceutically-useful compounds, which compounds are useful as inhibitors of protein kinases (such as PI3Ks and the PIM family kinases). The compounds are of potential utility in the treatment of diseases such as cancer. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to synthetic routes for their production.
Background of the Invention
The malfunctioning of protein kinases (PKs) is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders.
For a general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459 - 465.
PIM-1 is the protooncogene activated by murine leucemia virus (Provirus Integration site for Moloney murine leucemia virus - MoMuLV) that induces T-cell lymphoma [Cuypers, H.T., et. al. Cell, 1984, 37, 141-150].
The expression of the protooncogene produces a non-transmembrane serine/threonine kinase of 313 residues, including a kinase domain consisting of 253 amino acid residues. Two isoforms are known through alternative initiation (p44 and p33) [Saris, C.J.M. et al. EMBO J. 1991, 10, 655-664].
PIM-1, PIM-2 and PIM-3 phosphorylate protein substrates that are important in cancer neogenesis and progression. For example, PIM-1 phosphorylates inter alia p21 , Bad, c-myb, Cdc 25A and elF4B (see e.g. Quian, K. C. et al, J. Biol. Chem. 2005, 280(7), 6130-6137, and references cited therein).
Two PIM-1 homologs have been described [Baytel, D. Biochem. Biophys. Acta 1998, 1442, 274-285; Feldman, J. et al. J. Biol. Chem. 1998, 273, 16535.16543].
PIM-2 and PIM-3 are respectively 58% and 69% identical to PIM-1 at the amino acid level. PIM-1 is mainly expressed in thymus, testis, and cells of the hematopoietic system [Mikkers, H.; Nawijn, M.; Allen, J.; Brouwers, C;
Verhoeven, E.; Jonkers, J.; Berns, MoI. Cell. Biol. 2004, 24, 6104; Bachmann, M.; Moray, T. Int. J. Biochem. Cell Biol. 2005, 37, 726-730. 6115]. PIM-1 expression is directly induced by STAT (Signal Transducers and Activators of Transcription) transcription factors, and PIM-1 expression is induced by many cytokine signalling pathways such as interleukins (IL), granulocyte-macrophage colony stimulating factor (GM-CSF), α- and γ-interferon, erythropoietin, and prolactin [Wang, Z et al.. J. Vet. Sci. 2001 , 2, 167-179].
PIM-1 has been implicated in lymphoma development. Induced expression of PIM-1 and the protooncogene c-myc synergise to increase the incidence of lymphomagenesis [Breuer, M. et al. Nature 1989, 340, 61-63; van Lohuizen M. et al. Cell, 1991 , 65, 737-752]. PIM-1 functions in cytokine signalling pathways and has been shown to play a role in T cell development [Schmidt, T. et al. EMBO J. 1998, 17, 5349-5359; Jacobs, H. et al. JEM 1999, 190, 1059-1068]. Signalling through gp130, a subunit common to receptors of the IL-6 cytokine family, activates the transcription factor STAT3 and can lead to the proliferation of hematopoietic cells [Hirano, T. et al. Oncogene 2000, 19, 2548-2556]. A kinase- active PIM-1 appears to be essential for the gp130-mediated STAT3 proliferation signal. In cooperation with the c-myc PIM-1 can promote STAT3-mediated cell cycle progression and antiapoptosis [Shirogane, T. et si., immunity, 1999, 11 , 709-719]. PIM-1 also appears to be necessary for IL-3-stimulated growth in bone marrow-derived mast cells [Domen, J. et al., Blood, 1993, 82, 1445-1452] and survival of FDCP1 cells after IL-3 withdrawal [Lilly, M. et al., Oncogene, 1999, 18, 4022-4031].
Additionally, control of cell proliferation and survival by PIM-1 may be effected by means of its phosphorylation of the well-established cell cycle regulators cdc25
[Mochizuki, T. et al., J. Biol. Chem. 1999, 274, 18659-18666] and/or p21(Cip1/WAF1 ) [Wang Z. et al. Biochim. Biophys. Acta 2002, 1593, 45-55] or phosphorylation of heterochromatin protein 1 , a molecule involved in chromatin structure and transcriptional regulation [Koike, N. et al, FEBS Lett. 2000, 467, 17- 21].
Mice deficient for all three PIM genes showed an impaired response to hematopoietic growth factors and demonstrated that PIM proteins are required for efficient proliferation of peripheral T lymphocytes. In particular, it was shown that PIM function is required for efficient cell cycle induction of T cells in response to synergistic T-cell receptor and IL-2 signalling. A large number of interaction partners and substrates of PIM-1 have been identified, suggesting a pivotal role for PIM-1 in cell cycle control, proliferation, as well as in cell survival.
The oncogenic potential of this kinase has been first demonstrated in E μ PIM-1 transgenic mice in which PIM-1 over-expression is targeted to the B-cell lineage which leads to formation of B-cell tumors [van Lohuizen, M.et al.; Cell 1989, 56, 673-682. Subsequently PIM-1 has been reported to be over-expressed in a number of prostate cancers, erythroleukemias, and several other types of human leukemias [Roh, M.et al.;. Cancer Res. 2003, 63, 8079-8084; Valdman, A. et al; Prostate 2004, 60, 367-371.
For example, chromosomal translocation of PIM-1 leads to overexpression of PIM-1 in diffuse large cell lymphoma. [Akasaka, H.et al.; Cancer Res. 2000, 60, 2335-2341]. Furthermore, a number of missense mutations in PIM-1 have been reported in lymphomas of the nervous system and AIDS-induced non-Hodgkins' lymphomas that probably affect PIM-1 kinase activity or stability [Pasqualucci, L. et al, Nature 2001, 412, 341-346; Montesinos-Rongen, M. et al., Blood 2004, 103, 1869-1875; Gaidano, G. et al., Blood 2003, 102, 1833-184]. Thus, the strong linkage between reported overexpression data and the occurrence of PIM-1 mutations in cancer suggests a dominant role of PIM-1 in tumorigenesis.
Several other protein kinases have been described in the literature, in which the activity and/or elevated activity of such protein kinases have been implicated in diseases such as cancer, in a similar manner to PIM-1 , PIM-2 and PIM-3. Such protein kinases include PI3-K, CDK-2, SRC and GSK-3.
There is a constant need to provide alternative and/or more efficacious inhibitors of protein kinases, and particularly inhibitors of CDK-2, SRC, GSK-3, PI3-K, PIM- 1 , PIM-2 and/or PIM-3. Such modulators are expected to offer alternative and/or improved approaches for the management of medical conditions associated with activity and/or elevated activity of CDK-2, SRC, GSK-3, PI3-K, PIM-1 , PIM-2 and/or PIM-3 protein kinases
The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.
International patent application WO 2007/064797 discloses various compounds that may be useful in the treatment of cancer. However, there is no mention in that document of imidazothiadiazoles.
US patent applications US 2007/0049591 and US 2007/0093490 and international patent application WO 2004/058769 all disclose various compounds that may be useful as kinase inhibitors. Further, international patent application WO 2007/0136736 discloses various compounds that may be useful as Lck inhibitors. However, all these documents only mention compounds in which the core ring structure is a 6,5-ring system.
International patent application WO 2004/111060 discloses various imidazothiadiazoles that may be useful in the treatment of neurodegenerative diseases and cancer. However, this document primarily relates to 6-aryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles, substituted in the 2-position with a sulfur (or oxidised derivative thereof) linker group. Further, international patent application WO 03/051890 also discloses various imidazothiadiazoles, which may be useful in the treatment of neurodegenerative diseases and cancer. However, this document primarily relates to 6-aryl substituted imidazo[2,1-bj-1 ,3,4- thiadiazoles, substituted in the 2-position with a sulfonamide group.
Journal article European Journal of Medicinal Chemistry (2003), 38(7-8), 781-786 by Terzioglu et al discloses various compounds that may be useful in the treatment of cancer. However, this document only discloses compounds that contain a carbohydrazide moiety.
Italian journal article Arzneimittel-Forschung (2000), 50(6), 550-553 by Andreani et al discloses various compounds including specific imidazothiadiazoles. However, there is no mention in this journal article that the compounds disclosed therein may be useful as protein kinase inhibitors.
International patent application WO 97/11075 discloses various compounds imidazothiadiazoles as herbicides. However, there is no disclosure that such compounds may be useful as pharmaceuticals, e.g. in the treatment of cancer.
European patent application EP 662 477 and journal article Journal of the Indian Chemical Society (1979), 56(7), 716-17 by Joshi et al, both disclose various heterobicyclic compounds, including specific imidazolothiadiazole compounds, which may be active as fungicides. However, there is no disclosure in either of these documents that the compounds disclosed therein may be useful as protein kinase inhibitors.
Italian journal article Farmaco, Edizione Scientifica (1985), 40(3), 190-9 by Abignente et al and European patent application EP 41215 both disclose various imidazolothiadiazoles, which may have been tested for medicinal properties for research purposes.
Various imidazolothiadiazoles have also been disclosed in Journal of the Indian Chemical Society (1982), 59(10), 1170-3 as potential fungicides and/or bactericides. Various other imidazolothiadiazoles have also been disclosed in the CAS registry database, but to which compounds no use has apparently been ascribed.
Disclosure of the Invention
According to the invention, there is provided a compound of formula I,
Figure imgf000007_0001
wherein:
B represents -S-, -S(O)- or -SO2-;
Z represents a direct bond, -(CH2)n-O-, -(CH2)π-S-, -(CH2)n-N(Ra)-, -(CH2)n1-S(O)-, -(CH2)H-SO2-, -(CH2)n-NH-SO2-, -(CH2)nrSO2-NH-, -(CH2)n-N(Ra)-CO-, -(CH2)n-NH-CO-NH- or -(CH2)n-CO-N(R3)-;
n represents, on each occasion when used herein, 0, 1 or 2;
n1 represents, on each occasion when used herein, 1 or 2;
M represents a direct bond or C1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -ORb, -SRb or -N(Rb)2;
R1 represents hydrogen, halogen, -CN, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A1), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B1 and B2, respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B3 and B4, respectively);
X represents a direct bond, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-N(Rd)-, -S(O)-, -(CH2VSO2-, -(CH2)m-NH-SO2-, -(CH2)^SO2-NH-, -(CH2)m-NH-CO-, -(CH2)m-CO-N(Rd)-, -(CH2)m-NH-CO-NH- or C1-8 alkylene optionally substituted by one or more substituents selected from A2;
m represents, on each occasion when used herein, 0, 1 or 2;
R2 represents hydrogen, halo, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A3) or -T-Q;
T represents a direct bond or a C1-3 alkylene linker group optionally substituted by one or more substituents selected from A4;
Q represents C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B5 and B6, respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B7 and B8, respectively);
but wherein:
(i) when X represents a direct bond, then R2 does not represent hydrogen or halo; and (ii) when Z and M both represent direct bonds, then R1 does not represent hydrogen; and
(iii) when either Z and M represent direct bonds, then R1 does not represent halo;
A1, A2, A3 and A4 independently represent halo, -ORe, -S-C1-4 alkyl, -N(Re)2, -C(O)2R6, -C(O)N(Re)2, -N(Re)-C(O)-Re, -C(O)R6, -CN, -SO2N(R6)2 and/or phenyl (optionally substituted by one or more halo and/or -OR6 substituents);
B1, B2, B3, B4, B5, B6, B7 and B8 independently represent halo, -ORe, -C(O)2R6, -C(O)R6, -C(O)N(R6)2, -N(Re)-C(O)-Re, -CN, -S(O)2R6, -S(O)2N(Re)2, -N(Re)2 and/or C1-4 alkyl optionally substituted by one or more substituents selected from halo, -OR6 and -C(O)2R6; or, B1, B2, B5 and B6 may alternatively and independently represent =O;
R3 represents hydrogen, halo, -Rf, -ORf, -SRf, cyano or -N(Rf)2; Ra, Rb, Rd, Re and Rf represent independently, on each occasion when used herein, hydrogen, phenyl (optionally substituted by one or more halo or C1-3 alkyl substituents) and/or C1-4 alkyl optionally substituted with one or more substituents selected from halo, -ORh and -N(Rh)2;
Rh represents, on each occasion when used herein, hydrogen or C1-3 alkyl optionally substituted by one or more halo atoms,
or a pharmaceutically acceptable ester, amide, solvate or salt thereof,
provided that when B represents -S-:
(a) X represents a direct bond, R2 represents unsubstituted phenyl, R3 represents hydrogen, M represents -(CH2)2- and R1 represents bromo, then Z does not represent -S-;
(b) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent methyl substituted by -OH;
(c) Z and M both represent a direct bond, then:
(I) R2 does not represent unsubstituted 1 ,2,4-triazol-3-yl when X represents -S- or -SO2-:
(A) R1 represents -CH2CH3 and R3 represents -CH2CH3 or -CH3; or
(B) R1 represents -CH3 and R3 represents -CH2CH3, -CH3 or Cl; or
(II) R2 does not represent 1 ,2,4-triazol-3-yl substituted in the 1-position by -C(O)N(CH2CH3)2 when X represents -SO2-: (A) R1 represents -CH2CH3, and R3 represents -CH2CH3 or -CH3,
(B) R1 represents -CH3, and R3 represents -CH2CH3, -CH3 or Cl;
(d) Z and M represents direct bonds, R3 represents -CH3, then:
(I) when R1 represents 4-methoxyphenyl, -X-R2 does not represent -CH2-C(O)OCH3, -C(=C(H)-OCH3)-C(O)-NHCH3, -C(=C(H)- CH2CH3)-C(O)-OCH3 or -C(=C(H)-OCH3)-C(O)-OCH3;
(II) when R1 represents te/t-butyl, -X-R2 does not represent -C(=C(H)-OCH3)-C(O)-OCH3;
(e) Z and M represent direct bonds, R1 represents -CH3, R3 represents hydrogen, then R2 does not represent unsubstituted phenyl when X represents a direct bond; (f) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent -CO2H (or an ethyl ester thereof);
(g) Z, and M represent direct bonds, R1 and R3 represent tert-butyl, then R2 does not represent hydrogen when X represents -NH-; (h) Z, M and X represent direct bonds, R3 represents H, then:
(I) when R1 represents 4-chlorophenyl or unsubstituted phenyl, then R2 does not represent unsubstituted phenyl or 4- chlorophenyl;
(II) when R1 represents 4-methoxyphenyl, then R2 does not represent 4-chlorophenyl or unsubstituted phenyl;
(i) Z and M represent direct bonds, R1 represents -CH3, X represents -CH=CH- (i.e. ethenylene) and R2 represents -CO2H, then R3 does not represent tert-butyl or methyl;
G) Z, M and X represent direct bonds, R3 represents H, then: (I) R2 does not represent 4-fluoro-1-naphthyl when R1 represents pentyl, butyl or isopropyl;
(II) R2 does not represent 3-chloro-4-fluoro-1-naphthyl when R1 represents pentyl, methyl or ethyl;
(III) R2 does not represent 3-methyl-4-fluoro-1-naphthyl when R1 represents pentyl, methyl, ethyl or n-propyl
(IV) R2 does not represent 2-methyl-4-fluoro-1-naphthyl when R1 represents trifluoromethyl;
(k) X and M represent direct bonds, R2 represents methyl, R3 represents ethyl, then: (I) when Z represents -NHC(O)-, then R1 does not represent unsubstituted methyl or methyl substituted by -C(O)CH3; (II) when Z represents -NH-, then R1 does not represent hydrogen; (I) X, M and Z all represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent -CH3, -CO2H or unsubstituted phenyl; (m) X represents a direct bond, Z represents -S-, M represents -CH2- (i.e. methylene) and R1 represents unsubstituted phenyl, then:
(I) when R3 represents -CH3, then R2 does not represent -CO2CH2CH3; or
(II) when R3 represents hydrogen, then R2 does not represent -CH3; (n) X, M and Z represent direct bonds, R1 represents -CH2CH3 and R3 represents -CH3, then R2 does not represent -CO2H; (o) X, Z and M all represent direct bonds, R3 represents hydrogen, then R2 does not represent 1-piperidinyl when R1 represents unsubstituted phenyl,
which compounds, esters, amides, solvates and salts are referred to hereinafter as "the compounds of the invention".
Pharmaceutically-acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
By "pharmaceutically acceptable ester, amide, solvate or salt thereof, we include salts of such an ester or amide, and solvates of such an ester, amide or salt. For instance, pharmaceutically acceptable esters and amides such as those defined herein may be mentioned, as well as pharmaceutically acceptable solvates or salts.
Pharmaceutically acceptable esters and amides of the compounds of the invention are also included within the scope of the invention. Pharmaceutically acceptable esters and amides of compounds of formula I may have an appropriate group, for example an acid group (e.g. when R1 and/or R2 represent -CO2H), converted to the appropriate ester or amide. For example, pharmaceutically acceptable esters (of carboxylic acids) that may be mentioned include optionally substituted C1-6 alkyl, C5-10 aryl and/or C5-10 aryl-C1.6 alkyl- esters. Pharmaceutically acceptable amides (of carboxylic acids) that may be mentioned include those of the formula -C(O)N(R21 )Rz2, in which Rz1 and Rz2 independently represent optionally substituted C1-6 alkyl, C5-10 aryl, or C5-10 aryl- C-I-6 alkylene-. Preferably, C1-6 alkyl groups that may be mentioned in the context of such pharmaceutically acceptable esters and amides are not cyclic, e.g. linear and/or branched.
Preferably, specific esters and amides of compounds of the invention that may be mentioned include esters and amides of compounds of the invention in which R1 and/or R2 represent -CO2H. Hence, R1 and R2 may each independently represent -CO2RX (wherein Rx represents C1-4 alkyl optionally substituted by one or more halo atoms or -ORh) or -C(O)N(Rh)2, wherein, in each case, Rh is as hereinbefore defined.
Further compounds of the invention that may be mentioned include carbamate, carboxamido or ureido derivatives, e.g. such derivatives of existing amino functional groups.
For the purposes of this invention, therefore, prodrugs of compounds of the invention are also included within the scope of the invention.
The term "prodrug" of a relevant compound of the invention includes any compound that, following oral or parenteral administration, is metabolised in vivo to form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)). For the avoidance of doubt, the term "parenteral" administration includes all forms of administration other than oral administration.
Prodrugs of compounds of the invention may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesising the parent compound with a prodrug substituent. Prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfhydryl, carboxy or carbonyl group in a compound of the invention is bonded to any group that may be cleaved in vivo to regenerate thefree hydroxyl, amino, sulfhydryl, carboxy or carbonyl group, respectively.
Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs" p. 1-92, Elesevier, New York-Oxford (1985).
Compounds of the invention may contain double bonds and may thus exist as E (entgegen) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.
Compounds of the invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.
Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.
Unless otherwise stated, the terms C1-q alkyl, and C-i-q alkylene, groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number of carbon atoms, be branched-chain, saturated or unsaturated (so forming, for example, an alkenyl or alkynyl group). C3.q cycloalkyl groups (where q is the upper limit of the range) that may be mentioned may be monocyclic or bicyclic alkyl groups, which cycloalkyl groups may further be bridged (so forming, for example, fused ring systems such as three fused cycloalkyl groups). Such cycloalkyl groups may be saturated or unsaturated containing one or more double or triple bonds (forming for example a cycloalkenyl or cycloalkynyl group). Substituents may be attached at any point on the cycloalkyl group. Further, where there is a sufficient number (i.e. a minimum of four) such cycloalkyl groups may also be part cyclic.
The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.
Heterocycloalkyl groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between five and ten. Such heterocycloalkyl groups may also be bridged. Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C2-q heterocycloalkenyl (where q is the upper limit of the range) or a C7-q heterocycloalkynyl group. C2-q heterocycloalkyl groups that may be mentioned include 7-azabicyclo[2.2.1]heptanyl, 6- azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2.1]-octanyl, 8-azabicyclo-
[3.2.1]octanyl, aziridinyl, azetidinyl, dihydropyranyl, dihydropyridyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1 ,3-dioxolanyl), dioxanyl (including 1 ,3-dioxanyl and 1 ,4-dioxanyl), dithianyl (including 1 ,4-dithianyl), dithiolanyl (including 1 ,3-dithiolanyl), imidazolidinyi-, imidazolinyl, morpholinyl, 7- oxabicyclo[2.2.1]heptanyl, 6-oxabicyclo-[3.2.1]octanyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolanyl, 3-sulfolenyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridyl (such as 1 ,2,3,4-tetrahydropyridyl and 1 ,2,3,6-tetrahydropyridyl), thietanyl, thiiranyl, thiolanyl, thiomorpholinyl, trithianyl (including 1 ,3,5-trithianyl), tropanyl and the like. Substituents on heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heterocycloalkyl groups may also be in the N- or S- oxidised form.
For the avoidance of doubt, the term "bicyclic" (e.g. when employed in the context of heterocycloalkyl groups) refers to groups in which the second ring of a two-ring system is formed between two adjacent atoms of the first ring. The term "bridged" (e.g. when employed in the context of cycloalkyl or heterocycloalkyl groups) refers to monocyclic or bicyclic groups in which two non-adjacent atoms are linked by either an alkylene or heteroalkylene chain (as appropriate).
Aryl groups that may be mentioned include C6-10 aryl groups. Such groups may be monocyclic, bicyclic or tricyclic and have between 6 and 10 ring carbon atoms, in which at least one ring is aromatic. C6-10 aryl groups include phenyl, naphthyl and the like, such as 1 ,2,3,4-tetrahydronaphthyl. The point of attachment of aryl groups may be via any atom of the ring system. However, when aryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring.
Unless otherwise specified, the term "heteroaryl" when used herein refers to an aromatic group containing one or more heteroatom(s) (e.g. one to four heteroatoms) preferably selected from N, O and S. Heteroaryl groups include those which have between 5 and 10 members and may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic (so forming, for example, a mono-, bi-, or tricyclic heteroaromatic group). However, when heteroaryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring. Heteroaryl groups that may be mentioned include acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1 ,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiadiazolyl (including 2,1 ,3-benzothiadiazolyl), benzothiazolyl, benzoxadiazolyl (including 2,1 ,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1 ,4- benzoxazinyl), benzoxazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1 ,3-benzoselenadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1 ,2-a]pyridyl, indazolyl, indolinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiaziolyl, isothiochromanyl, isoxazolyl, naphthyridinyl (including 1,6-naphthyridinyl or, preferably, 1 ,5-naphthyridinyl and 1 ,8-naphthyridinyl), oxadiazolyl (including 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl and 1 ,3,4-oxadiazolyl), oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolizinyl, quinoxalinyl, tetrahydroisoquinolinyl (including 1 ,2,3,4-tetrahydroisoquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl), tetrahydroquinolinyl (including 1 ,2,3,4- tetrahydroquinolinyl and 5,6,7,8-tetrahydroquinolinyl), tetrazolyl, thiadiazolyl (including 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl and 1 ,3,4-thiadiazolyl), thiazolyl, thiochromanyl, thiophenetyl, thienyl, triazolyl (including 1 ,2,3-triazolyl, 1 ,2,4-triazolyl and 1 ,3,4-triazolyl) and the like. Substituents on heteroaryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heteroaryl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heteroaryl groups may also be in the N- or S- oxidised form.
It may be specifically stated that the heteroaryl group is monocyclic or bicyclic. In the case where it is specified that the heteroaryl is bicyclic, then it may be consist of a five-, six- or seven-membered monocyclic ring (e.g. a monocyclic heteroaryl ring) fused with another a five-, six- or seven-membered ring (e.g. a monocyclic aryl or heteroaryl ring).
Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulphur.
For the avoidance of doubt, in cases in which the identity of two or more substituents in a compound of the invention may be the same, the actual identities of the respective substituents are not in any way interdependent. For example, in the situation in which there is more than one A1 substituent present, then those A1 substituents may be the same or different. Further, in the case where there are two A1 substituents present, in which one represents -ORe and the other represents -C(O)2R8, then those Re groups are not to be regarded as being interdependent. Similarly, in specific case when R3 represents -N(Rf)2, then those two Rf groups may be the same or different. Linker groups, for example as defined by X and Z are specified with hyphens C'-"s) at the respective ends, depicting the points of attachment with the rest of the compound of formula I. For the avoidance of doubt, in relation to the linker groups defined by X and Z, the first hyphen of the linking moiety is the point at which that moiety links to the requisite 5,5-bicycle of formula I (and the last hyphen depicts the linking point to -R2, in the case of the X linker group, or -M-R1, in the case of the Z linker group). For example, when Z represents -(CH2)n-N(Ra)-, it is the -(CH2)n- portion that is attached to the 5,5-bicycle of formula I.
For the avoidance of doubt, when a term such as "R8 to Rf" is employed herein, this will be understood by the skilled person to mean Ra, Rb, Rd, Re and Rf, inclusively. Likewise, a term such as "B1 to B8" when employed herein, will be understood by the skilled person to mean B1, B2, B3, B4, B5, B6, B7 and B8, inclusively.
The skilled person will appreciate that in certain preferred embodiments of the compounds of the invention, some or all of the provisos (a) to (p) above will become redundant. For instance, where it is stated herein in relation to compounds of the invention that preferred such compounds include those in which "when R2 represents aryl, then it is a monocyclic aryl group", then in relation to such a preferred aspect of the invention, at least proviso (j) above will become redundant.
B1, B2, B3, B4, B5, B6, B7 and B8 independently represent halo, -ORe, -C(O)2R8,
-C(O)R8, -C(O)N(Re)2, -CN, -S(O)2R8, -S(O)2N(Re)2, -N(R8)2 and/or C1-4 alkyl optionally substituted by one or more substituents selected from halo, -ORe and
-C(O)2R6; or,
B1, B2, B5 and B6 may alternatively and independently represent =O; Ra, Rb, Rd, Re and Rf (e.g. Ra, Rb, Rd and Rf) represent independently, on each occasion when used herein, hydrogen and/or C1-4 alkyl optionally substituted with one or more substituents selected from halo and -ORh; when Z represents -(CH2)n-N(Ra)-CO-, then Ra represents hydrogen.
Compounds of the invention that may be mentioned include those in which: when X represents -(CH2)m-SO2-NH-, then m represents 1 or 2; X does not represent -(CH2)m-SO2-NH- (i.e. X preferably represents a direct bond, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-N(Rd)- -S(O)-, -(CH2WSO2-, -(CH2)m-NH-SO2-, -(CH2VNH-CO-, -(CH2)m-CO-N(Rd)-, -(CH2)m-NH-CO-NH- or C1-8 alkylene optionally substituted by one or more substituents selected from A2).
Compounds of the invention that may be mentioned include those in which: for example when either Z and M represent direct bonds, then R1 does not represent halo; for example when X represents a direct bond, then R2 does not represent halo; when Z and M both represent direct bonds, then R1 does not represent hydrogen; for example when Z, M and X all represent direct bonds, then:
(i) R1 does not represent hydrogen or (e.g. when Z and M represent direct bonds) halo; and/or (ii) R2 does not represent hydrogen or (e.g. when X represents a direct bond) halo.
Further compounds of the invention that may be mentioned include those in which: for example when Z, M and X all represent direct bonds, then:
(i) R1 represents -CN, -CO2H or, more preferably, C1-8 alkyl (optionally substituted by one or more substituents selected from A1), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B1 and B2, respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B3 and B4, respectively);
(ii) R2 represents -CO2H or, more preferably, C1-8 alkyl (optionally substituted by one or more substituents selected from A3) or -T-Q;
T represents -CH2-, -(CH2)2- or, preferably, a direct bond (hence R2 preferably represents halo or, preferably, -CO2H or, more preferably, C1-8 alkyl (optionally substituted by one or more substituents selected from A3) or C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B5 and B6, respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B7 and B8, respectively)). Further compounds of the invention that may be mentioned include those in which:
R1 represents halogen, or, preferably, hydrogen, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A1), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B1 and B2, respectively), aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B3 and B4, respectively); when Z represents -(CH2)n-O-, then n represents 0; when Z represents -(CH2)n-S-, then n represents 0;
R3 represents hydrogen, halo, -Rf or -ORf;
Z represents -(CH2)n-O-, -(CH2)n-S-, -(CH2)n-N(Ra)-, -(CH2)π1-S(O)-,
-(CHz)n-SO2-, -(CHa)n-NH-SO2-; -(CH2)n1-SO2-NH-, -(CHz)n-NH-CO-, -(CHz)n-NH-CO-NH- or -(CH2)n-CO-N(Ra)-;
M represents C1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -ORb, -SRb or N(Rb)2; when X represents -(CH2)m-O-, then m represents 0; when X represents -(CH2)m-S-, then m represents 0; X is selected from -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-N(Rd)-, -S(O)-, -(CH2)m-SO2-,
-(CH2VNH-SO2-, -(CH2)m-SO2-NH-, -(CH2U-NH-CO-, -(CH2)m-CO-N(Rd)-,
-(CH2)m-NH-CO-NH- or C1-8 alkylene optionally substituted by one or more substituents selected from A2; m and n independently represent 2, preferably, 1 or, more preferably, 0.
Further compounds of the invention that may be mentioned include those in which:
Z represents -S- or, preferably, -(CH2)n-SO2-, or, more preferably, a direct bond,
-O-, -(CH2)n-N(Ra)-, -(CH2V-NH-SO2-, -(CHz)n-NH-CO-, -(CH2)n-NH-CO-NH- or -(CHz)n-CO-N(R3)- when R2 represents aryl, then it is a monocyclic aryl group.
For instance in one embodiment, preferred compounds of the invention include those in which: R1 represents optionally substituted aryl, or optionally substituted monocyclic or bicyclic heteroaryl;
X represents a single bond or C1-3 alkylene (optionally substituted as defined herein); and/or R2 represents optionally substituted aryl or heteroaryl.
For instance in another embodiment, preferred compounds of the invention include those in which:
R1 preferably represents aryl, monocyclic heteroaryl or bicyclic heteroaryl; X represents a single bond; and/or
R2 represents halo or, preferably, -CO2H or, more preferably, C1-S alkyl, C3-6 cycloalkyl or heterocycloalkyl, which latter three groups are optionally substituted as defined herein).
For instance in another embodiment, preferred compounds of the invention include those in which:
M represents a direct bond or C1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -ORb, C1-4 alkylthio or -N(Rb)2;
R1 represents C3-6 cycloalkyl; and/or X represents a single bond.
Preferred aryl and heteroaryl groups that R1 and R2 may independently represent include optionally substituted phenyl, naphthyl, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, pyridyl, indazolyl, indolyl, indolinyl, isoindolinyl, quinolinyl, isoquinolinyl, quinolizinyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, chromanyl, benzothienyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, quinazolinyl, quinoxalinyl, 1 ,3-benzodioxolyl, tetrazolyl, benzothiazolyl, and/or benzodioxanyl.
Preferred C1-8 alkyl groups that R1 and R2 may independently represent include optionally substituted C1-6 alkyl, which alkyl group may be unsaturated, linear (for example, methyl, ethyl, n-propyl) or branched (e.g. branched C1-5 alkyl, such as 1- methyl-isobutyl, 1-methyl-n-propyl or 2,2-dimethylpropyl). Preferred heterocycloalkyl groups that R1 and R2 may independently represent include optionally substituted 5- or 6-membered heterocycloalkyl groups containing one to three heteroatoms selected from sulfur, or preferably, nitrogen and/or oxygen, so forming for example a piperidinyl, morpholinyl, imidazolidinyl or tetrahydropyranyl group.
Preferred substituents on aryl, heteroaryl, C1-8 alkyl, C3-6 cycloalkyl or heterocycloalkyl groups that R1 and R2 may represent include (as appropriate): =O (e.g. in the case of cycloalkyl or, preferably, heterocycloalkyl groups); -CN; halo (e.g. fluoro, chloro or bromo);
C1-4 alkyl, which alkyl group may be cyclic, part-cyclic, unsaturated or, preferably, linear or branched (e.g. C1-4 alkyl (such as ethyl, n-propyl, isopropyl, f-butyl or, preferably, n-butyl or methyl), all of which are optionally substituted with one or more substituents selected from -ORz1, -N(Rz4)Rz5 (so forming for example a -CH2-CH2-OH or -CH2-CH2-N(CH3)2 group) and, preferably, halo (e.g. fluoro; so forming, for example, fluoromethyl, difluoromethyl or, preferably, trifluoromethyl); aryl (e.g. phenyl), if appropriate (e.g. when a substitutent on an alkyl group, thereby forming e.g. a benzyl group); -ORz1; -C(O)R"2; -C(O)OR23; -N(Rz4)Rz5; -S(O)2R26; -S(O)2N(Rz7)Rz8; -N(Rz9)Rz10; wherein Rz1 to Rz1° independently represent, on each occasion when used herein, H or C1-4 alkyl (e.g. ethyl, n-propyl, f-butyl or, preferably, n-butyl, methyl or isopropyl) optionally substituted by one or more halo (e.g. fluoro) groups (so forming e.g. a trifluoromethyl group).
Preferred compounds of the invention include those in which: at least one of X and Z is other than a direct bond; B represents -S-; Z represents a direct bond, -O-, -S-, -(CH2)n-N(Ra)- or -(CH2)n-N(H)-C(O)-; Ra represents H; n represents 0;
M represents a direct bond or C1-3 alkylene (e.g. -CH2- or -(CH2)2-), which group may be unsaturated (so forming, for example a ethenylene (i.e. -CH=CH-) group or, preferably an ethynylene group);
R1 represents -CO2H or an amide thereof (i.e. -C(O)N(Rh)2), C1-6 alkyl optionally substituted by A1, C3-6 cycloalkyl (e.g. cyclopropyl or cyclohexyl) optionally substituted by B1 (but preferably unsubstituted), heterocycloalkyl optionally substituted by B2, aryl (e.g. phenyl) optionally substituted by B3, or heteroaryl optionally substituted by B4, when R1 represents C1-6 alkyl, then it preferably represents methyl, ethyl, n-propyl or optionally branched C1-5 alkyl such as 1-methyl-isobutyl, 1-methyl-n-propyl or 2,2-dimethylpropyl), which C1-6 alkyl groups may be substituted by A1 (e.g. by - ORe, so forming, for example a hydroxyalkyl group, such as hydroxypropyl, 1- hydroxymethylisobutyl or 1-hydroxymethyl-n-propyl); when R1 represents heterocycloalkyl, then such a group preferably represents a 5- or 6-membered heterocycloalkyl group containing one or two heteroatoms selected from nitrogen and/or oxygen, so forming for example a piperidinyl (e.g. 1-piperidinyl), morpholinyl (e.g. 4-morpholinyl), imidazolidinyl (e.g. 1- imidazolidinyl) or tetrahydropyranyl (e.g. 4-tetrahydropyranyl) group; when R1 represents heteroaryl, then it preferably represent a 5- or 6-membered monocyclic heteroaryl group such as pyrazolyl (e.g. 4-pyrazolyI), pyrazinyl (e.g. 2-pyrazinyl), furanyl (e.g. 2-furanyl), pyrrolyl (e.g. 2-pyrrolyl), imidazolyl (e.g. 1- imidazolyl), thienyl (e.g. 2-thienyl) or pyridyl (e.g. 3-pyridyl); X represents a direct bond, -O-, -(CH2)m-N(Rd)-, -(CH2)m-N(H)-CO, -(CH2)m-CO-N(Rd)-, -(CH2)m-NH-SO2- or C1-3 alkylene (e.g. -CH2- or -(CH2)2-), which group may be unsaturated (so forming, for example a ethenylene (i.e. -CH=CH-) group or, preferably an ethynylene group); m represents 0; Rd represents H;
R2 represents halo (e.g. iodo), C1-6 (e.g. C1-4) alkyl (e.g. methyl or ethyl) optionally substituted by A3, C3-6 cycloalkyl (e.g. cyclohexyl), heterocycloalkyl (e.g. tetrahydropyranyl, such as 4-tetrahydropyranyl or morpholinyl, such as 4- morpholinyl) optionally substituted by B6, aryl (e.g. naphthyl or, preferably, phenyl) optionally substituted by B7, or, heteroaryl (e.g. pyrazolyl, such as 4- pyrazolyl, indolyl, such as 2- or 5-indolyl, pyridyl, such as 3-pyridyl) optionally substituted by B8;
A1 to A4 independently represent halo, -ORe, -CO2Re, -N(Re)-C(O)-Re or phenyl optionally substituted by -ORe; B1 to B8 independently represent -N(Re)-C(O)Re, preferably, -C(O)N(Re)2, or, more preferably, halo (e.g. fluoro or chloro), -ORe, -C(O)2R8,
-C(O)R8, -CN, -S(O)2R8, -S(O)2N(R8)2, -N(Re)2 and/or C1-3 alkyl (e.g. methyl or optionally unsaturated ethyl, e.g. ethenyl), which alkyl group is optionally substituted by one or more substituents selected from halo (e.g. fluoro, so forming, for example, a trifluoromethyl group), -ORe (so forming for example a hydroxymethyl group) or -C(O)2R8 (so forming, for example, a -CH=CH-COOH group); or
B1, B2, B5 and B6 may alternatively and independently represent =O;
Ra, Rb, Rd, Re and Rf independently represent hydrogen or C1-3 alkyl (e.g. methyl) optionally substituted by one or more substituents selected from -N(Rh)2, -ORh and, preferably, halo (e.g. fluoro);
Rh represents H or C1-2 alkyl (e.g. ethyl or, preferably, methyl);
R3 represents hydrogen, C1-2 alkyl (e.g. methyl) or halo (e.g. fluoro).
Further preferred compounds of the invention include those in which: when:
(I) Z represents -N(R3)- or -NH-CO- (which compounds of the invention are particularly preferred), then preferably:
M represents a direct bond or C1-3 alkylene as defined herein; R1 is hereinbefore defined;
X is direct bond, -O-, -CO-N(H)-, -NHSO2-
(II) Z represents -S-, then preferably: M represents a direct bond;
R1 represents aryl (e.g. phenyl) optionally substituted as defined herein; X represents -NH-;
(III) Z represents -O-, then preferably:
M represents a direct bond or C1-3 alkylene as defined herein, R1 represents -CO2H or an amide thereof (i.e. -C(O)N(Rh)2), C1-3 alkyl or aryl (e.g. phenyl), which latter two groups are optionally substituted as hereinbefore defined; X represents -NH- or a direct bond; (IV) Z represents a direct bond, then, preferably: M represents C1-3 alkylene as defined herein (e.g. ethynylene); R1 represents aryl as defined herein; R2 represents halo (e.g. iodo), heterocycloalkyl, aryl or heteroaryl, all of which are as defined herein; X represents -N(H)- or a direct bond.
Preferred R2 groups that may be mentioned include those in which: when R2 represents aryl, naphthyl (which group is preferably unsubstituted; e.g. unsubstituted 2-naphthyl) or, preferably, unsubstituted phenyl, (3- trifluoromethyl)phenyl, 3-cyanophenyl, 3-fluorophenyl, 3,5-difluorophenyl, 4- cyanophenyl, 4-trifluoromethylphenyl, 3-acetylphenyl, 3-aminophenyl, 4- aminophenyl, (3-chloro-4-fluoro)phenyl, 3-methanesulfonylphenyl, (4- trifluoromethoxy)phenyl, 4-hydroxyphenyl, (4-acrylic acid)phenyl, 4- carboxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl and 3-chloro-4- fluorophenyl; when R2 represents heteroaryl, thienyl (e.g. 2- or 3-thienyl) or, preferably, pyrazolyl (such as 1-methyl-4-pyrazolyl), indolyl (such as 5-indolyl or 2-indolyl), 5- methoxy-3-pyridyl and 6-methoxy-3-pyridyl; when R2 represents C1-8 alkyl, C3.6 cycloalkyl or heterocyclalkyl (e.g. a monocyclic 5- or 6-membered heterocycloalkyl group, containing one or two heteroatoms selected from nitrogen and/or oxygen), ethyl, cyclohexyl, carboxy-methyl and 4- morpholinyl.
More preferred compounds of the invention include those in which: B1 to B7 substituents independently represent -N(H)-C(O)CH3, -N(CH3)2| -C(O)N(H)-CH2CH2-N(CH3)2, C(O)N(CH3)2, -C(O)N(H)-CH2CH2-OH or, preferably, trifluoromethyl, -CN, halo (e.g. fluoro or chloro), -COOH, -C(O)CH3, -NH2, -OH, -S(O)2NH2, -S(O)2CH3, -OCF3, -CH3, -OCH3, -CF3, -CH=CH-COOH, and, if applicable, =O;
A1 represents halo or, more preferably, -ORe;
A3 represents -CO2Re, -N(Re)-C(O)-Re (e.g. -N(H)-C(O)-CH3) or phenyl optionally substituted by -ORe; B1 represents -OH; B2 represents methyl or =O;
B3 represents -SO2NH2, fluoro, -OCH3, chloro, -C(O)CH3; B4 represents methyl;
B7 represents -N(H)-C(O)CH3, -OCH3, -N(CH3)2, -C(O)N(H)-CH2CH2-N(CH3)2, C(O)N(CH3)2, -C(O)N(H)-CH2CH2-OH or, preferably, F, Cl, -CF3, -CN, -OCF3, -C(O)CH3, -NH2, -C(O)2H, -S(O)2CH3, -OH, -CH=CH-COOH; B8 represents -CH3, -OCH3; Ra represents hydrogen.
Particularly preferred compounds of the invention include those in which:
Z represents -(CH2)n-O- or, preferably, a direct bond or -(CH2)n-N(Ra)-;
M represents a direct bond or C1-2 alkylene, which is preferably unsubstituted
(e.g. -(CH2)2- or, preferably, -CH2-);
R1 represents C1-6 (e.g. C1-4) alkyl (optionally substituted by one or more substituents selected from A1) or, R1 preferably represents C3-6 (e.g. C3-5) cycloalkyl (e.g. cyclopropyl) or aryl (e.g. phenyl), optionally substituted by one or more substituents selected from B3;
X represents -(CH2)m-N(Rd)-, -(CH2)m-C(O)-N(Rd)-, C1-2 alkylene, which is preferably unsubstituted (e.g. -CH2-), or, X more preferably represents a direct bond; m represents 0 (e.g. when X represents -(CH2)m-C(O)-N(Rd)-) or 1 (e.g. when X represents -(CH2)m-N(Rd)-);
Rd represents hydrogen or, preferably, C1-2 alkyl (e.g. methyl) (e.g. when X represents -(CH2)m-N(Rd)- or -(CH2)m-C(O)-N(Rd)-); R2 represents hydrogen, preferably, halo (e.g. iodo) or, more preferably, -T-Q;
T represents unsubstituted C1-2 alkylene (e.g. -CH2-CH2- or -CH2-) or, preferably, a direct bond;
T preferably represents a direct bond when X represents a direct bond;
Q represents heterocycloalkyl (e.g. morpholinyl, such as 4-morpholinyl) or, Q more preferably represents aryl (e.g. naphthyl or, preferably, phenyl) optionally substituted by one or more substituents selected from B7, or, heteroaryl (e.g. thienyl, such as 2- or 3-thienyl, pyrazolyl, such as 4-pyrazolyl, or, more preferably, indolyl, such as 6-indolyl, or pyridyl, such as 4-pyridyl or, preferably, 3-pyridyl) optionally substituted by one or more substituents selected from B8; B1 to B8 independently represent -N(Re)-C(O)Re, preferably, -CN, -C(O)N(Re)2, -ORe, -N(Re)2, or, more preferably, halo (e.g. fluoro or chloro), -C(O)R6 or C1-2 alkyl (e.g. methyl) optionally substituted by -ORe;
Re represents hydrogen or C1-3 alkyl (e.g. ethyl or, preferably, methyl), optionally substituted (e.g. at the terminal position) with one or more (e.g. one) substituent selected from -N(Rh)2 and, preferably -ORh (but which alkyl group is preferably unsubstituted); most preferably, Re represents hydrogen or methyl; R3 represents halo (e.g. chloro), Rf or, preferably, hydrogen; Rf represents C1-3 (e.g. C1-2) alkyl (such as methyl);
Rh represents hydrogen (e.g. when appended to an oxygen atom, i.e. in the case of -ORh) or C1-2 alkyl such as methyl (e.g. when appended to a nitrogen atom, i.e. in the case of -N(Rh)2).
Further preferred compounds of the invention include those in which:
B3 represents halo (e.g. fluoro or chloro);
B7 represents -N(Re)-C(O)Re (e.g. -N(H)-C(O)CH3) or, preferably, halo (e.g. chloro or fluoro), -CN, -C(O)Re (e.g. -C(O)CH3), -ORe (e.g. -OH, -OCH3 Or -OCF3),
-N(Re)2 (e.g. -N(CH3)2) or -C(O)N(Re)2 (e.g. -C(O)N(H)-CH2CH2-N(CH3)2 or, preferably, C(O)N(CH3)2 or -C(O)N(H)-CH2CH2-OH);
B8 represents -ORe (e.g. -OH, -OCF3 or, preferably, -OCH3).
Preferred Z groups include a direct bond, -N(H)-, -N(CH3)- and -O-.
Preferred "-M-R1" groups include: phenyl (e.g. unsubstituted phenyl, 4-fluorophenyl or 4-methoxyphenyl);
C1-6 part cyclic alkyl (e.g. cyclopropylmethyl); optionally substituted C1-6 (e.g. C1-2) alkyl such as ethyl (e.g. methoxyethyl or phenoxyethyl), isobutyl, methyl (for example, -M-R1 represents methyl when Z represents -N(CH3)-) or methyl substituted by phenyl (e.g. benzyl, such as 3,4- dichlorobenzyl, 4-fluorobenzyl, 2-methylbenzyl4-methoxybenzyl, 4- dimethylaminobenzyl) or heteroaryl (e.g. thienyl, furanyl or pyridyl);
C5-6 cycloalkyl (e.g. cyclohexyl);
5- or 6-membered heterocycloalkyl (e.g. containing one or two heteroatoms, e.g. tetrahydropyranyl (e.g. 4-tetrahydropyranyl)); 5- or 6-membered heteroaryl, e.g. pyridyl, furanyl or thienyl; hydrogen (e.g. when Z represents -N(H)-).
Preferred "-X-R2" groups include: pyridyl (e.g. 3-pyridyl, 6-methoxypyrid-3-yl, 5-methoxy-3-pyridyl, 4-pyridyl); indolyl (e.g. 6-indolyl); phenyl (e.g. unsubstituted phenyl, 3-acetylphenyl (i.e. 3-(C(O)CH3)-phenyl), 4-
(hydroxymethyl)phenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4- methoxyphenyl, 3,4-dimethoxyphenyl, 3-(dimethylamino)phenyl, 4-acet- amidophenyl, 3-acetamidophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3-trifluoromethoxyphenyl, 3-chloro-4-fluorophenyl, 3- trifluoromethylphenyl, 3-methoxy-4-hydroxyphenyl, 4-cyanophenyl, 3,5-dimethyl-
4-hydroxyphenyl, 3-(dimethylamido)phenyl, 3-[-C(O)N(H)-CH2-CH2-N(CH3)2]- phenyl and 4-[-C(O)N(H)-CH2-CH2-OH]-phenyl); naphthyl (e.g. 2-naphthyl); thienyl (e.g. 2-thienyl and 3-thienyl); pyrazolyl (e.g. 1-methyl-4-pyrazolyl); morpholinylmethyl (e.g. 4-morphoiinylmethyl);
-CH2-N(CH3)-CH2-CH2-phenyl; -C(O)-N(CH3)-CH2-phenyl; and
-CH2-N(H)-phenyl (e.g. -CH2-N(H)-(3-acetylphenyl), -CH2-N(H)-(3,4- dimethoxyphenyl) and -CH2-N(H)-(3-chloro-4-fluorophenyl)).
Particularly preferred compounds of the invention include those of the examples described hereinafter.
Compounds of the invention may be made in accordance with techniques that are well known to those skilled in the art, for example as described hereinafter.
According to a further aspect of the invention there is provided a process for the preparation of a compound of formula I which process comprises:
(i) for compounds of formula I in which X represents a direct bond, and R2 represents optionally substituted C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, or for compounds of formula I in which X represents a C1-8 alkylene linker group and R2 is as hereinbefore defined, reaction of a corresponding compound of formula II,
Figure imgf000028_0001
wherein L1 represents a suitable leaving group, such as iodo, bromo, chloro or a sulfonate group (e.g. -OS(O)2CF3, -OS(O)2CH3 or -OS(O)2PhMe), and Z, M, R1, B and R3 are as hereinbefore defined, with a compound of formula III,
L2-χa-R2a in
or a compound of formula IV,
L2-Xb-R2 IV
respectively, wherein L2 represents a suitable group such as -B(OH)2, -B(OR1^)2 or -Sn(R^)3, in which each R^ independently represents a C1-6 alkyl group, or, in the case of -B(OR^)2, the respective R^ groups may be linked together to form a 4- to 6-membered cyclic group (such as a 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl group), Xa represents a direct bond, R2a represents C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryi or heterocycloalkyl, all of which are optionally substituted as hereinbefore defined, Xb represents C1-8 alkylene optionally substituted as hereinbefore defined in the definition of X, and R2 is as hereinbefore defined. This reaction may be performed, for example in the presence of a suitable catalyst system, e.g. a metal (or a salt or complex thereof) such as CuI, Pd/C, PdCl2, Pd(OAc)2, Pd(Ph3P)2Cl2, Pd(Ph3P)4 (i.e. palladium tetrakistriphenylphosphine), Pd2(dba)3 or NiCl2 and a ligand such as f-Bu3P, (C6Hn)3P, Ph3P, AsPh3, P(O-ToI)3, 1 ,2-bis(diphenylphosphino)ethane, 2,2'-bis(di- førf-butylphosphino)-1,1'-biphenyl, 2,2'-bis(diphenylphosphino)-1 ,1'-bi-naphthyl, 1 , 1 '-bis(diphenyl-phosphino-ferrocene), 1 ,3-bis(diphenylphosphino)propane, xantphos, or a mixture thereof, together with a suitable base such as, Na2CO3, K3PO4, Cs2CO3, NaOH, KOH, K2CO3, CsF, Et3N, (/-Pr)2NEt, f-BuONa or £-BuOK (or mixtures thereof) in a suitable solvent such as dioxane, toluene, ethanol, dimethylformamide, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, N-methylpyrrolidinone, tetrahydrofuran or mixtures thereof. The reaction may also be carried out for example at room temperature or above (e.g. at a high temperature such as the reflux temperature of the solvent system). The reaction may also be carried out under microwave irradiation reaction conditions, for example at elevated temperature (e.g. at above 100°C, such as at about 135 to 140°C). Alternative L2 groups that may be mentioned include alkali metal groups (e.g. lithium) and halo groups, which may be converted to a magnesium halide (i.e. a Grignard reagent), in which the magnesium may undergo a 'trans-metallation' reaction, thereby being exchanged with, for example, zinc. The skilled person will appreciate that various compounds of formula I in which the groups as defined by -Z-M-R1 represent similar moieties may also be prepared in a similar manner;
(ii) for compounds of formula I in which X represents -O-, -S- or -N(Rd)-, reaction of a compound of formula Il as hereinbefore defined, with a compound of formula V,
HXC-R2 V
wherein Xc represents -O-, -S- or -N(Rd)-, and R2 is as hereinbefore defined, for example optionally in the presence of an appropriate metal catalyst (or a salt or complex thereof) such as Cu, Cu(OAc)2, CuI (or Cul/diamine complex), copper tris(triphenyl-phosphine)bromide, Pd(OAc)2, Pd2(dba)3 or NiCl2 and an optional additive such as Ph3P, 2,2'-bis(diphenylphosphino)-1 ,1'-binaphthyl, xantphos, NaI or an appropriate crown ether such as 18-crown-6-benzene, in the presence of an appropriate base such as NaH, Et3N, pyridine, N.N-dimethylethylenediamine, Na2CO3, K2CO3, K3PO4, Cs2CO3, f-BuONa or f-BuOK (or a mixture thereof, optionally in the presence of 4A molecular sieves), in a suitable solvent (e.g. dichloromethane, dioxane, toluene, ethanol, isopropanol, dimethylformamide, ethylene glycol, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, N-methylpyrrolidinone, tetrahydrofuran or a mixture thereof). This reaction may be carried out under microwave irradiation reaction conditions, for example a described in process step (i) above. Alternatively, the reaction may be performed as described herein, under such microwave irradiation reaction conditions, but in the absence of other reagents such as catalyst, base and even solvent (i.e. the reaction mixture may contain only compound of formula Il and compound of formula IVA);
(iii) for compounds of formula 1 in which Z represents -(CH2)n-N(Ra)- or -(CH2)n-O-, M represents a direct bond, and R1 represents optionally substituted aryl, heteroaryl or, preferably, C1-8 alkyl, C3-6 cycloalkyl or heterocycloalkyl, reaction of a corresponding compound of formula I in which Z represents -(CH2)n-N(Ra)- or -(CH2)n-O-, M represents a direct bond, and R1 represents H, with a compound of formula Vl,
R1a-L1 Vl
wherein L1 is as hereinbefore defined, and R1a represents aryl, heteroaryl or, preferably, C1-8 alkyl, C3-6 cycloalkyl or heterocycloalkyl, all of which are optionally substituted as hereinbefore defined in respect of corresponding R1 substituents, for example at around room temperature or above in the presence of a suitable base (e.g. pyridine, triethylamine, dimethylaminopyridine, diisopropylamine, sodium hydroxide, or mixtures thereof), an appropriate solvent (e.g. pyridine, dichloromethane, chloroform, tetrahydrofuran, dimethylformamide, triethylamine, dimethylsulfoxide, water or mixtures thereof) and, in the case of biphasic reaction conditions, optionally in the presence of a phase transfer catalyst. The skilled person will appreciate that the -(CH2)n-N(Ra)- group, e.g. when Ra represents hydrogen, may need to be protected (and subsequently deprotected) in order to effect this transformation. Further, the skilled person will also appreciate which values of R1 in compounds of formula Vl (in obtaining compounds of formula I) would be suitable in such a process step;
(iv) for compounds of formula I in which Z represents -O-, -S- or -(CH2)n-N(Ra)- in which n represents 0, reaction of a compound of formula VII,
Figure imgf000030_0001
wherein L1, B1 X, R2 and R3 are as hereinbefore defined, with a compound of formula VIII1
H-Za-M-R1 VIII
wherein Za represents -O-, -S- or -N(Ra)-, and Ra, R1 and M are as hereinbefore defined, under standard conditions, for example, such as those hereinbefore described in respect of process step (i) or (ii) above (preferably process step (ii) above);
(v) for compounds of formula I in which Z represents a direct bond and M represents C1-8 alkylene optionally substituted as hereinbefore defined, reaction of a compound of formula VII as hereinbefore defined, with a compound of formula IX,
L1-Ma-R1 IX
wherein Ma represents C1-8 alkylene optionally substituted by one or more substituents selected from halo, -ORb, -SRb and -N(Rb)2, and R1 and L1 are as hereinbefore defined, for example under reaction conditions such as those hereinbefore described in respect of process step (i);
(vi) compounds of formula I in which B, Z or X represents -S(O)- or -S(O)2 may be prepared by oxidation of a corresponding compound of formula I in which B, Z or X represents -S-, under standard conditions, for example in the presence of a suitable oxidising agent, such as KMnO4 or mefø-chloroperbenzoic acid (mCPBA), optionally in the presence of a suitable solvent;
(vii) compounds of formula I in which Z represents -NHS(O)2, -NHC(O)- or -NHC(O)NH- may be prepared by reaction of a corresponding compound of formula I in which Z represents -N(Ra)-, Ra represents H1 M represent a direct bond and R1 represents hydrogen, with a compound of formula X,
L1-Q1-M-R1 X wherein L1 is as hereinbefore defined and preferably represents chloro, Q1 represents -S(O)2-, -C(O)- or -C(O)NH-, and M and R1 are as hereinbefore defined, under standard reaction conditions, for example such as those hereinbefore described in respect of process step (iii) above. The skilled person will appreciate that similar groups defined by X in the compound of formula I may also be prepared in a similar manner;
(viii) compounds of formula I in which X represents -NH- and R2 represents optionally substituted C1-8 alkyl, may be prepared by the reductive amination of a corresponding compound of formula I in which X represents -NH- and R2 represents hydrogen, with a compound of formula Xl,
R2b-CHO Xl
wherein R2b represents C1-7 alkyl optionally substituted by one or more substituents selected from A3, and A3 is as hereinbefore defined, under standard reaction conditions, for example in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride, optionally in the presence of a suitable solvent such as an alcohol (e.g. ethanol or methanol);
(ix) compounds of formula I in which X represents -CH2-NH- may be prepared by a reductive amination of a compound of formula XII,
Figure imgf000032_0001
wherein Z, M, R1, B and R3 are as hereinbefore defined, with a compound of formula XIII1
R2-NH2 XIII
wherein R2 is as hereinbefore defined, for example under conditions such as those described hereinbefore in respect of process step (viii) above; (x) for compounds of formula I in which X represents -CH2-N(Rd)- and R2 represents hydrogen or optionally substituted C1-β alkyl, provided that at least one of R2 and Rd is other than hydrogen (so forming a secondary or tertiary amine), or, for compounds of formula I in which -X-R2 represents -CH2-heterocycloalkyl, in which the heterocycloalkyl group is attached to the relevant -CH2- moiety via a nitrogen atom of the heterocycloalkyl group (so forming a tertiary amino moiety; for example -CH2-[4-morpholinyl]), reaction of a compound of formula XIIIA,
Figure imgf000033_0001
wherein Z, M, R1, B and R3 are as hereinbefore defined, with formaldehyde and a compound of formula XIIIB,
Xd-R2d XIIIB
wherein Xd represents -N(Rd)- and R2d represents hydrogen or C1-8 alkyl (optionally substituted by one or more substituents selected from A3), provided that at least one of Rd and R2d is other than hydrogen (so forming a secondary or tertiary amine), or with a compound of formula XIIIC,
heta XIIIC
wherein heta represents a heterocycloalkyl group containing a -N(H)- moiety that is integral to the cyclic group (e.g. morphline, piperidine, pyrrolidine, etc), i.e. a secondary amino group, both of which may be performed under reaction conditions known to those skilled in the art, for example in the presence of glacial acetic acid and an appropriate solvent (e.g. an alcohol, such as methanol), which is preferably dry, under an inert atmosphere;
(xi) compounds of formula I in which X represents -CH2-O- and R2 represents hydrogen may be prepared by reduction of a corresponding compound of formula XII as hereinbefore defined, in the presence of a suitable reducing agent, for example, a borohydride such as NaBH4, LiBH4 or LiAIH4, in the presence of a suitable solvent, e.g. an alcohol (e.g. methanol or ethanol);
(xii) compounds of formula I in which X represents -(CH2)m-C(O)N(Rd)- may be prepared by reaction of a compound corresponding to a compound of formula I but in which -X-R2 represents -(CH2)m-C(O)OH with a compound of formula XIV,
H(Rd)N-R2 XIV
wherein Rd and R2 are as hereinbefore defined, under standard amide coupling reaction conditions, for example in the presence of a suitable coupling reagent (e.g. 1 ,1 '-carbonyldiimidazole, N./V-dicyclohexylcarbodiimide, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof) or N1N1- disuccinimidyl carbonate), optionally in the presence of a suitable base (e.g. sodium hydride, sodium bicarbonate, potassium carbonate, pyridine, triethylamine, dimethylaminopyridine, diisopropylamine, sodium hydroxide, potassium tert-butoxide and/or lithium diisopropylamide (or variants thereof) and an appropriate solvent (e.g. tetrahydrofuran, pyridine, toluene, dichloromethane, chloroform, acetonitrile, dimethylformamide, trifluoromethylbenzene, dioxane or triethylamine). Alternatively, the carboxylic acid group may be converted under standard conditions to the corresponding acyl chloride (e.g. in the presence of SOCl2 or oxalyl chloride), which acyl chloride is then reacted with a compound of formula XIV, for example under similar conditions to those mentioned above;
(xiii) for compounds of formula I in which there is a -CH2- group present, reduction of a corresponding compound of formula I in which there is a -C(OH)- group present, for example, in the presence of a suitable silicon based reducing agent such as (CH3)2SiCl2 and optionally in the presence of an additive such as NaI;
(xiv) for compounds of formula I in which X represents methylene substituted by -OH, and R2 represents optionally substituted C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, reaction of a compound of formula XII as defined above with a compound of formula XV,
R2a-M1 XV wherein M1 represents an appropriate alkali metal group (e.g. sodium, potassium or, especially, lithium), a -Mg-halide or a zinc-based group (e.g. a zinc halide group) and R2a is as hereinbefore defined, i.e. R2a represents C1-8 alkyl (optionally substituted by one or more A3 substituents), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B5 and B6, respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B7 and B8, respectively), under appropriate reaction conditions, for example under an inert atmosphere, in the presence of a suitable anhydrous solvent (e.g. an anhydrous polar aprotic solvent such a tetrahydrofuran, diethyl ether and the like);
(xv) compounds of formula I in which there is a -NH2 group present (e.g. when "-X-R2" or "-Z-M-R1" represent -NH2) may be prepared by the reduction of a corresponding compound of formula I in which there is a -NO2 group present, under standard reaction conditions known to those skilled in the art, for example in the presence of a suitable reducing agent, for example reduction by catalytic hydrogenation (e.g. in the presence of a palladium catalyst in a source of hydrogen) or employing an appropriate reducing agent (such as trialkylsilane, e.g. triethylsilane). The skilled person will appreciate that where the reduction is performed in the presence of a -C(O)- group (e.g. when T represents -C(O)-), a chemoselective reducing agent may need to be employed;
(xvi) compounds of formula I in which -X-R2 represents -C(O)OH, may be prepared by oxidation of a corresponding compound of formula XII as hereinbefore defined, in the presence of a suitable oxidising agent such as a peroxide (e.g. f-butylhydroperoxide);
(xvii) compounds of formula I in which X represents -(CH2)m-S(O)2N(H)- may be prepared by reaction of a compound corresponding to a compound of formula I but in which -X-R2 represents -(CH2)m-S(O)2OH (or an activated derivative thereof; see process step (xii) above), with a compound of formula XIV as hereinbefore defined but in which Rd represents hydrogen, for example under reaction conditions hereinbefore described in respect of process step (xii) above. Compounds of formula Ii in which L1 represents halo, may be prepared by reaction of a corresponding compound of formula XIIIA, with a source of halide ions, for instance an electrophile that provides a source of iodide ions includes iodine, diiodoethane, diiodotetrachloroethane or, preferably, W-iodosuccinimide, a source of bromide ions includes N-bromosuccinimide and bromine, and a source of chloride ions includes N-chlorosuccinimide, chlorine and iodine monochloride. Compounds of formula Il in which R3 represents halo (and L1 preferably represents halo) may be prepared from a corresponding compound of formula Il in which R3 represents hydrogen, using the above-mentioned compounds that provide a source of halide ions, under standard reaction conditions.
Other compounds of formula Il may also be prepared under standard conditions, for instance such as those described herein. For example, for synthesis of compounds of formula Il in which L1 represents a sulfonate group, reaction of a compound corresponding to a compound of formula Il but in which L1 represents -OH with an appropriate sulfonyl halide, under standard reaction conditions, such as in the presence of a base (e.g. as hereinbefore described in respect of preparation of compounds of formula I (process step (iii)).
Compounds corresponding to a compound of formula I but in which -X-R2 represents -(CH2)m-S(O)2OH, may be prepared by reaction of a corresponding compound of formula XIIIA, in the presence of an appropriate reagent for the introduction of the sulfonic acid group, e.g. oleum (or the like).
Compounds of formula XII may be prepared by reaction of a corresponding compound of formula XIIIA, with dimethylformamide, under standard conditions, and optionally in the presence of POCI3 (so forming for example, a Vilsmeir- Haack reagent), oxalyl chloride, phosgene or the like, in optionally in the presence of a further solvent other than DMF (e.g. dichloromethane).
Compounds of formula XIIIA in which R3 represents hydrogen or C1-4 alkyl optionally substituted by one or more halo atoms, reaction of a compound of formula XVI,
Figure imgf000037_0001
wherein Z, M, R1 and B are as hereinbefore defined, with a compound of formula XVII,
CI-CH2-C(O)-R33 XVII
wherein R3a represents hydrogen or C1-4 alkyl optionally substituted by one or more halo atoms, under standard conditions known to those skilled in the art. For example, the compound of formula XVII may already be present in water, and hence, the reaction may be performed in the presence of water as a solvent, optionally in the presence of a further solvent, such as an alcohol (e.g. n-butanol), for example at room temperature or, preferably, elevated temperature such as at reflux.
Compounds of formula XVI in which Z represents -(CH2)n-N(Ra)-, Ra represents hydrogen, n represents 0, M represents a direct bond and R1 represents hydrogen, may be prepared by intramolecular reaction of a compound of formula XVIII,
H2N-C(S)-NH-NH-C(S)-NH2 XVIII
for example, under standard conditions, e.g. in the presence of an activating group such as dicyclohexylcarbodiimide (DCC) or, preferably, 1-ethyl-3-(3- dimethyllaminopropyl)carbodiimide hydrochloride (EDCHCI), optionally in the presence of hydrogen peroxide (e.g. 50% H2O2).
Compounds of formula XV may be prepared by reaction of a corresponding compound of formula XIX,
R2aLx XIX wherein Lx represents halo, and R2a is as hereinbefore defined, by, in the case of the formation of a compound of formula XV in which:
(i) M1 represents a -Mg-halide, employing magnesium or a suitable reagent such as a mixture of C1-6 alkyl-Mg-halide and ZnCl2 or LiCI, under standard Qrignard conditions known to those skilled in the art (e.g. optionally in the presence of a catalyst (e.g. FeCI3));
(ii) M1 represents lithium, forming the corresponding lithiated compound under halogen-lithium exchange reaction conditions known to those skilled in the art (e.g. employing n-BuLi or f-BuLi in the presence of an anhydrous suitable solvent (e.g. a polar aprotic solvent such as THF)).
The skilled person will also appreciate that the magnesium of the Grignard reagent or the lithium of the lithiated species may be exchanged to a different metal (i.e. a transmetallation reaction may be performed), for example to zinc (e.g. using ZnCl2), so forming for example, the corresponding compound of formula XV in which M1 represent a zinc-based group.
Compounds of formula XVI may be prepared by reaction of a corresponding compound of formula XX,
Figure imgf000038_0001
wherein L1 and B are as hereinbefore defined, with a compound of formula VIII or IX as hereinbefore defined, for example under reaction conditions such as those hereinbefore described in respect of preparation of compounds of formula I (process steps (iv) and (v)).
Compounds of formula XX in which L1 represents halo, may be prepared by reaction of a corresponding compound of formula XXI,
Figure imgf000038_0002
wherein B is as hereinbefore defined, in the presence of a source of halide ions (e.g. in the case of bromide ions, bromine), such as those described hereinbefore in respect of preparation of compounds of formula II, for instance, in the presence of a suitable solvent, such as an alcohol (e.g. methanol) optionally in the presence of a suitable base, such as a weak inorganic base, e.g. sodium bicarbonate.
Compounds of formulae III, IV1 V, VII, IX, X, Xl, XIII, XIV, XVI, XVII, XVIII, XIX,
XXI (as well as some compounds of formula II, Vl, VIII1 XII and XX) are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. Further, the skilled person will appreciate that where reactions to introduce the "-Z-M-R1" moiety of compounds of formula I is described, similar reactions may be performed to introduce the "-X-R2" moiety in compounds of formula I and vice versa. Further, processes to prepare compounds of formula I may be described in the literature, for example in:
Werber.G. et al.; J. Heterocycl. Chem.; EN; 14; 1977; 823-827; Andanappa K. Gadad et al. Bioorg. Med. Chem. 2004, 12, 5651-5659;
Paul Heinz et al. Monatshefte fur Chemie, 1977, 108, 665-680;
MA El-Sherbeny et al. Boll. Chim. Farm. 1997, 136, 253-256;
Nicolaou, K. C; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 2-49;
Bretonnet et al. J. Med. Chem. 2007, 50, 1872 ; Asuncion Marin et al. Farmaco 1992, 47 (1), 63-75;
Severinsen, R. et al. Tetrahedron 2005, 61, 5565-5575;
Nicolaou, K. C; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 2-49;
M. Kuwahara et al., Chem. Pharm Bull., 1996, 44, 122;
Wipf, P.; Jung, J.-K. J. Org. Chem. 2000, 65(20), 6319-6337; Shintani, R.; Okamoto, K. Org. Lett. 2005, 7 (21), 4757-4759;
Nicolaou, K. C; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 2-49;
J. Kobe et al., Tetrahedron, 1968, 24, 239 ;
P.F. Fabio, A.F. Lanzilotti and S.A. Lang, Journal of Labelled Compounds and
Pharmaceuticals, 1978, 15, 407; F.D. Bellamy and K. Ou, Tetrahedron Lett, 1985, 25, 839; M. Kuwahara et al., Chem. Pharm Bull., 1996, 44, 122;
A. F. Abdel-Magid and CA Maryanoff. Synthesis, 1990, 537;
M. Schlosser et al. Organometallics in Synthesis. A Manual, (M. Schlosser, Ed.),
Wiley &Sons Ltd: Chichester, UK, 2002, and references cited therein; L. Wengwei et al. , Tetrahedron Lett. , 2006, 47, 1941 ;
M. Plotkin et al. Tetrahedron Lett., 2000, 41, 2269;
Seyden-Penne, J. Reductions by the Alumino and Borohydrides, VCH, NY, 1991;
O. C. Dermer, Chem. Rev., 1934, 14, 385;
N. Defacqz, et al., Tetrahedron Lett., 2003, 44, 9111 ; SJ. Gregson et al., J. Med. Chem., 2004, 47, 1161;
A. M. Abdel Magib, et al., J. Org. Chem., 1996, 61, 3849;
A. F. Abdel-Magid and CA Maryanoff. Synthesis, 1990, 537;
T. lkemoto and M. Wakimasu, Heterocycles, 2001, 55, 99;
E. Abignente et al., Il Farmaco, 1990, 45, 1075; T. lkemoto et al., Tetrahedron, 2000, 56, 7915;
T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Wiley,
NY1 1999;
S. Y. Han and Y.-A. Kim. Tetrahedron, 2004, 60, 2447;
J. A. H. Lainton et al., J. Comb. Chem., 2003, 5, 400; or Wiggins, J. M. Synth. Commun., 1988, 18, 741.
The substituents Z, M, R1, X, R2 and B in final compounds of the invention or relevant intermediates may be modified one or more times, after or during the processes described above by way of methods that are well known to those skilled in the art. Examples of such methods include substitutions, reductions, oxidations, alkylations, acylations, hydrolyses, esterifications, etherifications, halogenations or nitrations. Such reactions may result in the formation of a symmetric or asymmetric final compound of the invention or intermediate. The precursor groups can be changed to a different such group, or to the groups defined in formula I1 at any time during the reaction sequence. For example, in cases in which R1 represents an ester of -CO2H, the skilled person will appreciate that at any stage during the synthesis (e.g. the final step), the relevant ester group may be hydrolysed to form a carboxylic acid functional group. Compounds of the invention bearing a carboxyester functional group may be converted into a variety of derivatives according to methods well known in the art to convert carboxyester groups into carboxamides, N-substituted carboxamides, N,N-disubstituted carboxamides, carboxylic acids, and the like. The operative conditions are those widely known in the art and may comprise, for instance in the conversion of a carboxyester group into a carboxamide group, the reaction with ammonia or ammonium hydroxide in the presence of a suitable solvent such as a lower alcohol, dimethylformamide or a mixture thereof; preferably the reaction is carried out with ammonium hydroxide in a methanol/dimethylformamide mixture, at a temperature ranging from about 50°C to about 100°C. Analogous operative conditions apply in the preparation of N- substituted or N,N-disubstituted carboxamides wherein a suitable primary or secondary amine is used in place of ammonia or ammonium hydroxide. Likewise, carboxyester groups may be converted into carboxylic acid derivatives through basic or acidic hydrolysis conditions, widely known in the art. Further, amino derivatives of compounds of the invention may easily be converted into the corresponding carbamate, carboxamido or ureido derivatives.
Compounds of the invention may be isolated from their reaction mixtures using conventional techniques (e.g. recrystallisations).
It will be appreciated by those skilled in the art that, in the processes described above and hereinafter, the functional groups of intermediate compounds may need to be protected by protecting groups.
The protection and deprotection of functional groups may take place before or after a reaction in the above-mentioned schemes.
Protecting groups may be removed in accordance with techniques that are well known to those skilled in the art and as described hereinafter. For example, protected compounds/intermediates described herein may be converted chemically to unprotected compounds using standard deprotection techniques.
The type of chemistry involved will dictate the need, and type, of protecting groups as well as the sequence for accomplishing the synthesis. The use of protecting groups is fully described in "Protective Groups in Organic Synthesis", 3rd edition, T.W. Greene & P.G.M. Wutz, Wiley-lnterscience (1999).
Medical and Pharmaceutical Uses
Compounds of the invention are indicated as pharmaceuticals. According to a further aspect of the invention there is provided a compound of the invention, as hereinbefore defined but without provisos (a), (c), (d), (e), (g) and (j) to (o), for use as a pharmaceutical.
Compounds of the invention may inhibit protein kinases, such as CDK-2, SRC, GSK-3, and in particular may inhibit PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3, for example as may be shown in the tests described below and/or in tests known to the skilled person. Thus, the compounds of the invention may be useful in the treatment of those disorders in an individual in which the inhibition of such protein kinases (e.g. a PIM family kinase such as PIM-1 and/or PIM-2) is desired and/or required.
The term "inhibit" may refer to any measurable reduction and/or prevention of catalytic protein kinase (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1, PIM-2 and/or PIM-3) activity. The reduction and/or prevention of protein kinase activity may be measured by comparing the protein kinase activity in a sample containing a compound of the invention and an equivalent sample of protein kinase (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3- K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) in the absence of a compound of the invention, as would be apparent to those skilled in the art. The measurable change may be objective (e.g. measurable by some test or marker, for example in an in vitro or in vivo assay or test, such as one described hereinafter, or otherwise another suitable assay or test known to those skilled in the art) or subjective (e.g. the subject gives an indication of or feels an effect).
Compounds of the invention may be found to exhibit 50% inhibition of a protein kinase (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PlM family kinase such as PIM-1 , PIM-2 and/or PIM-3) at a concentration of 100 μM or below (for example at a concentration of below 50 μM, or even below 10 μM), when tested in an assay (or other test), for example as described hereinafter, or otherwise another suitable assay or test known to the skilled person.
Compounds of the invention are thus expected to be useful in the treatment of a disorder in which a protein kinase (and particularly CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) is known to play a role and which are characterised by or associated with an overall elevated activity of that protein kinase (due to, for example, increased amount of the kinase or increased catalytic activity of the kinase). Such disorders include cancer (particularly lymphomas or a cancer as described hereinafter), inflammatory diseases (such as asthma, allergy and Chrohn's disease), immunosuppression (such as transplantation rejection and autoimmune diseases), and other associated diseases. Other associated diseases that may be mentioned (particularly due to the key role of kinases in the regulation of cellular proliferation) include other cell proliferative disorders and/or non- malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
As stated above, the compounds of the invention may be useful in the treatment of cancer. More, specifically, the compounds of the inventiona may therefore be useful in the treatment of a variety of cancer including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate and skin, as well as squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.
Further, the protein kinases (e.g. CDK-2, SRC, GSK-3 or, more particularly, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) may also be implicated in the multiplication of viruses and parasites. They may also play a major role in the pathogenesis and development of neurodegenerative disorders. Hence, compounds of the invention may also be useful in the treatment of viral conditions, parasitic conditions, as well as neurodegenerative disorders.
Compounds of the invention are indicated both in the therapeutic and/or prophylactic treatment of the above-mentioned conditions. ■
According to a further aspect of the present invention, there is provided a method of treatment of a disease which is associated with the inhibition of protein kinase
(e.g. CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as
PIM-1, PIM-2 and/or PIM-3) is desired and/or required (e.g. cancer or another disease as mentioned herein), which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined but without the provisos, to a patient suffering from, or susceptible to, such a condition.
"Patients" include mammalian (including human) patients.
The term "effective amount" refers to an amount of a compound, which confers a therapeutic effect on the treated patient. The effect may be objective (e.g. measurable by some test or marker) or subjective (e.g. the subject gives an indication of or feels an effect).
Compounds of the invention may be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form. Compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like. The type of pharmaceutical formulation may be selected with due regard to the intended route of administration and standard pharmaceutical practice. Such pharmaceutically acceptable carriers may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use.
Such formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice. Otherwise, the preparation of suitable formulations may be achieved non-inventively by the skilled person using routine techniques and/or in accordance with standard and/or accepted pharmaceutical practice.
According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without provisos (a), (c), (d), (e), (g) and Q) to (o), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
Depending on e.g. potency and physical characteristics of the compound of the invention (i.e. active ingredient), pharmaceutical formulations that may be mentioned include those in which the active ingredient is present in at least 1% (or at least 10%, at least 30% or at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e. the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1:99 (or at least 10:90, at least 30:70 or at least 50:50) by weight.
The amount of compound of the invention in the formulation will depend on the severity of the condition, and on the patient, to be treated, as well as the compound(s) which is/are employed, but may be determined non-inventively by the skilled person.
The invention further provides a process for the preparation of a pharmaceutical formulation, as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined but without provisos (a), (c), (d), (e), (g) and (j) to (o), or a pharmaceutically acceptable ester, amide, solvate or salt thereof with a pharmaceutically-acceptable adjuvant, diluent or carrier.
Compounds of the invention may also be combined with other therapeutic agents that are inhibitors of protein kinases (e.g. CDK-2, SRC, GSK-3 or, preferably, PI3- K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3) and/or useful in the treatment of a cancer and/or a proliferative disease. Compounds of the invention may also be combined with other therapies.
According to a further aspect of the invention, there is provided a combination product comprising:
(A) a compound of the invention, as hereinbefore defined but without the provisos (for example without provisos (a), (c), (d), (e), (g) and (j) to (o)); and
(B) another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
Such combination products provide for the administration of a compound of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent).
Thus, there is further provided:
(1 ) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos (for example, without provisos (a), (c), (d), (e), (g) and G) to (o)), another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and a pharmaceutically- acceptable adjuvant, diluent or carrier; and
(2) a kit of parts comprising components: (a) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos (for example without provisos (a), (c), (d), (e), (g) and (j) to (o)), in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
(b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
The invention further provides a process for the preparation of a combination product as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined but without the provisos (for example, without provisos (a), (c), (d), (e), (g) and (j) to (o)), or a pharmaceutically acceptable ester, amide, solvate or salt thereof with the other therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
By "bringing into association", we mean that the two components are rendered suitable for administration in conjunction with each other.
Thus, in relation to the process for the preparation of a kit of parts as hereinbefore defined, by bringing the two components "into association with" each other, we include that the two components of the kit of parts may be: (i) provided as separate formulations (i.e. independently of one another), which are subsequently brought together for use in conjunction with each other in combination therapy; or
(ii) packaged and presented together as separate components of a "combination pack" for use in conjunction with each other in combination therapy. Depending on the disorder, and the patient, to be treated, as well as the route of administration, compounds of the invention may be administered at varying therapeutically effective doses to a patient in need thereof. However, the dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable timeframe. One skilled in the art will recognize that the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by inter alia the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the potency of the specific compound, the age, condition, body weight, sex and response of the patient to be treated, and the stage/severity of the disease.
Administration may be continuous or intermittent (e.g. by bolus injection). The dosage may also be determined by the timing and frequency of administration. In the case of oral or parenteral administration the dosage can vary from about 0.01 mg to about 1000 mg per day of a compound of the invention.
In any event, the medical practitioner, or other skilled person, will be able to determine routinely the actual dosage, which will be most suitable for an individual patient. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of the invention may have the advantage that they are effective inhibitors of protein kinases (such as CDK-2, SRC, GSK-3 or, preferably, PI3-K or a PIM family kinase such as PIM-1 , PIM-2 and/or PIM-3).
Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the above- stated indications or otherwise. Examples/Biological Tests
PIM-1 biochemical assay
The biochemical assay to measure PIM-1 activity relies on the ADP Hunter assay kit (DiscoveRx Corp., Cat. # 90-0077), that determines the amount of ADP as direct product of the kinase enzyme activity.
The enzyme has been expressed and purified in-house as a recombinant human protein with a C-terminal histidine tag. The protein is active and stable.
Assay conditions were as indicated by the kit manufacturers with the following adaptations for the kinase activity step:
• Kinase assay buffer and assay volume stay as recommended (15 mM HEPES, pH 7.4, 20 mM NaCI, 1 mM EGTA, 0.02% Tween 20, 10 mM MgCl2 and 0.1 mg/ml bovine γ-globulins/75 μl assay volume)
• Incubation time and temperature: 60 min at 30°C • PIM-1 concentration: 50 pg/μl
• ATP concentration: 100 μM
• PIM-1 substrate peptide: PIMtide (ARKRRRHPSGPPTA)
• Peptide concentration: 60 μM
• Positive control for kinase activity inhibition: 1-10 μM Staurosporine • DMSO concentration have to stay below 2% during the kinase reaction
Assays were performed in either 96 or 384-well plates. The final outcome of the coupled reactions provided by the kit is the release of the fluorescent product Resorufin and has been measured with a multilabel HTS counter VICTOR V (PerkinElmer) using an excitation filter at 544 nm and an emission filter at 580 nm. PIM-2 biochemical assay
The biochemical assay to measure PIM-2 activity relies on the ADP Hunter assay kit (DiscoveRx Corp., Cat. # 90-0077), that determines the amount of ADP as direct product of the kinase enzyme activity.
The enzyme has been expressed and purified in-house as a recombinant human protein with a N-terminal histidine tag. The protein is active and stable.
Assay conditions were as indicated by the kit manufacturers with the following adaptations for the kinase activity step:
• Kinase assay buffer and assay volume stay as recommended (15 mM HEPES, pH 7.4, 20 mM NaCI, 1 mM EGTA, 0.02% Tween 20, 10 mM MgCl2 and 0.1 mg/ml bovine γ-globulins/20 μl assay volume)
• Incubation time and temperature: 30 min at 30°C
• PIM-2 concentration: 350 pg/μl
• ATP concentration: 100 μM
• PIM-1 substrate peptide: PIMtide (ARKRRRHPSGPPTA) • Peptide concentration: 100 μM
• Positive control for kinase activity inhibition: 1-10 μM Staurosporine
• DMSO concentration have to stay below 2% during the kinase reaction
Assays were performed in either 96 or 384-well plates. The final outcome of the coupled reactions provided by the kit is the release of the fluorescent product Resorufin and has been measured with a multilabel HTS counter VICTOR V (PerkinElmer) using an excitation filter at 544 nm and an emission filter at 580 nm.
The compounds names given above were generated with MDL ISIS/DRAW 2.5 SP 2, Autonom 2000. Examples
The following Examples illustrate the invention.
General experimental conditions Compounds were analyzed on HPLC-MS (Agilent 1100 Series) with ESI+ (API 2000) and equipped with different brands of C18 columns. Analysis of final compounds was performed using RP-C18 Gemini column, (150 x 4.6 mm, 5μm). Elution was done with different gradients of A/B (B = CH3CN + 0.1% formic acid; A = H2O + 0.1 % formic acid) (15 min, flow rate = 1 mL/min). MW calculated is an isotopic average and the "found mass" refers to the most abundant isotope detected in the LC-MS. NMR was recorded in a Bruker Avance Il 300 spectrometer.
Intermediate 1 2-Phenyl-imidazo[2,1-b][1 ,3,4]thiadiazole
To a suspension of 2-amino-5-phenylthiadiazole (1 g, 5.40 mmol) in water (30 mL) was added a water solution of chloroacetaldehyde (50% wt, 1.5 eq, 1 mL). n- Butanol (5 mL) was added in order to solubilize the starting material. The mixture was heated at reflux for 30 hours. After cooling down to room temperature, the mixture was neutralized with sodium bicarbonate (sat. aq. solution) and extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried over sodium sulfate and the solvent evaporated under vacuum. The crude product was purified by flash chromatography (Biotage ™, ethyl acetate:hexane, 3:7 to 7:3) to provide 490 mg of 2-phenyl-imidazo[2,1-b][1,3,4]thiadiazole (45% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ 7.84 (d, J = 5.4 Hz, 2H), 7.75 (s, 1 H), 7.49 (s, 3H),
7.31 (s, 1 H).
MS (ES+) m/z 202 (M+H)+ (MW: 201.2)
Intermediate 2
2-Amino-5-bromo-[1,3,4]thiadiazole
Sodium bicarbonate (8.14 g, 96.90 mmol) and bromine (2.5 mL, 48.45 mmol) were added to a solution of 2-amino-1 ,3,4-thiadiazole (5 g, 48.45 mmol) in methanol (70 mL). The reaction mixture was stirred at room temperature until disappearance of starting material (30-40 minutes). The solvent was removed under vacuum and the crude product was triturated with methanol-diethyl ether to yield 2-amino-5-bromo-[1 ,3,4]thiadiazole as white solid. The mother liquor containing a bit of product was submitted to flash chromatography eluting with dichloromethane-methanol (99% yield). 1H NMR (300 MHz, DMSO-d6): δ 7.52 (br s, 2H). MS (ES+) m/z 181 (M+H)+ (MW: 180.0)
intermediate 3 2-Bromo-imidazo[2,1-b][1,3,4]thiadiazole To a suspension of 2-amino-5-bromo-1 ,3,4-thiadiazoie (1.65 g, 9.15 mmol) in water (27 mL) was added a water solution of chloroacetaldehyde (50% wt, 1.7 mL). The mixture was stirred at reflux. After 10 hours, a second addition of chloroacetaldehyde (1.5 eq, 1.7 mL) was done and stirring was continued until disappearance of starting material (20 hours). After cooling, the reaction mixture was neutralized with sodium bicarbonate (sat. aq. solution) and extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried over sodium sulphate and the solvent evaporated under vacuum. The crude product was triturated with diethyl ether to yield 2-bromo-imidazo[2,1-b][1 ,3,4]thiadiazole as a white solid. The mother liquor was purified by flash chromatography (Biotage ™, ethyl acetate:hexane, 3:7 to 7:3) to yield another batch of compound (20% global yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ 7.64 (s, 1 H), 7.24 (s, 1 H). MS (ES+) m/z 204 (M+H)+ (MW: 204.05).
General procedure A for the preparation of intermediates 4-8
2-Bromo-imidazo[2,1-b][1 ,3,4]thiadiazole (1 eq) and the appropriate amine (e.g. cycloprapanemethyl amine) (4.5 eq) were stirred at 135°C under microwave irradiation (200W) for 5 minutes. After cooling down to room temperature, the reaction mixture was diluted with dichloromethane and purified by flash chromatography (Biotage ™, silica, dichloromethane:methanol) to yield the desired product (e.g. cyclopropylmethyl-imidazoβ.i-bjπ .S^thiadiazol-2-yl- amine). Intermediate 4 Cyclopropylmethyl-imidazo[2,1-b][1,3,4]thiadiazoI-2-yl-amine
The title compound was obtained in 89% yield.
1H NMR (300 MHz, CDCI3): δ 7.27 (brs, 1 H), 7.21 (d, J = 1.3, 1 H), 6.83 (s, 1 H), 3.01 (dd, J = 5.1 , 6.9, 2H), 1.04 - 0.80 (m, 1 H), 0.43 - 0.28 (m, 2H), 0.13 - 0.05 (m, 2H). MS (ES+) m/z 195.10 (M+H)+ (MW: 194.26).
Intermediate 5 (3,4-DichlorobenzyI)-imidazo[2,1-b][1,3,4]thiadiazol-2-yI-amine
The title compound was obtained as a white solid in a 65% yield. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.45 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 1.3 Hz, 1 H), 7.63 (dd, J = 5.0, 3.2 Hz, 2H), 7.37 (dd, J = 8.3, 1.9 Hz, 1 H), 6.99 (d, J = 1.2 Hz, 1 H), 4.50 (d, J = 5.6 Hz, 2H). MS (ES+) m/z 299 (M+H)+ (MW: 299.2).
Intermediate 6 (4-Fluoro-benzyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl-amine
The title compound was obtained in 58% yield. 1H NMR (300 MHz, CDCI3): δ 7.98 (brs, 1H), 7.47 - 7.31 (m, 3H), 7.06 (t, J = 8.7, 2H), 6.63 (d, J = 1.4, 1 H), 4.54 (d, J = 5.2, 2H). MS (ES+) m/z 249.05 (M+H)+ (MW: 248.28).
Intermediate 7 lmidazo[2,1-b][1,3,4]thiadiazol-2-yl-(2-methoxy-ethyl)-amine
The title compound was obtained in 84% yield.
1H NMR (300 MHz, CDCI3): δ 7.67 (brs, 1 H), 7.43 (s, 1 H), 7.06 (s, 1 H), 3.68 -
3.47 (m, 4H), 3.35 (s, 3H).
MS (ES+) m/z 199.10 (M+H)+ (MW: 198.25).
Intermediate 8 lmidazo[2,1-b][1,3,4]thiadiazol-2-yl-isobutyl-amine
The title compound was obtained in 89% yield. 1H NMR (300 MHz, CDCI3): δ 7.95 (t, J = 5.5, 1 H), 7.44 (d, J = 1.3, 1 H), 7.01 (d, J = 1.4, 1 H), 3.20 (dd, J = 5.7, 6.9, 2H), 2.00 (dp, J = 6.7, 13.4, 1 H), 0.99 (d, J = 6.7, 6H).
MS (ES+) m/z 197.10 (M+H)+ (MW: 196.28).
General procedure B for the synthesis of intermediates 9-14. A mixture of the appropriate imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-substituted amine (e.g. imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-isobutyl-amine) (1.0 eq) and N- iodosuccinimide (1.1 eq) in N,N-dimethylformamide (about 4 mL/mmol) was stirred at room temperature for 16 hours. The reaction was diluted with dichloromethane and washed with 10% solution of sodium thiosulphate and saturated solution of sodium chloride. The organic layer was dried (sodium sulfate), filtered and concentrated. The crude mixture was purified to give the desired product (e.g. (5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-isobutyl-amine).
Intermediate 9
(3,4-Dichlorobenzyl)-(5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine The title compound was obtained as a white solid in a 45% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:hexane 2.5:7.5 to 7.5:2.5).
1H NMR (300 MHz, DMSOd6): δ 8.49 (t, J = 5.4, 1 H), 7.45 (dd, J = 5.7, 8.1 , 2H), 7.20 (t, J = 8.6, 2H), 7.04 (s, 1H), 4.48 (d, J = 5.5, 2H). MS (ES+) m/z 374 (M+H)+ (MW: 374.18).
Intermediate 10
(5-lodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-(2-methoxy-ethyl)-amine
The title compound was obtained in 52% yield after purification by column chromatography (Biotage/Flash, silica, methanohdichloromethane 0.1 :9.9 to 1 :9). 1H NMR (300 MHz, CDCI3): δ 7.13 (s, 1 H), 5.84 (brs, 1 H), 3.70 - 3.53 (m, 4H), 3.42 (s, 3H).
MS (ES+) m/z 324.90 (M+H)+ (MW: 324.14). Intermediate 11
(5-lodo-imidazo[2,1 -b][1 ,3,4]thiadiazol-2-yl)-isobutyl-amine
The title compound was obtained in 59% yield after purification by column chromatography (Biotage/Flash, silica, ethylacetate:dichloromethane 0.1 :9.9 to 3:7).
1H NMR (300 MHz, CDCI3): δ 7.03 (s, 1 H), 5.64 (brs, 1 H)1 3.12 (td, J = 0.9, 6.4, 2H), 1.90 (dt, J = 6.7, 13.4, 1 H), 0.94 (s, 3H), 0.92 (s, 3H). MS (ES+) m/z 323.00 (M+H)+ (MW: 322.17).
Intermediate 12
Cyclopropylmethyl-(5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine
The title compound was obtained in 59% yield after purification by column chromatography (Biotage/Flash, silica, ethylacetate:dichloromethane 0.1 :9.9 to 3:7). 1H NMR (300 MHz, CDCI3): δ 7.10 (s, 1 H), 5.21 (brs, 1 H), 3.24 (dd, J = 5.4, 7.1 , 2H), 1.14 (ddd, J = 4.9, 7.6, 12.3, 1H), 0.73 - 0.50 (m, 2H), 0.31 (q, J = 5.1 , 2H). MS (ES+) m/z 321.00 (M+H)+ (MW: 320.15).
Intermediate 13 5-lodo-2-phenyl-imidazo[2,1-b][1,3,4]thiadiazole
The title compound was obtained in a 62% yield after purification by column chromatography (Biotage/Flash, silica, hexane:ethyl acetate, 7.5:2.5 to 2.5:7.5). 1H NMR (300MHz, CDCI3): δ 7.87 (m, 2H), 748 (m, 3H)1 7.30 (s, 1 H). MS (ES+) m/z 328 (M+H)+ (MW: 327.1).
Intermediate 14
(3,4-Dichlorobenzyl)-(5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine The title compound was obtained as a yellow solid in a 52% yield after purification by column chromatography (Biotage/Flash, silica, hexane:ethyl acetate, 7.5:2.5 to 2.5:7.5).
1H NMR (300 MHz, CDCI3): δ 8.55 (t, J = 5.7Hz, 1H), 7.66 (dd, J = 5.0, 14.2Hz, 2H), 7.40 (dd, J = 1.8, 8.3 Hz, 1 H), 7.04 (s, 1 H), 4.50 (d, J = 5.7 Hz, 2H). MS (ES+) m/z 425 (M+H)+ (MW: 425.1). General procedure C for the synthesis of intermediates 15-18.
A mixture of the appropriate iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-substituted- amine (e.g. (5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-isobutyl-amine) (1.0 eq) and N-chlorosuccinimide (1.1 eq) in acetonitrile (about 6 mL/mmol) was heated under microwave irradiation at 180°C for 15 minutes. The reaction was diluted with dichloromethane and washed with water. The organic layer was dried (sodium sulfate), filtered and concentrated. The crude mixture was purified by column chromatography (Biotage™/Flash, silica) to give the desired product (e.g. (6-chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-isobutyl-amine).
Intermediate 15
(6-Chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-(4-fluoro-benzyl)-amine The title compound was obtained in 48% yield after purification by column chromatography (Biotage/Flash, silica, methanokdichloromethane 0.1 :9.9 to 1 :9). 1H NMR (300 MHz, CDCI3): δ 7.37 (dd, J = 5.5, 8.5, 2H), 7.15 - 6.99 (m, 2H), 5.47 (brs, 1 H), 4.57 (d, J = 5.2, 2H). MS (ES+) m/z 408.90 (M+H)+ (MW: 408.62).
Intermediate 16 (6-Chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-(2-methoxy-ethyI)- amine
The title compound was obtained in 89% yield after purification by column chromatography (Biotage/Flash, silica, methanokdichloromethane 0.1 :9.9 to 3:7). 1H NMR (300 MHz, CDCI3): δ 6.16 (brs, 1H), 3.70 - 3.52 (m, 4H), 3.39 (s, 3H). MS (ES+) m/z 458.90 (M+H)+ (MW: 358.59).
Intermediate 17 (6-Chloro-5-iodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yI)-isobutyl-amine
The title compound was obtained in 89% yield after purification by column chromatography (Biotage/Flash, silica, ethylacetate:dichloromethane 0.1:9.9 to
1 :9).
1H NMR (300 MHz, CDCI3): δ 5.54 (brs, 1H), 3.09 (ddd, J = 2.3, 6.8, 13.5, 2H),
1.93 - 1.78 (m, 1 H), 0.88 (s, 3H), 0.87 (s, 3H).
MS (ES+) m/z 356.90 (M+H)+ (MW: 356.61). Intermediate 18
(θ-Chloro-5-iodo-imidazop.i-blti.S^lthiadiazol-2-yO-cyclopropylmethyl- amine
The title compound was obtained in 42% yield after purification by column chromatography (Biotage/Flash, silica, ethylacetate:dichloromethane 0.1 :9.9 to 3:7).
1H NMR (300 MHz, CDCI3): δ 5.52 (brs, 1H), 3.26 (ddd, J = 4.1 , 7.9, 12.0, 2H), 1.18 - 1.14 (m, 1H), 0.69 - 0.52 (m, 2H), 0.39 - 0.21 (m, 2H). MS (ES+) m/z 354.90 (M+H)+ (MW: 354.55).
General procedure D for the synthesis of examples 1-12. Cesium carbonate (3.0 eq) dissolved in water (about 1 mL/mmol) was added over a mixture of the appropriate 5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-substituted compound (e.g. 5-iodo-2-phenyl imidazo[2,1-b][1 ,3,4]thiadiazole) (1.0 eq), the corresponding boronic acid (e.g. phenylboronic acid) (1.1 eq) and tetrakis(triphenylphosphine)palladium(0) (10%mol) in 1 ,4-dioxane (about 3.7 mL/mmol). The mixture was heated under microwave irradiation at 135 - 140°C for 30 minutes. The reaction mixture was diluted with dichloromethane and washed with water. (Alternatively the reaction mixture was filtered through a celite pad which was washed with dichloromethane). The organic layer was dried (sodium sulphate), filtered and concentrated in vacuo. The crude mixture was purified by column chromatography (different methods) to give the desired product (e.g. 2,5-diphenyl-imidazo[2,1-b][1,3,4]thiadiazole).
Example 1
2,5-Diphenyl-imidazo[2,1-b][1,3,4]thiadiazole
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a syrup in a 79% yield. 1H NMR (300 MHz, CDCI3): δ 7.89 (m, 4H), 7.54 (s, 1 H), 7.44 (m, 5H), 7.27 (t, J = 7.4 Hz, 1H). MS (ES+) m/z 278 (M+H)+ (MW: 277.3). Example 2 6-(2-Phenyl-imidazo[2,1-b][1,3,4]thiadiazole-5-yl)-1H-indole
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a yellow solid in a 65% yield.
1H NMR (300 MHz, CDCI3): δ 8.41 (s, 1 H = NH), 8.07 (s, 1H), 7.86 (m, 2H), 7.59 (m, 3H), 7.44 (m, 3H), 7.19 (dd, J = 2.2, 4.9 Hz, 1 H), 6.52 (s, 1 H). MS (ES+) m/z 317 (M+H)+ (MW: 316.4).
Example 3
[4-(2-Phenyl-imidazo[2,1-b][1,3,4]thiadiazole-5-yl)-phenyl]methanol
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 48% yield. 1H NMR (300 MHz, DMSO-d6): δ 8.02 (m, 4H), 7.81 (s,1 H)1 7.62 (m, 3H), 7.46 (d, J = 8.1 Hz, 2H), 5.26 (t, J = 5.7 Hz, 1 H), 4.55 (d, J = 5.7 Hz, 2H). MS (ES+) m/z 308 (M+H)+ (MW: 307.4).
Example 4 5-(4-Fluorophenyl)-2-phenyl-imidazo[2,1-b][1,3,4]thiadiazole
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 49% yield.
1H NMR (300 MHz, CDCI3): δ 7.96 (m, 4H), 7.52 (m, 4H), 7.16 (t, J = 8.7 Hz, 2H). MS (ES+) m/z 296 (M+H)+ (MW: 295.3).
Example 5 2-Phenyl-5-pyridin-3-yl-imidazo[2,1-b][1,3,4]thiadiazole
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isolute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 69% yield.
1H NMR (300 MHz, CDCI3): δ 9.23 (d, J = 2.2 Hz, 1 H), 8.54 (d, J = 4.8 Hz, 1 H),
8.27 (d, J = 8.0 Hz, 1 H), 7.65 (s, 1 H), 7.91 (m, 2H), 7.48 (m, 3H), 7.38 (dd, J =
4.8, 8.0 Hz, 1H). MS (ES+) m/z 279 (M+H)+ (MW: 278.3). Example 6
^{S-^Cyclopropylmethyl-amino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]- phenyl}-ethanone The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isoiute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 38% yield.
1H NMR (300 MHz, DMSO-d6): δ 8.60 (s, 1 H), 8.24 (s, 1 H), 8.17 (d, J = 12.8 Hz, 1 H), 7.59 (m, 2H), 3.25 (t, J = 6.0 Hz, 2H), 2.63 (s, 3H), 1.20 (m, 1 H), 0.53 (d, J = 6.5 Hz, 2H), 0.31 (d, J = 4.6 Hz, 2H). MS (ES+) m/z 313 (M+H)+ (MW: 312.4).
Example 7
1-{3-[2-(3,4-Dichlorobenzyl-amino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]- phenyl}-ethanone
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isoiute cartridge flash Si II, 5g, hexane:ethyl acetate) as a white solid in a 33% yield.
1H NMR (300 MHz, DMSO-d6): δ 8.70 (s, 1 H), 8.53 (s, 1 H), 8.12 (d, J = 7.9 Hz, 1 H), 7.85 (d, J = 7.8 Hz, 1 H), 7.73 (s, 1 H), 7.61 (m, 3H), 7.47 (d, J = 8.2 Hz, 1 H), 4.58 (d, J = 5.3 Hz, 2H), 2.59 (s, 3H). MS (ES+) m/z 417 (M+H)+ (MW: 417.32).
Example 8 4-[2-(4-Fluorobenzylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenol
The title compound was obtained after filtration of the reaction mixture through a celite pad and purification by chromatography (Isoiute cartridge flash Si II, 5g, hexane:ethyl acetate) as a brownish solid in a 24% yield.
1H NMR (300 MHz, methanol-d4): δ 7.67 (d, J = 8.7 Hz, 2H), 7.40 (dd, J = 5.6, 8.3 Hz, 2H), 7.17 (s, 1H), 7.04 (t, J = 8.7 Hz, 2H), 6.79 (d, J = 8.7, 2H), 4.49 (s, 2H). MS (ES+) m/z 341(M+H)+(MW: 340.38). Example 9
[6-Chloro-5-(4-methoxy-phenyl)-imiclazo[2,1-b][1,3,4]thiadiazol-2-yl]^^ fluoro-benzyl)-amine
The title compound was obtained in 7% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1 :9.9 to 3:7) and by semi-preparative-HPLC (Gemini C18 (150 x 10 mm; 5um), Solvent A: water with 0.1% formic acid; Solvent B: acetonitrile with 0.1% formic acid. Gradient: 60% of A to 20% of B).
1H NMR (300 MHz, CDCI3): δ 9.37 (s, 1 H), 7.73 (d, J = 8.9, 2H), 7.37 (dd, J = 5.5, 8.3, 2H), 6.96 (t, J = 9.2, 4H), 4.57 (d, J = 5.9, 2H), 3.79 (s, 3H). MS (ES+) m/z 389.00 (M,,)+ (MW: 388.85).
Example 10
[6-Chloro-5-(3,4-dimethoxy-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-(2- methoxy-ethyl)-amine
The title compound was obtained in 19% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1 :9.9 to 3:7).
1H NMR (300 MHz, CDCI3): δ 7.51 (dd, J = 1.1, 7.2, 2H), 6.97 (d, J = 8.8, 1 H), 3.94 (s, 6H), 3.63 - 3.57 (m, 6H), 3.40 (s, 3H). MS (ES+) m/z 369.00 (M+H)+ (MW: 368.07).
Example 11
1-[3-(6-Chloro-2-isobutylamino-imidazo[2,1-b][1,3,4]thiad!azol-5-yl)-phenyl]- ethanone
The title compound was obtained in 31% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1 :9.9 to
3:7).
1H NMR (300 MHz1 CDCI3): δ 7.51 (dd, J = 1.1, 7.2, 2H), 6.97 (d, J = 8.8, 1 H), 3.94 (s, 6H), 3.63 - 3.57 (m, 6H), 3.40 (s, 3H).
MS (ES+) m/z 369.00 (M+H)+, (MW: 348.85). Example 12
[6-Chloro-5-(3-dimethylamino-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]- cyclopropylmethyl-amine
The title compound was obtained in 37% yield after purification by column chromatography (Biotage/Flash, silica, ethyl acetate:dichloromethane 0.1:9.9 to 3:7).
1H NMR (300 MHz, CDCI3): δ 7.36 - 7.24 (m, 3H), 6.70 (d, J = 7.5, 1H), 5.38 (brs, 1H), 3.34 - 3.17 (m, 2H), 3.00 (s, 6H), 1.13 (ddd, J = 4.3, 7.4, 12.0, 1H), 0.68 - 0.51 (m, 2H), 0.32 - 0.27 (m, 2H). MS (ES+) m/z 348.00 (M+H)+, (MW: 347.87).
General procedure E for the preparation of examples 13-14
To a solution of the appropriate imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-amine (e.g. cyclopropylmethyl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl-amine) (1 eq) in dry methanol (5 mL/mmmol) were added the appropriate secondary amine (e.g. morpholine) (1.2 eq), glacial acetic acid (0.125 mL/mmol) and formaldehyde (37% aq. sol., 5 eq). The mixture was heated at reflux for 2 hours under argon atmosphere. Methanol was removed under vacuum and the residue was diluted with dichloromethane and water. The aqueous layer was extracted with dichloromethane (3 x) and the combined organic layers were washed with brine and dried over sodium sulfate. The crude product was purified by flash chromatography (methanokdichlormethane, 0:10 to 2.5:7.5) to yield the required product (e.g. cyclopropylmethyl-(5-morpholin-4-ylmethyl-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl)-amine).
Example 13
Cyclopropylmethyl^δ-morpholin^-ylmethyl-imidazo[2,1-b][1,3,4]thiadiazol-
2-yl)-amine
The title compound was isolated as a syrup in a 32% yield. 1H NMR (300 MHz, CDCI3): δ 7.20 (s, 1 H), 6.34 (br s, 1 H), 3.95 (m, 6H), 3.44 (t, J
=6.0Hz, 2H), 2.77 (d, J = 4.3 Hz, 4H), 1.36 (m, 1H), 0.82 (q, J = 5.6 Hz, 2H), 0.53
(q, J = 4.9 Hz, 2H).
MS (ES+) m/z 294 (M+H)+ (MW: 293.4). Example 14
2-Dimethylamino-imidazo[2,1-b][1,3,4]thiadiazole-5-carboxylic acid benzyl- methyl-amide
2-Dimethylamino-imidazo[2,1-b][1 ,3,4]thiadiazole-5-carbaldehyde (116 mg, 0.591 mmol) was dissolved in dry acetonitrile (4 mL) and N-methylbenyzlamine (0.768 mmol, 0.1 mL) and f-butylhydroperoxide (0.768 mmol, 5.5M, 0.14 mL) were added. The mixture was heated at 80°C for 10 hours. The reaction mixture was diluted with water (4 mL) at room temperature and extracted with dichloromethane (3 x 8 mL). The combined organic layer was dried over sodium sulphate and concentrated in vacuo. The crude product was purified by flash chromatography (Isolute cartridge Sill, ethyl acetate:dichloromethane, 1 :9 to 10:0) yielding 54 mg of 2-dimethylamino-imidazo[2,1-b][1 ,3,4]thiadiazole-5- carboxylic acid benzyl-methyl-amide as yellowish solid (29% yield). 1H NMR (300 MHz, CDCI3) δ ppm 7.26 (m, 6H), 4.72 (s, 2H), 3.06 (s, 6H), 3.01 (s, 3H).
MS (ES+) m/z 316 (M+H)+ (MW: 315.4).
Intermediate 19 2-(4-Fluoro-phenoxy)-imidazo[2,1-b][1,3,4]thiadiazole A mixture of 2-bromo-imidazo[2,1-b][1,3,4]thiadiazole (1.0 g, 4.90 mmol) and 4- fluorophenol (2.2 g, 19.60 mmol) was heated under microwave irradiation at 135°C for 3.5 hours. On cooling, the mixture was diluted with dichloromethane (7 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanol:dichloromethane 0.2:9.8 to 2:8) to give 2-(4-fluoro-phenoxy)- imidazo[2,1-b][1 ,3,4]thiadiazole as a white solid (610 mg, 53% yield).
1H-NMR (300 MHz, CDCI3): δ 7.54 (d, J = 1.3 Hz, 1 H), 7.29 (m, 2H), 7.21 (d, J =
1.2 Hz, 1 H), 7.14 (m, 2H).
MS (ES+) m/z 236 (M+H)+ (MW: 235.24).
Intermediate 20
2-(4-Fluoro-phenoxy)-5-iodo-imidazo[2,1-b][1,3,4]thiadiazole
2-(4-Fluoro-phenoxy)-imidazo[2,1-b][1 ,3,4]thiadiazole (0.6 g, 2.55 mmol) was dissolved in N,N-dimethylformamide (10 mL) and N-iodosuccinimide (0.63 g, 2.81 mmol) was added in one portion. The reaction mixture was stirred at room temperature overnight in the absence of light. The yellow suspension was filtered and rinsed with diethylether (2 x 2 mL) to give 2-(4-fluoro-phenoxy)-5-iodo- imidazo[2,1-b][1 ,3,4]thiadiazole as a white solid (0.65 g, 71%). The filtrate was evaporated and the residue was triturated with diethylether (6 mL) and filtered.
This solid was purified by column chromatography (Biotage™/FIash, silica, methanolidichloromethane 0:10 to 1:9) to give 2-(4-fluoro-phenoxy)-5-iodo- imidazo[2,1-b][1 ,3,4]thiadiazole as a white solid (0.15 g, 16% yield).
1H-NMR (300 MHz, CDCI3): δ 7.24 (dd, J = 4.3, 9.1 Hz, 2H), 7.17 (s, 1H), 7.07 (t,
J = 8.5 Hz, 2H).
MS (ES+) m/z 360 (M+H)+, (MW: 361.13)
Example 15
{3-[2-(4-Fluoro-phenoxy)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenyl}- dimethyl-amine
2-(4-Fluoro-phenoxy)-5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazole (0.13 g, 0.36 mmol) was suspended in 1,4-dioxane (1.5 mL) at room temperature and argon was bubbled into the mixture while tetrakis(triphenylphosphine)palladium(0) (42 mg,
0.036 mmol), 3-(N,N-dimethylamino)phenylboronic acid (68 mg, 0.41 mmol), cesium carbonate (235 mg, 0.72 mmol, 2.0 eq), and water (1.5 mL) were added.
The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 1 hour. On cooling, the mixture was diluted with dichloromethane (7 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanol:dichloromethane 0.2:9.8 to
2:8). The obtained residue was crystallized from methanol: 1,2-dichloroethane
(1 :1, 1.5 mL) and filtered to give {3-[2-(4-fluoro-phenoxy)-imidazo[2,1- b][1 ,3,4]thiadiazol-5-yl]-phenyl}-dimethyl-amine as a white solid (13 mg, 10% yield).
1H-NMR (300 MHz, CDCI3) δ 7.51 (s, 1H), 7.37 (m, 2H), 7.29 (m, 2H), 7.16 (m,
3H), 6.75 (d, J = 8.2 Hz, 1 H), 2.94 (s, 6H).
MS (ES+) m/z 355 (M+H)+ (MW: 354.41).
Example 16
4-[2-(4-Fluoro-phenoxy)-lmidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenol
2-(4-Fluoro-phenoxy)-5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazole (0.15 g, 0.42 mmol) was suspended in 1,4-dioxane (1.5 mL) at room temperature and argon was bubbled into the mixture while tetrakis(triphenylphosphine)palladium(0) (48 mg, 0.042 mmol), 4-hydroxyphenylboronic acid (66 mg, 0.48 mmol), cesium carbonate (271 mg, 0.83 mmol) and water (1.5 mL) were added. The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 20 minutes. On cooling, the mixture was diluted with dichloromethane (7 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanohdichloromethane 0.2:9.8 to 1.5:7.5). The product obtained was treated with dichloromethane (5 mL) and filtered to give 4-[2-(4-fluoro-phenoxy)- imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenol as a white solid (37 mg, 27% yield). 1H-NMR (300 MHz, DMSO-d6) δ 9.69 (s, 1 H), 7.67 (m, 4H), 7.53 (s, 1 H), 7.44 (t, J = 8.8 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H). MS (ES+) m/z 328 (M+H)+ (MW: 327.34).
Example 17
N-{4-[2-(4-Fluoro-phenoxy)-imidazo[2,1-b][1,3,4]thiadiazoI-5-yl]-phenyl}- acetamide
2-(4-Fluoro-phenoxy)-5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazole (0.15 g, 0.42 mmol) was suspended in 1 ,4-dioxane (1.5 mL) at room temperature and argon was bubbled into the mixture while dichlorobis(triphenylphosphine)palladium(ll) (29 mg, 0.042 mmol), 4-acetamidophenylboronic acid (85 mg, 0.48 mmol), cesium carbonate (271 mg, 0.83 mmol) and water (1.5 mL) were added. The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 20 minutes. On cooling, the resulting suspension was diluted with dichloromethane (7 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanohdichloromethane 0.2:9.8 to 2:8). The residue obtained was treated with diethylether (7 mL) and filtered to give 66 mg of N-{4-[2-(4-fluoro-phenoxy)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenyl}-acetamide as a white solid (43%).
1H-NMR (300 MHz, DMSO-d6): δ 10.04 (s, 1 H), 7.78 (d, J = 8.7 Hz, 2H), 7.63 (m, 5H), 7.41 (dd, J = 5.7, 11.8 Hz, 2H), 2.05 (s, 3H). MS (ES+) m/z 369 (M+H)+ (MW: 368.39).
Intermediate 21 (4-FIuoro-phenyI)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl-amine
A mixture of 2-bromo-imidazo[2,1-b][1,3,4]thiadiazole (1.0 g, 4.90 mmol) and 4- fluoroaniline (1.86 mL, 19.60 mmol) was heated under microwave irradiation at 135°C for 15 minutes. On cooling, the mixture was diluted with dichloromethane (10 mL) and purified by column chromatography (Biotage™/Flash, silica, methanolidichloromethane 0.2:9.8 to 1:9). The residue obtained was treated with dichloromethane (5 mL) and filtered to give (4-fluoro-phenyl)-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl-amine as a beige solid (117 mg, 10% yield).
1H-NMR (300 MHz, DMSO-d6): δ 10.47 (s, 1 H), 7.87 (d, J = 1.3 Hz, 1 H), 7.57 (m, 2H), 7.23 (t, J = 8.9 Hz, 2H), 7.10 (d, J = 1.3 Hz, 1 H). MS (ES+) m/z 235 (M+H)+ (MW: 234.25).
Intermediate 22
(4-Fluoro-phenyl)-(5-iodo-imidazo[2,1-b][1,3,4]thiadiazoI-2-yl)-amine
(4-Fluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-amine (0.117 g, 0.50 mmol) was suspended in N,N-dimethylformamide (3 mL) and N-iodosuccinimide (0.124 g, 0.55 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 2 hours in the absence of light. The mixture was evaporated and the residue was purified by column chromatography (Biotage™/Flash, silica, methanoLdichloromethane 0.4:9.6 to 1:9) to give 0.13 g of (4-fluoro-phenyl)-(5- iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine as an off-white solid (72% yield). 1H-NMR (300 MHz, DMSOd6): δ 10.59 (s, 1 H), 7.59 (dd, J = 4.8, 9.1 Hz, 2H), 7.27 (t, J = 8.9 Hz, 2H), 7.15 (s, 1 H).
MS (ES+) m/z 360 (M+H)+ (MW: 360.15).
Example 18 4-[2-(4-Fluoro-phenylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenoI (4-Fluoro-phenyl)-(5-iodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine (0.065 g, 0.18 mmol) was suspended in 1 ,4-dioxane (1 mL) at room temperature, and argon was bubbled into the mixture while tetrakis(triphenylphosphine)- palladium(0) (21 mg, 0.018 mmol), 4-hydroxyphenylboronic acid (21 mg, 0.21 mmol), cesium carbonate (118 mg, 0.36 mmol) and water (1 mL) were added. The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 30 minutes. On cooling, the mixture was diluted with dichloromethane (5 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanokdichloromethane 0.4:9.6 to 1 :9) to give 4-[2-(4-fluoro-phenylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenol as a beige solid (21 mg, 36% yield). 1H-NMR (300 MHz, DMSO-d6): δ 10.55 (s, 1 H), 9.63 (s, 1 H), 7.75 (d, J = 8.4 Hz, 2H), 7.60 (dd, J = 4.6, 8.7 Hz, 2H); 7.37 (s, 1H), 7.27 (t, J = 8.7 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H).
MS (ES+) m/z 327 (M+H)+ (MW: 326.35).
Example 19
N-{4-[2-(4-Fluoro-phenylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phenyl}- acetamide
(4-Fluoro-phenyl)-(5-iodo-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl)-amine (0.065 g, 0.18 mmol) was suspended in 1 ,4-dioxane (1 mL) at room temperature, and Argon was bubbled into the mixture while dichlorobis(triphenylphosphine)- palladium(ll) (13 mg, 0.018 mmol), 4-acetamidophenylboronic acid (37 mg, 0.21 mmol), cesium carbonate (118 mg, 0.36 mmol) and water (1 mL) were added. The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 30 minutes. On cooling, the mixture was diluted with dichloromethane (5 mL), adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanoLdichloromethane 0.4:9.6 to 1.5:8.5). The product obtained was treated with diethylether (7 mL) and filtered to give N-{4-[2-(4-fluoro-phenylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenyl}- acetamide as an off-white solid (10 mg, 15% yield).
1H-NMR (300 MHz, DMSO-d6): δ 10.58 (s, 1 H), 10.04 (s, 1 H), 7.87 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 7.61 (dd, J = 4.7, 8.7 Hz, 2H), 7.49 (s, 1H), 7.28 (t, J = 8.8 Hz, 2H), 2.07 (s, 3H). MS (ES+) m/z 368 (M+H)+ (MW: 367.41 ).
Intermediate 23 lmidazo[2,1-b][1,3,4]thiadiazol-2-yl-(4-methoxyphenyl)amine
A mixture of 2-bromo-imidazo[2,1-b][1 ,3,4]thiadiazole (1.0 g, 4.90 mmol) and p- anisidine (19.6 mmol, 2.41 g) in trifluoroethanol (12 mL) was heated under microwave irradiation at 170°C for 1 hour. On cooling, the mixture was diluted with dichloromethane (10 mL) and purified by column chromatography (Biotage™/Flash, silica, methanol:dichloromethane 0.2:9.8 to 1 :9). The residue obtained was triturated with diethylether and few drops of methanol to give imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-(4-methoxyphenyl)amine as a white solid (355 mg, 29% yield). 1H-NMR (300 MHz, CDCI3): δ 8.01 (s, 1 H), 7.55 (s, 1 H), 7.44 (d, J = 8.9, 2H), 7.22 (s, 1H), 6.90 (d, J = 8.8, 2H), 3.80 (s, 3H). MS (ES+) m/z 247 (M+H)+ (MW: 246.29).
Intermediate 24
(5-lodo-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-(4-methoxyphenyl)amine lmidazo[2,1-b][1 ,3,4]thiadiazol-2-yl-(4-methoxyphenyl)amine (0.455 g, 1.85 mmol) was dissolved in N,N-dimethylformamide (8 mL) and N-iodosuccinimide (2.03 mmol, 0.48 g) was added in one portion. The reaction mixture was stirred at room temperature for 22 hours in the absence of light. Solvent was evaporated and the residue was purified by column chromatography (Biotage™/Flash, silica, ethylacetate:dichloromethane 2:8 to 0:10) to give 0.11 g of (5-iodo-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl)-(4-methoxyphenyl)amine as an off-white solid (16% yield). 1H-NMR (300 MHz, DMSO-d6): δ 10.30 (s, 1 H), 7.59 (d, J = 9.0 Hz, 2H), 7.06 (s, 1H), 6.93 (d, J = 9.0 Hz, 2H), 3.68 (s, 3H). MS (ES+) m/z 373 (M+H)+ (MW: 372.19).
Example 20
{5-[3-Dimethylamino-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]}-(4- methoxyphenyl)amine
(5-lodo-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-(4-methoxyphenyl)amine (55 mg, 0.10 mmol) was suspended in 1 ,4-dioxane (1 mL) at room temperature and argon was bubbled into the mixture while tetrakis(triphenylphosphine)palladium(0) (0.011 mmol, 12 mg), 3-(N,N-dimethylamino)phenylboronic acid (0.202 mmol, 33 mg), cesium carbonate (0.268 mmol, 88 mg) and water (1 mL) were added. The mixture was deoxygenated for 10 minutes and heated under microwave irradiation at 140°C for 1 hour. On cooling, the mixture was diluted with dichloromethane, adsorbed in silica and purified by column chromatography (Biotage™/Flash, silica, methanokdichloromethane 0.2:9.8 to 2:8). The obtained residue was further purified by preparative HPLC to give {5-[3- dimethylaminophenyl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl]}-(4-methoxyphenyl)- amine as a white solid (4 mg, 7% yield).
1H-NMR (300 MHz, DMSOd6): δ 8.43 (br s, 1 H), 7.60 - 7.54 (m, 2H), 7.54 - 7.52 (s, 1 H), 7.52 - 7.49 (m, 1 H), 7.25 (t, J = 7.9, 1 H), 7.14 (d, J = 7.8, 1 H), 6.94 (d, J = 9.0, 2H), 6.67 (dd, J = 2.2, 8.0, 1 H), 3.75 (s, 3H), 2.99 (s, 6H). MS (ES+) m/z 366 (M+H)+ (MW: 365.46).
Intermediate 25 2-Bromo-7,7a-dihydro-imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde 3-Bromo-imidazothiazole (1 g, 4.9 mmol) was added over a mixture of dimethylformamide (10 mL) and phosphorus oxychloride (1.5 mL, 16.1 mmol) (Vilsmeier-Haack reagent) at 0°C. The mixture was stirred at 0°C for 30 minutes, at room temperature for 2 hours and at 60°C for additional 2 hours. The reaction mixture turned dark red-brown and was poured in aqueous solution of sodium carbonate. The resulted mixture was stirred at 90°C for 2 hours. The reaction mixture was cooled to room temperature, diluted with water (30 mL) and extracted with chloroform (3 x 40 mL). The combined organic layers were washed with water (3 x 40 mL), dried over anhydrous sodium sulphate and concentrated. The crude was purified by column chromatography (Biotage/flash, silica, methanol:dichloromethane 0:10 to 0.7:9.3), yielding a fraction containing the title compound and a byproduct. Both compounds were separated employing flash column chromatography (Isolute II-5 g, methanokdichloromethane, 0:10 to 0.6:9.4), giving 2-bromo-7,7a-dihydro-imidazo[2,1-b][1 ,3,4]thiadiazole-5- carbaldehyde as a pale-brown solid (0.085 g, 7.5% yield). 1H NMR (300 MHz, CDCI3): δ 9.86 (s, 1 H), 7.98 (s, 1 H) MS (APCI+) m/z 233.9, 231.9 (M+H)+ (MW: 232.06).
General Procedure F for the preparation of intermediates 26-29
2-Bromo-7,7a-dihydro-imidazo[2,1-b][1 ,3,43thiadiazole-5-carbaldehyde (1 eq) and appropiate amine (1.1 eq) (e. g. 4-amino-phenyl-ethanone) were mixed in dichloroethane (14 mL/mmol) and treated with sodium triacetoxyborohydride (1.4 eq) and acetic acid (1 eq). The mixture was stirred at room temperature under inert atmosphere (N2) for 3 hours. The reaction mixture was quenched with 2M aqueous potassium hydroxyde and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulphate and concentrated, yielding the required product without additional purification needed (e. g. 1-{4-[(2-bromo-imidazo[2,1-b][1 ,3,4]thiadiazol-5-ylmethyl)-amino]- phenylj-ethanone). Intermediate 26
1-{4-[(2-Bromo-imidazo[2,1-b3[1,3,4]thiadiazol-5-yImethyl)-amino]-phenyI}- ethanone
The title compound was obtained in 90% yield. 1H NMR (300 MHz, CDCI3): δ 7.22 - 7.06 (m, 4H), 6.81 (d, J = 8.1 , 1H), 4.56 (s, 2H), 3.91 (s br, 1H), 2.48 (m, 3H). MS (ES+) m/z 352.9, 351.9 (M+H)+ (MW:351.23).
Intermediate 27 (2-Bromo-imidazo[2,1-b][1,3,4]thiadiazol-5-ylmethyl)-(3,4-dimethoxy- phenyl)-amine
The title compound was obtained in 75% yield. MS (ES+) m/z 369.0, 371.0 (M+H)+ (MW:369.24).
Intermediate 28
(2-Bromo-imidazo[2,1-b]t1,3,4]thiadiazol-5-ylmethyl)-(3-chloro-4-fluoro- phenyl)-amine
The title compound was obtained in 51% yield. MS (ES+) m/z 360.0, 362.0 (M+H)+ (MW: 361.62)
Intermediate 29
2-Dimethylamino-7,7a-dihydro-imidazo[2,1-b][1,3,4]thiadiazole-5- carbaldehyde
The title compound was isolated as a by-product in the preparation of 2-bromo- 7,7a-dihydro-imidazo[2,1-b][1 ,3,4]thiadiazole-5-carbaldehyde. The required product was obtained as a dark cream solid (35 mg, 3.6% yield). 1H NMR (300 MHz, CDCI3): δ 9.76 (s, 1 H), 7.75 (s, 1 H), 3.11(s, 3H), 3.08(s, 3H) MS (APCI+) m/z 197.0 (M+H)+ (MW: 196.23).
General Procedure G for the preparation of examples 21-26.
A mixture of the appropriate bromide (e.g. (2-bromo-imidazo[2,1- b][1,3,4]thiadiazol-5-ylmethyl)-(3-chloro-4-fluoro-phenyl)-amine) (1 eq) and the adequate amine (e.g. isobutylamine) (4 eq) in 1,4-dioxane (about 25 mL/mmol) was heated at 145°C by microwave irradiation for several hours (from 2 to 4 hours depending upon the corresponding amine). The reaction mixture was diluted with dichloromethane, washed with water (x 2), brine, dried over anhydrous sodium sulphate and concentrated. The residue was purified by column chromatography on flash silica gel to give the desired product (e.g. {5-[(3- Chloro-4-fluoro-phenylamino)-methyl]-7,7a-dihydro-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl}-isobutyl-amine).
Example 21
1-{3-[(2-Dimethylamino-7,7a-dihydro-imidazo[2,1-b][1,3,4]thiadiazol-5- ylmethyl)-amino]-phenyl}-ethanone The title compound was obtained in 30% yield after purification by column chromatography on flash silica gel (methanohdichloromethane, 0:10 to 0.7:9.3).
1H NMR (300 MHz, CDCI3): δ 7.35-7.07 (m, 3H), 6.96 (s, 1H), 6.91-6.70 (m, 1 H),
4.46 (s, 2H), 3.06 (s, 6H), 2.49 (s, 3H).
MS (ES+) m/z 316.1 (M+H)+ (MW: 315.40).
Example 22
1-{3-[(2-lsobutylamino-7,7a-dihydro-imidazo[2,1-b][1,3,4]thladiazol-5- ylmethyl)-amino]-phenyl}-ethanone
The title compound was obtained in 34% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
1H NMR (300 MHz, CDCI3): δ 7.36-7.08 (m, 3H), 6.88-6.73 (m, 1 H), 6.29 (s, 1 H),
4.44 (s, 2H), 3.11 (d, J = 6.3 Hz, 2H), 2.51 (m, 3H), 1.89 (dt, J = 6.7 Hz, 13.4 Hz,
1 H), 0.92 (d, J = 6.7 Hz, 6H).
MS (ES+) m/z 344.1 (M+H)+ (MW: 343.45).
Example 23
1-(3-{[2-(2-Methoxy-ethylamino)-7,7a-dihydro-imidazo[2,1-b][1,3,4]thiadiazol-
5-ylmethyl]-amino}-phenyl)-ethanone
The title compound was obtained in 34% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
1H NMR (300 MHz, CDCI3): δ 7.42-7.01 (m, 3H), 6.81 (d, J = 7.9 Hz, 1 H), 6.30 (s,
1 H), 4.44 (s, 2H), 3.63-3.40 (m, 4H), 3.40-3.18 (m, 3H), 2.57-2.32 (m, 3H).
MS (ES+) m/z 346.1 (M+H)+ (MW: 345.43). Example 24
{5-[(3,4-Dimethoxy-phenylamino)-methyI]-7,7a-dihydro- imidazo[2,1 b][1 ,3,4]thiadiazol-2-yl}-(2-methoxy-ethyl)-amine
The title compound was obtained in 34% yield after purification by column chromatography on flash silica gel (methanolidichloromethane, 0:10 to 0.5:9.5).
1H NMR (300 MHz, CDCI3): δ 6.95 (s, 1 H)1 6.68 (d, J = 8.5 Hz, 1 H)1 6.34-6.10 (m,
2H), 5.75 (s, 1 H), 4.37 (s, 2H), 3.75 (d, J = 9.2 Hz, 6H), 3.64-3.43 (m, 4H), 3.33
(s, 3H), 2.99-2.70 (m, 2H).
MS (ES+) m/z 364.1 (M+H)+(MW: 363.44).
Example 25
{5-[(3,4-Dimethoxy-phenylamino)-methyl]-7,7a-dihydro-imidazo[2,1- b][1,3,4]thiadiazoI-2-yI}-(tetrahydro-pyran-4-yl)-amine
The title compound was obtained in 26% yield after purification by column chromatography on flash silica gel (methanokdichloromethane, 0:10 to 0.5:9.5).
1H NMR (300 MHz, CDCI3): δ 6.95 (s, 1 H), 6.68 (d, J = 8.5 Hz, 1 H), 6.33-6.06 (m,
3H), 4.38 (s, 2H), 3.95 (m, 2H), 3.81 - 3.61 (m, 6H), 3.46 (m, 2H), 2.35 (1 H, m),
2.04 (m, 2H), 1.59 (m, 2H).
MS (ES+) m/z 390.1 (M+H)+ (MW: 389.48).
Example 26
{5-[(3-Chloro-4-fluoro-phenylamino)-methyl]-7,7a-dihydro-imidazo[2,1- b][1 ,3,4]thiadiazol-2-yl}-isobutyl-amine
The title compound was obtained in 26% yield after purification by column chromatography on flash silica gel (methanohdichloromethane, 0:10 to 0.5:9.5).
1H NMR (300 MHz, CDCI3): δ 6.89 (s, 1 H), 6.65 (m, 1 H), 6.52 - 6.32 (m, 1 H),
4.35 (s, 2H), 3.22 - 3.05 (m, 2H), 1.90 (dt, J - 6.7 Hz, 13.4 Hz, 1 H), 0.94 (s, 6H).
MS (ES+) m/z 354.1 (M+H)+ (MW:353.85).
Intermediate 30
2-Bromo-imidazo[2,1-b][1,3,4]thiadiazole-5-suIfonic acid
The starting 2-bromo-imidazo[2,1-b][1,3,4]thiadiazole (2.0 g; 9.9 mmol) was dissolved in oleum (4.0 mL) and the resulting solution was heated at 80°C for 8 hours. The reaction was allowed to cool to room temperature and then poured onto crushed ice. One spoon of sodium chloride was added and the resulting precipitate was isolated by vacuum filtration and washed with cold water. It was dried by azeotrope distillation with toluene. The title compound 2-bromo- imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid was isolated as a beige solid, (2.33 g; 83% yield).
1H NMR (300 MHz, DMSO-d6): δ 7.30 (1 H, s). MS (ES+) m/z 283.9 (M+H)+ (MW: 218.08).
Intermediate 31 2-Bromo-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonyl chloride
2-Bromo-imidazo[2,1-b][1 ,3,4]thiadiazole-5-sulfonic acid (1.1 g; 3.87 mmol) was reacted with phosphorus oxychloride (2.53 mL; 27.1 mmol) and phosphorus pentachloride (0.56 g; 2.7 mmol) in anhydrous 1 ,2-dichloroethane (4 mL) at 90°C for 5 hours. The reaction mixture was allowed to cool and a mixture (1 :1) of dichloromethane and ether was added. A brown oil was separated. The supernatant was decanted and the oil washed with ether and the crude product used immediately. 0.85 g was isolated.
General Procedure H for the preparation of intermediates 32-34 2-Bromo-imidazo[2,1-b][1 ,3,4]thiadiazole-5-sulfonyl chloride (1 eq) was dissolved in acetonitrile (6 mL/mmol) and triethylamine (1 eq) was added to the solution. The resulting mixture was cooled in an ice bath and the appropriate amine (e.g. morpholine) (2.5 eq) was added. The reaction was stirred for 30 minutes at 0°C, then at room temperature for 2 hours. The solvent was evaporated and the crude product was taken up in dichloromethane and sodium hydrogen carbonate- solution. Extraction with dichloromethane, drying with sodium sulphate and evaporation gave the crude material that was washed with etheπhexane (1 :3) to give the desired sulphonamide (e.g. 2-bromo-5-(morpholine-4-sulfonyl)- imidazo[2,1-b][1 ,3,4]thiadiazole) of good purity.
Intermediate 32
2-Bromo-5-(morpholine-4-sulfonyl)-imidazo[2,1-b][1,3,4]thiadiazole
The title compound was isolated in 29% yield.
1H NMR (300 MHz, DMSOd6): δ 7.84 (1H1 s), 3.58 (4H, m), 3.04 (4H, m). Intermediate 33 2-Bromo-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid ethylamide
The title compound was isolated in 35% yield.
1H NMR (300 MHz, DMSOd6): δ 7.77 (1 H, s), 5.21 (1 H, m), 3.07 (2H, m), 1.10 (3H, t, J = 7.3 Hz).
Intermediate 34 2-Bromo-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid phenylamide
The title compound was isolated in 59% yield. MS (ES+) m/z 360.90 (M+H)+ (MW: 359.22).
General Procedure I for the preparation of example 27-29
The appropriate 2-bromo-imidazo[2,1-b][1 ,3,4]thiadiazole sulphonamide (e.g. 2- bromo-imidazo[2,1-b][1 ,3,4]thiadiazole-5-sulfonic acid phenylamide) (1 eq) was added to 4-fluorobenzyl amine (10 eq) and the mixture was heated in a microwave reactor at 200 W for 20 minutes at 135°C. The reaction mixture was taken up in sodium bicarbonate and dichloromethane and extracted. The solvent was evaporated and the residue was purified on silica gel (ethyl acetate) to give the desired product (e.g. 2-(4-fluoro-benzylamino)-imidazo[2,1-b][1,3,4]thia- diazole-5-sulfonic acid phenylamide).
Example 27
2-(4-Fluoro-benzylamino)-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid phenylamide The title compound was isolated in 10% yield.
1H NMR (300 MHz, DMSOd6): δ 9.17 (1 H, s), 7.61 (1 H, s), 7.41 (2H, dd, J = 5.6, 8.5 Hz), 7.37 (1H, s), 7.11 (4H, m), 7.01 (2H, t, J = 8.8 Hz), 6.92 (1H, ddd, J = 2.8, 5.8, 8.4 Hz), 4.55 (2H, d, J = 5.7 Hz). MS (ES+) m/z 404.0 (M+H)+ (MW: 403.46).
Example 28
(4-Fluoro-benzyl)-[5-(morphoIine-4-sulfonyl)-imidazo[2,1-b][1,3,4]thiadiazol- 2-ylj-amine
The title compound was isolated in 13% yield. 1H NMR (300 MHz, DMSO-d6): δ 7.73 (1 H, s), 7.37 (3H, m), 7.00 (2H, t, J = 8.8 Hz), 4.51 (2H, d, J - 5.7 Hz), 3.49 (4H, m), 2.97 (4H, m). MS (ES+) m/z 398.05 (M+H)+ (MW: 397.45).
Example 29
2-(4-Fluoro-benzylamino)-imida2θ[2,1-b][1,3,4]thiadiazole-5-sulfonic acid ethylamide
The title compound was isolated in 9% yield.
1H NMR (300 MHz, DMSOd6): δ 7.65 (1 H, s), 7.37 (3H, m), 6.99 (2H, t, J = 8.8 Hz), 6.46 (1 H, t, J = 5.5 Hz), 4.51 (2H, d, J = 5.7 Hz), 2.93 (2H1 m), 0.91 (3H, t, J = 7.2 Hz). MS (ES+) m/z 356.12 (M+H)+ (MW: 355.42).
General Procedure J for the preparation of Example 30-33 The appropriate 2-bromo-imidazo[2,1-b][1 ,3,4]thiadiazole sulphonamide (e.g. 2- bromo-imidazo[2,1-b][1 ,3,4]thiadiazole-5-sulfonic acid phenylamide) (1 eq) was dissolved in anhydrous acetonitrile (6 mL/mmol) and reacted at room temperature for 16 hours with an aliphatic amine (e.g. cyclopropanemethylamine) (2.5 eq) in the presence of triethylamine (1 eq). The solvent was removed in vacuo and the reaction mixture was taken up in sodium bicarbonate and dichloromethane and extracted. Drying over sodium sulphate and evaporation of the solvent gave the product (e.g. 2-(cyclopropylmethyl-amino)-imidazo[2,1-b][1,3,4]thiadiazole-5- sulfonic acid phenylamide) that was further purified by washing with etheπhexane (1 :3).
Example 30
2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1,3,4]thiadiazole-5-suIfonic acid phenylamide
The title compound was isolated in 22% yield. 1H NMR (300 MHz, DMSOd6): δ 9.09 (1 H1 s), 7.39 (1 H, m), 7.14 (3H, m), 6.92 (1H, t, J = 8.8 Hz), 3.46 (1H, s), 3.19 (2H, m), 1.07 (1H, m), 0.46 (2H, m). 0.20 (2H, m). MS (ES+) m/z 350.1 (M+H)+ (MW: 349.44). Example 31
2-lsobutylamino-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid phenyl- amide
The title compound was isolated in 14% yield. 1H NMR (300 MHz, DMSO-d6): δ 9.18 (1 H1 s), 7.36 (1 H, s), 7.15 (5H, m), 6.92 (1H, t, J = 6.9 Hz), 3.17 (2H, t, J = 6.2 Hz), 1.92 (1 H, m), 0.87 (6H, d, J = 6.7 Hz). MS (ES+) m/z 352.1 (M+H)+ (MW: 351.45).
Example 32 Cyclopropylmethyl-Iδ^morphollne-Φsulfonyl)-lmidazop.i- b][1 ,3,4]thiadiazol-2-yl]-amine
The title compound was isolated in 66% yield.
1H NMR (300 MHz, DMSO-d6): δ 7.34 (1 H, s), 3.55 (4H, m), 3.18 (2H, dd, J = 5.3, 6.8 Hz), 3.08 (4H, m), 6.92 (1H, W = 6.9 Hz), 1.06 (1 H, m), 0.42 (2H1 m), 0.20 (2H, m).
MS (ES+) m/z 344.1 (M+H)+ (MW: 343.43).
Example 33 2-EthyIamino-imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid ethylamide 2-Bromo-imidazo[2,1-b][1 ,3,4]thiadiazole-5-sulfonyl chloride (0.15 g; 0.50mmol) was dissolved in dry acetonitrile (5 mL). Triethylamine (69 μl_; 0.50 mmol) was added, and the reaction mixture was cooled at 0°C for 10 minutes before adding ethylamine (2M in tetrahydrofuran, 2.5 mL; 5.0 mmol). The reaction was allowed to reach room temperature and stirred overnight. The solvent was evaporated and the crude taken up in dichloromethane and sodium hydrogen carbonate solution. Extraction with dichloromethane, drying over sodium sulphate and evaporation of the solvent gave a brown gum that was purified on silica gel (ethyl acetate: hexane 4:1 ). The title product 2-ethylamino-imidazo[2,1- b][1 ,3,4]thiadiazole-5-sulfonic acid ethylamide was isolated as a white powder (43 mg, 31%).
1H NMR (300 MHz, DMSO-d6): δ 7.29 (1 H, s), 7.14 (1 H, s), 6.50 (1 H, s), 3.34 (2H1 m), 2.98 (2H, m), 1.16 (3H, X, J = 7.2 Hz), 0.97 (3H, t, J = 7.2 Hz). MS (ES+) m/z 276.0 (M+H)+ (MW: 275.35). Example 34
The following compounds were either made according to the procedures described herein, or, were acquired from publicly-available sources:
(1 ) 1-[3-(2-lsobutylamino-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl)-phenyl]-ethanone;
(2) i-p^-Cyclohexylamino-imidazo[2,1-b][1,3,4]thiadiazol-5-ylVphenyl]ethan- one;
(3) [5-(3-Dimethylamino-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yO-isobutyl- amine;
(4) (5-Naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-(2-phenoxy-ethyl)- amine;
(5) [5-(3-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-pyridin-2-yl-ethyl)- amine; (6) [5-(4-Chloro-phenyl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl]-(2-pyridin-2-yl-ethyl)- amine;
(7) N-{3-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenyl}-acetamide;
(8) (2-Methoxy-ethyl)-(5-naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)- amine;
(9) (2-Pyridin-2-yl-ethyl)-[5-(3-trifluoromethoxy-phenyl)-imidazo[2,1-b][1 ,3,4]thia- diazol-2-yl]-amine;
(10)Cyclopropylmethyl^δ-naphthalen-2-yl-imidazo[2,1-b][1,3,4]thiadiazol-2 -yl)-amine; (11) (5-Naphthalen-2-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-(tetrahydro-pyran-4- ylmethyl)-amine;
(12) (4-Methoxy-benzyl)-(5-naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)- amine;
(13) [5-(3-Chloro-4-fluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-isobutyl- amine;
(14) [5-(3-Chloro-4-fluoro-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-(2-meth- oxyethyl)-amine;
(15) (2-Pyridin-2-yl-ethyl)-[5-(3-trifluoromethyl-phenyl)-imidazo[2,1-b][1,3,4]thia- diazol-2-yl]-amine; (16) [5-(3-Dimethylamino-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-ylHtetrahydro- pyran-4-ylmethyl)-amine;
(17) N-(3-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b3[1 ,3,4]thiadiazol-5-yl}- phenyl)-acetamide; (18) Cyclopropylmethyl-[5-(3-trifluoromethyl-phenyl)-imidazo[2, 1 -b][1 ,3,4]thia- diazol-2-yl]-amine;
(19) [5-(3-Dimethylamino-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-methoxy- ethyl)-amine;
(20) (Tetrahydro-pyran-4-yImethyl)-[5-(3-trifluoromethoxy-phenyl)-imidazo[2, 1 -b]- [1 ,3,4]thiadiazol-2-yl]-amine;
(21 ) 1-(3-{2-[(Tetrahydro-pyran-4-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol- 5-yl}-phenyl)-ethanone;
(22) 1-(3-{2-[(Thiophen-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}- phenyl)-ethanone; (23) [5-(3-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(tetrahydro-pyran-4- ylmethyl)-amine;
(24) 4-(2-Cyclohexylamino-imidazo[2, 1 -b][1 ,3,4]thiadiazol-5-yl)-phenol;
(25) 4-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl3-2-meth- oxyphenol; (26) N-(3-{2-[(Thiophen-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}- phenyl)-acetamide;
(27) [5-(3-Chloro-phenyl)-imidazo[2,1 -b][1 ,3,4]thiadiazol-2-yl]-(2-methoxy-ethyl)- amine;
(28) N-{3-[2-(2-Pyridin-2-yl-ethylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenyl}-acetamide;
(29) [5-(4-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl3-(tetrahydro-pyran-4- ylmethyl)-amine;
(30) Isobutyl-[δ^S-trifluoromethoxy-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]- amine; (31 ) [5-(4-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-methoxy-ethyl)- amine;
(32) lsobutyl-(5-naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(33) [5-(3-Chloro^-fluoro-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yO^-meth- oxybenzyl)-amine; (34) [5-(3-Dimethylamino-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-methyl- benzyl)-amine;
(35) lsobutyl-[5-(6-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]- amine; (36) Benzyl-(5-pyridin-4-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine;
(37) (4-Fluoro-benzyl)-[5-(6-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol- 2-yl]-amine;
(38) [5-(3-Dimethylamino-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(4-fluoro- benzyl)-amine; (39) Cyclopropylmethyl-Cδ^S-trifluoromethoxy-phenyl)-imidazo[2,1-b][1,3,4]thia- diazol-2-yl]-amine;
(40) 4-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1,3,4]thiadiazol-5-yl}-phenol;
(41 ) N-{3-[2-(4-Fluoro-benzylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenyl}- acetamide; (42) 4-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}-2-meth- oxyphenol;
(43) Benzyl-[5-(3-dimethylamino-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]- amine;
(44) i-{3-[2-(2-Methoxy-ethylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenyl}- ethanone;
(45) (4-Fluoro-benzyl)-(5-pyridin-4-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(46) (2-Methoxy-ethyl)-[5-(3-trifluoromethoxy-phenyl)-imidazo[2, 1 -b][1 ,3,4]thia- diazol-2-yl]-amine;
(47) Cyclohexyl-fδ^δ-methoxy-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]- amine;
(48) (2-Pyridin-2-yl-ethyl)-(5-thiophen-3-yl-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl)- amine; (49) 4-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenol;
(50) N-{3-[2-(2-Methoxy-ethylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenyl}- acetamide;
(51 ) 2-Methoxy-4-[2-(2-methoxy-ethylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenol;
(52) 4-[2-(2-Methoxy-ethylamino)-imidazo[2,1 -b][1 ,3,4]thiadiazol-5-yl]-benzonitrile;
(53) [5-(3-Chloro-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-cyclopropylmethyl- amine; (54) Cyclopropylmethyl-[5-(6-methoxy-pyridin-3-yl)-imiclazo[2,1-b][1,3,4]thia- diazol-2-yl]-amine;
(55) Isobutyl^δ-thiophen-3-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine; (56) ^^Chloro-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-y]-isobutyl-amine; (57) (4-Fluoro-benzyl)-(5-pyridin-3-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(58) 4-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-2,6- dimethylphenol;
(59) CyclopropylmethyKδ-thiophen-3-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)- amine; (60) (2-Methoxy-ethyl)-(δ-thiophen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)- amine;
(61 ) 3-(2-lsobutylamino-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl)-N,N-dimethyl-benz- amide;
(62) Benzo[1 ,3]dioxol-5-ylmethyl-[5-(3-chloro-4-fluoro-phenyl)-imidazo[2,1- b][1 ,3,4]-thiadiazol-2-yl]-amine;
(63) lsobutyl-[δ-(5-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]- amine;
(64) [5-(3-Fluoro-phenyI)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-methoxy-ethyl)- amine; (65) 1-{3-[2-(2-Morpholin-4-yl-ethylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenyl}-ethanone;
(66) (5-Phenyl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-(2-pyridin-2-yl-ethyl)-amine;
(67) (Tetrahydro-pyran-4-ylmethyl)-(5-thiophen-3-yl-imidazo[2,1-b][1,3,4]thia- diazol-2-yl)-amine; (68) [5-(6-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(tetrahydro- pyran-4-ylmethyl)-amine;
(69) [δ-(δ-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazoI-2-yl]-(tetrahydro- pyran-4-ylmethyl)-amine;
(70) lsobutyl-(δ-pyridin-4-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine; (71 ) Cyclopropylmethyl-p^S^-dimethoxy-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol- 2-yl]-amine;
(72) 3-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-N-(2- dimethylamino-ethyl)-benzamide;
(73) [5-(3-Fluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazo[-2-yl]-(tetrahydro-pyran-4- ylmethyl)-amine; (74) Furan-2-ylmethyl-(5-thiophen-3-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(75) Cyclopropylmethyl-tδ^δ-methoxy-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadia- zol-2-yl]-amine;
(76) (2-Methoxy-ethyl)-[5-(6-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol- 2-yl]-amine;
(77) [5-(2-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl3-(tetrahydro-pyran-4- ylmethyl)-amine;
(78) (5-Phenyl-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl)-(tetrahydro-pyran-4-ylmethyl)- amine; (79) Cyclopropylmethyl-[5-(1-methyl-1 H-pyrazol-4-yl)-imidazo[2,1-b][1 ,3,4]thia- diazol-2-yl]-amine;
(80) 3-[2-(Cyclopropylmethyl-amino)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-5-yl]-N,N- dimethyl-benzamide;
(81 ) (2-Methyl-benzyl)-(5-pyridin-3-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine; (82) [5-(3-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(4-fluoro-benzyl)- amine;
(83) N-fS-P^-Dimethylamino-benzylaminoVinnidazopJ-^[I .SΛ^hiadiazol-5-yl]- phenyl}-acetamide;
(84) lsobutyl-(5-pyridin-3-yl-imidazo[2,1-b][1 ,3,43thiadiazol-2-yl)-amine; (85) (5-Naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-(2-pyridin-2-yl-ethyl)- amine;
(86) Cyclopropylmethyl^S-pyridin-3-yl-innidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine;
(87) [5-(2-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(2-pyπidin-2-yl- ethyl)amine; (88) 4-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}-2,6- dimethyl-phenol;
(89) Cyclopropylmethyl-(5-phenyl-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl)-amine;
(90) Benzyl-(5-pyridin-3-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(91 ) lsobutyl-(5-phenyl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine; (92) Benzyl-[5-(6-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]- amine;
(93)CyclopropylmethyKS-pyridin^-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-amine;
(94) (4-Fluoro-benzyl)-[5-(5-methoxy-pyridin-3-yl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-
2-yl]-amine; (95) 4-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiacliazol-5-yl]-N-(2- hydroxy-ethyl)-benzamide;
(96) (4-Methoxy-benzylH5-pyridin-4-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)- amine; (97) [5-(2-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-cyclopropylmethyl- amine;
(98) 1-(3-{2-[(Benzot1,3]dioxol-5-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]tlπiadiazol- 5-yl}-phenyl)-ethanone;
(99) Furan-2-ylmethyl-[5-(1 -methyl-1 H-pyrazol-4-yl)-imidazo[2, 1 -b][1 ,3,4]thia- diazol-2-yl]-amine;
(100) (4-Fluoro-benzylH5-naphthalen-2-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)- amine;
(101) [5-(3,4-Dimethoxy-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-isobutyl- amine; (102) [5-(2-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-isobutyl-amine; (103) N-(2-Hydroxy-ethyl)-4-{2-[(tetrahydro-pyran-4-ylmethyl)-amino]-imidazo[2, 1 - b][1,3,4]thiadiazol-5-yl}-benzamide; (104) Cyclohexyl-(5-pyridin-3-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
(105) (5-Naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-thiophen-2- ylmethylamine;
(106) [5-(5-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yO-thiophen-2- ylmethyl-amine;
(107) [5-(6-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yO-thiophen-2- ylmethyl-amine; (108) BenzoCI.Sldioxol-5-ylmethyKδ-pyridin-3-yl-imidazop.i-bJCI .SΛthiadiazol- 2-yl)-amine;
(109) Benzo[1 ,3]dioxol-5-ylmethyl-[5-(4-chloro-phenyl)-imidazo[2, 1 -b][1 ,3,4]thia- diazol-2-yl]-amine;
(110) [5-(4-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(4-fluoro-benzyl)- amine;
(111) 1-{3-[2-(4-Methoxy-benzylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-phen- yljethanone;
(112) (2-Methoxy-ethyl)-(5-thiophen-3-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)- amine; (113) Benzyl-[5-(5-methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]- amine.
Example 35 The following examples are also prepared in accordance with the methods described herein.
2-[5-(3-Trifluoromethyl-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino]- acetamide;
[5-(3-Cyano-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino]-acetic acid; 2-[5-(3-Fluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino]-acetamide;
(2-Piperidin-1 -yl-ethyl)-[5-(3-trifluoromethoxy-phenyl)-imidazo[2, 1 -b][1 ,3,4]thi- adiazol-2-yl]-amine;
4-[5-(3-Trifluoromethyl-phenyl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-ylamino]- cyclohexanol; [5-(3,5-Difluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl3-(2-morpholin-4-yl- ethyl)-amine;
Cyclopropylmethyl-(5-phenyl-imidazo[2J-b][1 A4]thiadiazol-2-yl)-amine;
4-(2-Phenylsulfanyl-imidazo[2,1-b][1 ,3,4]thiadiazol-5-ylamino)-benzonitrile;
(3-Fluoro-phenyl)-(2-phenoxy-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl)-amine; (2-Methoxy-imidazo[2, 1 -b][1 ,3,4]thiadiazol-5-yl)-(3-trifluoromethyl-phenyl)-amine;
Cyclopropylmethyl-[5-(4-trifluoromethyl-phenyl)-imidazo[2,1-b][1 ,3,4]thiadi-azol-2- yl]-amine;
4-[(5-Naphthalen-2-yl-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-ylamino)-methyl]- benzenesulfonamide; 4-[2-(3-Hydroxy-propylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-benzonitrile;
[5-(3-Amino-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-[2-(5-methyl-1H-pyrazol-
4-yl)-ethyl]-amine;
S-^^-Pyrazin-2-yl-ethylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yO-benzoic acid;
1-(3-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}-phenyl)- ethanone;
[5-(3-Chloro-4-fluoro-phenyl)-imidazo[2, 1 -b][1 ,3,4]thiadiazol-2-yl]-(1 H-pyrrol-2- ylmethyl)-amine;
2-[5-(3-Chloro-4-fluoro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino]-ethanol;
2-(5-Naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino)-ethanol; i^-tδ^S-Methanesulfonyl-phenyl)-innidazop.i-bl[I .S^^hiacliazol-a-ylamino]- ethyl}-imidazolidin-2-one;
(3-lmidazol-1 -yl-propyl)-[5-(4-trifluoromethoxy-phenyl)-imidazo[2, 1 -b][1 ,3,4]- thiadiazol-2-yl]-amine; 4-[2-(4-Fluoro-benzylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-phenol;
(E)-3-(4-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}- phenyl)-acrylic acid;
(E)-3-{4-[2-((S)-1-Hydroxymethyl-2-methyl-propylamino)-imidazo[2,1- b][1 ,3,4]thiadiazol-5-yl]-phenyl}-acrylic acid; 4-[2-(4-Methoxy-benzylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-benzoic acid;
4-[2-(3,4-Dichloro-benzylamino)-imidazo[2, 1 -b][1 ,3,4]thiadiazoI-5-yl]-benzoic acid;
4-{2-[(Furan-2-ylmethyl)-amino]-imidazo[2,1-b][1,3,4]thiadiazo!-5-yl}-benzoic acid;
[5-(1-Methyl-1 H-pyrazol-4-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-thiophen-2- ylmethyl-amine; (E)-3-[4-(2-Propylamino-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl)-phenyl]-acrylic acid;
(E)-3-{4-[2-(3,4-Dichloro-benzylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenylj-acrylic acid;
4-[2-(3-Chloro-benzylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-benzoic acid;
(E)-3-{4-[2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]- phenylj-acrylic acid;
(4-Fluoro-benzyl)-[5-(1H-indol-5-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-amine;
Cyclopropylmethyl-^1H-indol-5-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-amine;
[5-(4-Amino-phenyI)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-pyridin-3-ylmethyl-amine;
(E)-3-(4-{2-[(Pyridin-3-ylmethyl)-amino]-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl}- phenyl)-acrylic acid;
4-{[2-(Cyclopropyimethyl-amino)-imidazo[2,1-b][1,3,4]thiadiazole-5-carbonyl]- amino}-benzoic acid;
2-(Cyclopropylmethyl-amino)-imidazo[2,1-b][1 ,3,43thiadiazole-5-carboxylic acid
(3-acetyl-phenyl)-amide; Ethanesulfonic acid [2-(3,4-dichloro-benzylamino)-imidazo[2,1-b][1 ,3,4]thia- diazol-5-yl]-amide;
(4-Methoxy-benzyl)-(5-phenylethynyl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)-amine;
4-[(5-Cyclohexyl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino)-methyl]- benzenesulfonamide; 4-[2-(3,4-Dichloro-benzylamino)-6-methyl-imidazo[2,1-b][1,3,4]thiaciiazol-5-yl]- benzoic acid;
2-(6-Fluoro-5-naphthalen-2-yl-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yIamino)-ethanol;
3-Acetylamino-N-[2-(3,4-dichloro-benzylamino)-imidazo[2,1-b][1,3,4]thiadiazol-5- yl]-propionamide;
{[2-(3,4-Dichloro-benzylamino)-6-methyl-imidazo[2,1-b][1,3,4]thiadiazole-5- carbonyl]-amino}-acetic acid;
4-[2-(3-Chloro-benzoylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-benzoic acid;
4-[2-(Methylcarbamoylmethyl-amino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-ylj-benzoic acid;
N-[5-(3-Acetyl-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-propionamide;
2-[5-(4-Chloro-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yloxy]-N-methyl- acetamide;
4-(2-Phenylethynyl-imidazo[2, 1 -b][1 ,3,4]thiadiazol-5-yl)-benzoic acid; 3-[2-(3-Chloro-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazoi-5-ylamino]-benzoic acid;
1-{4-[5-(4-Methoxy-benzylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-phenyl}- ethanone;
[2-(3,4-Dimethoxy-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-(tetrahydro-pyran-
4-yl)-amine; [5-(5-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-(tetrahydro-pyran-
4-yl)-amine;
4-[2-(Tetrahydro-pyran-4-ylamino)-imidazo[2,1-b][1 ,3,4]thiadiazol-5-yl]-benzoic acid;
[5-(1 H-lndol-2-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl]-(tetrahydro-pyran-4-yl)- amine;
[5-(3,4-Dimethoxy-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-(tetrahydro-pyran-
4-yl)-amine;
2-[5-(3,4-Dimethoxy-phenyl)-imidazo[2,1-b][1 ,3,4]thiadiazo[-2-ylannino]-butan-1-ol;
[5-(3,4-Dimethoxy-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-propyl-amine; 4-{[5-(6-Methoxy-pyridin-3-yl)-imidazo[2,1-b][1 ,3,4]thiadiazol-2-ylamino]-methyl}- benzenesulfonamide;
2-(4-Chloro-3-fluoro-benzyloxy)-5-morpholin-4-yl-imidazo[2,1-b][1 ,3,4]thiadi- azole;
[5-(3-Chloro-4-fluoro-phenoxy)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-(2,2-dimethyl- propyl)-amine; Example 36
Compounds of the examples were tested in the biological tests described above and were found to exhibit 50% inhibition of PIM-1 or PIM-2 (as appropriate) at a concentration of 50 μM or below (e.g. at a concentration of 10 μM).
For example, the following representative compounds of the examples exhibited the following approximate percentage of PIM-1 inhibition at a concentration of 10 μM.
Figure imgf000085_0001

Claims

Claims
1. A compound of formula I,
Figure imgf000086_0001
wherein:
B represents -S-, -S(O)- or -SO2-;
Z represents a direct bond, -(CH2)n-O-, -(CH2)n-S-, -(CH2)n-N(R3)-, -(CH2)n1-S(O)-, -(CH2)n-SO2-, -(CH2)n-NH-SO2-, -(CH2)n1-SO2-NH-,
-(CH2)n-N(R3)-CO-, -(CH2)n-NH-CO-NH- or -(CH2)n-CO-N(R3)-;
n represents, on each occasion when used herein, 0, 1 or 2;
n1 represents, on each occasion when used herein, 1 or 2;
M represents a direct bond or C1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -ORb, -SRb and -N(Rb)2;
R1 represents hydrogen, halogen, -CN, -CO2H, C1-S alkyl (optionally substituted by one or more substituents selected from A1), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B1 and B2, respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B3 and B4, respectively);
X represents a direct bond, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-N(Rd)-, -S(O)-, -(CH2)m-SO2-, -(CH2)m-NH-SO2-, -(CH2)m-SO2-NH-, -(CH2)m-NH-CO-, -(CH2)m-CO-N(Rd)-, -(CH2)m-NH-CO-NH- or C1-8 alkylene optionally substituted by one or more substituents selected from A2; m represents, on each occasion when used herein, 0, 1 or 2;
R2 represents hydrogen, halo, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A3) or -T-Q;
T represents a direct bond or a C1-3 alkylene linker group optionally substituted by one or more substituents selected from A4;
Q represents C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B5 and B6, respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B7 and B8, respectively);
but wherein: (i) when X represents a direct bond, then R2 does not represent hydrogen or halo; and
(ii) when Z and M both represent direct bonds, then R1 does not represent hydrogen; and
(iii) when either Z and M represent direct bonds, then R1 does not represent halo;
A1, A2, A3 and A4 independently represent halo, -ORe, -S-C1-4 alkyl, -N(Re)2, -C(O)2R6, -C(O)N(Re)2, -N(Re)-C(O)-Re, -C(O)Re, -CN, -SO2N(Re)2 and/or phenyl (optionally substituted by one or more halo and/or -ORe substituents);
B1, B2, B3, B4, B5, B6, B7 and B8 independently represent halo, -ORe, ^C(O)2R6, -C(O)R6, -C(O)N(Re)2, -N(Re)-C(O)-Re, -CN, -S(O)2R6, -S(O)2N(Re)2, -N(Re)2 and/or C1-4 alkyl optionally substituted by one or more substituents selected from halo, -ORe and -C(O)2Re; or, B1, B2, B5 and B6 may alternatively and independently represent =O;
R3 represents hydrogen, halo, -Rf, -ORf, -SRf, cyano or -N(Rf)2;
Ra, Rb, Rd, Re and Rf represent independently, on each occasion when used herein, hydrogen, phenyl (optionally substituted by one or more halo and/or C1-3 alkyl substituents) and/or C1-4 alkyl optionally substituted with one or more substituents selected from halo, -ORh and -N(Rh)2;
Rh represents, on each occasion when used herein, hydrogen or C1-3 alkyl optionally substituted by one or more halo atoms,
or a pharmaceutically acceptable ester, amide, solvate or salt thereof,
provided that when B represents -S-: (a) X represents a direct bond, R2 represents unsubstituted phenyl, R3 represents hydrogen, M represents -(CH2)2- and R1 represents bromo, then Z does not represent -S-;
(b) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent methyl substituted by -OH; (c) Z and M both represent a direct bond, then:
(I) R2 does not represent unsubstituted 1 ,2,4-triazol-3-yl when X represents -S- or -SO2-:
(A) R1 represents -CH2CH3 and R3 represents -CH2CH3 or -CH3; or
(B) R1 represents -CH3 and R3 represents -CH2CH3, -CH3 or Cl; or (II) R2 does not represent 1 ,2,4-triazol-3-yl substituted in the 1-position by
-C(O)N(CH2CH3)2 when X represents -SO2-:
(A) R1 represents -CH2CH3, and R3 represents -CH2CH3 or -CH3,
(B) R1 represents -CH3, and R3 represents -CH2CH3, -CH3 or Cl; (d) Z and M represents direct bonds, R3 represents -CH3, then: (I) when R1 represents 4-methoxyphenyl, -X-R2 does not represent
-CH2-C(O)OCH3, -C(=C(H)-OCH3)-C(O)-NHCH3! -C(=C(H)- CH2CH3)-C(O)-OCH3 or -C(=C(H)-OCH3)-C(O)-OCH3; (II) when R1 represents te/f-butyl, -X-R2 does not represent -C(=C(H)-OCH3)-C(O)-OCH3; (e) Z and M represent direct bonds, R1 represents -CH3, R3 represents hydrogen, then R2 does not represent unsubstituted phenyl when X represents a direct bond;
(f) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent -CO2H (or an ethyl ester thereof); (g) Z, and M represent direct bonds, R1 and R3 represent tert-butyl, then R2 does not represent hydrogen when X represents -NH-; (h) Z, M and X represent direct bonds, then:
(I) when R1 represents 4-chlorophenyl or unsubstituted phenyl, then R2 does not represent unsubstituted phenyl or 4- chlorophenyl;
(II) when R1 represents 4-methoxyphenyl, then R2 does not represent 4-chlorophenyl or unsubstituted phenyl;
(i) Z and M represent direct bonds, R1 represents -CH3, X represents -CH=CH- (i.e. ethenylene) and R2 represents -CO2H, then R3 does not represent tert-butyl or methyl; G) Z, M and X represent direct bonds, R3 represents H, then:
(I) R2 does not represent 4-fluoro-1-naphthyl when R1 represents pentyl, butyl or isopropyl; (II) R2 does not represent 3-chloro-4-fluoro-1-naphthyl when R1 represents pentyl, methyl or ethyl;
(III) R2 does not represent 3-methyl-4-fluoro-1-naphthyl when R1 represents pentyl, methyl, ethyl or n-propyl
(IV) R2 does not represent 2-methyl-4-fluoro-1-naphthyl when R1 represents trifluoromethyl;
(k) X and M represent direct bonds, R2 represents methyl, R3 represents ethyl, then:
(I) when Z represents -NHC(O)-, then R1 does not represent unsubstituted methyl or methyl substituted by -C(O)CH3; (II) when Z represents -NH-, then R1 does not represent hydrogen;
(I) X, M and Z all represent direct bonds, R1 and R3 represent -CH3, then
R2 does not represent -CH3, -CO2H or unsubstituted phenyl;
(m) X represents a direct bond, Z represents -S-, M represents -CH2- (i.e. methylene) and R1 represents unsubstituted phenyl, then: (I) when R3 represents -CH3, then R2 does not represent
-CO2CH2CH3; or
(II) when R3 represents hydrogen, then R2 does not represent -CH3;
(n) X, M and Z represent direct bonds, R1 represents -CH2CH3 and R3 represents -CH3, then R2 does not represent -CO2H; (o) X, Z and M all represent direct bonds, R3 represents hydrogen, then R2 does not represent 1-piperidinyl when R1 represents unsubstituted phenyl.
2. A compound of formula I,
Figure imgf000090_0001
wherein:
B represents -S-, -S(O)- or -SO2-;
Z represents a direct bond, -(CH2)n-O-, -(CH2)n-S-, -(CH2)n-N(Ra)-, -(CH2)nrS(O)-, -(CH2)H-SO2-, -(CH2)n-NH-SO2-, -(CH2)π1 -SO2-N H-,
-(CH2)n-N(Ra)-CO-, -(CH2)n-NH-CO-NH- or -(CH2)n-CO-N(Ra)-;
n represents, on each occasion when used herein, 0, 1 or 2;
n1 represents, on each occasion when used herein, 1 or 2;
M represents a direct bond or C1-8 alkylene optionally substituted by one or more substituents independently selected from halo, -ORb, -SRb and -N(Rb)2;
R1 represents hydrogen, halogen, -CN, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A1), C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B1 and B2, respectively) aryl or heteroaryl (which latter two groups are optionally substituted with one or more substituents selected from B3 and B4, respectively);
X represents a direct bond, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-N(Rd)-, -S(O)-, -(CH2Xn-SO2-, -(CH2)m-NH-SO2-, -(CH2)m-SO2-NH-, -(CH2)m-NH-CO-, -(CH2)m-CO-N(Rd)-, -(CH2VNH-CO-NH- or C1-8 alkylene optionally substituted by one or more substituents selected from A2; m represents, on each occasion when used herein, 0, 1 or 2;
R2 represents hydrogen, halo, -CO2H, C1-8 alkyl (optionally substituted by one or more substituents selected from A3) or -T-Q;
T represents a direct bond or a C1-3 alkylene linker group optionally substituted by one or more substituents selected from A4;
Q represents C3-6 cycloalkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from B5 and B6, respectively), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from B7 and B8, respectively);
but wherein:
(i) when X represents a direct bond, then R2 does not represent hydrogen or halo; and
(ii) when Z and M both represent direct bonds, then R1 does not represent hydrogen; and (iii) when either Z and M represent direct bonds, then R1 does not represent halo;
A1, A2, A3 and A4 independently represent halo, -ORe, -S-C1-4 alkyl, -N(Re)2, -C(O)2R6, -C(O)N(Re)2, -N(Re)-C(O)-Re, -C(O)R6, -CN, -SO2N(R6)2 and/or phenyl (optionally substituted by one or more halo or -OR6 substituents);
B1, B2, B3, B4, B5, B6, B7 and B8 independently represent halo, -OR6, -C(O)2R8, -C(O)R6, -C(O)N(Re)2, -N(Re)-C(O)-R6, -CN, -S(O)2R6, -S(O)2N(R6)2, -N(Re)2 and/or C1-4 alkyl optionally substituted by one or more substituents selected from halo, -OR6 and -C(O)2R6; or,
B1, B2, B5 and B6 may alternatively and independently represent =O;
R3 represents hydrogen, halo, -Rf, -ORf, -SRf, cyano or -N(Rf)2; Ra, Rb, Rd, Re and Rf represent independently, on each occasion when used herein, hydrogen, phenyl (optionally substituted by one or more halo and/or C-1-3 alkyl substituents) and/or C1-4 alkyl optionally substituted with one or more substituents selected from halo, -ORh and -N(Rh)2;
Rh represents, on each occasion when used herein, hydrogen or C1-3 alkyl optionally substituted by one or more halo atoms,
or a pharmaceutically acceptable ester, amide, solvate or salt thereof,
provided that when B represents -S-:
(b) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent methyl substituted by -OH;
(f) Z, M and X represent direct bonds, R1 and R3 represent -CH3, then R2 does not represent -CO2H (or an ethyl ester thereof);
(h) Z, M and X represent direct bonds, then:
(I) when R1 represents 4-chlorophenyl or unsubstituted phenyl, then R2 does not represent unsubstituted phenyl or 4- chlorophenyl; (II) when R1 represents 4-methoxyphenyl, then R2 does not represent 4-chlorophenyl or unsubstituted phenyl; (i) Z and M represent direct bonds, R1 represents -CH3, X represents -CH=CH- (i.e. ethenylene) and R2 represents -CO2H, then R3 does not represent tert-butyl or methyl; for use as a pharmaceutical.
3. A compound as claimed in Claim 1 or Claim 2, wherein:
B1, B2, B3, B4, B5, B6, B7 and B8 independently represent halo, -ORe, -C(O)2R8,
-C(O)Re, -C(O)N(Re)2, -CN, -S(O)2R8, -S(O)2N(Re)2, -N(Re)2 and/or C1-4 alkyl optionally substituted by one or more substituents selected from halo, -OR8 and -C(O)2R8; or,
B1, B2, B5 and B6 may alternatively and independently represent =O; Ra, Rb, Rd, Re and Rf (e.g. Ra, Rb, Rd and Rf) represent independently, on each occasion when used herein, hydrogen and/or C1-4 alkyl optionally substituted with one or more substituents selected from halo and -ORh; when Z represents -(CH2)n-N(Ra)-CO-, then Ra represents hydrogen.
4. A compound as claimed in any one of the preceding claims, wherein Z represents a direct bond, -O-, -S-, -(CH2)n-N(Ra)- or -(CH2)π-N(H)-C(O)-.
5. A compound as claimed in any one of the preceding claims, wherein M represents a direct bond or C1-3 alkylene.
6. A compound as claimed in any one of the preceding claims, wherein R1 represents: -CO2H or an amide thereof; C1-6 alkyl optionally substituted by A1; C3-6 cycloalkyl optionally substituted by B1; heterocycloalkyl optionally substituted by B2; aryl optionally substituted by B3; or heteroaryl optionally substituted by B4.
7. A compound as claimed in any one of the preceding claims, wherein A1 to A4 independently represent halo, -ORe, -CO2R8, -N(Re)-C(O)-Re or phenyl optionally substituted by -ORe.
8. A compound as claimed in any one of the preceding claims, wherein X represents a direct bond, -O-, -(CH2)m-N(Rd)-, -(CH2)m-N(H)-CO, -(CH2)m-CO-N(Rd)-, -(CH2)m-NH-SO2- or C1-3 alkylene.
9. A compound as claimed in any one of the preceding claims, wherein Ra and Rd independently represent H.
10. A compound as claimed in any one of the preceding claims, wherein m and n independently represent 0.
11. A compound as claimed in any one of the preceding claims, wherein R2 represents: halo; C1-6 alkyl optionally substituted by A3; C3-6 cycloalkyl; heterocycloalkyl optionally substituted by B6; aryl optionally substituted by B7; or, heteroaryl optionally substituted by B8.
12. A compound as claimed in any one of the preceding claims, wherein B1 to B8 independently represent halo, -OR6, -C(O)2R6, -C(O)R6, -CN, -S(O)2R8, -S(O)2N(R6)2, -N(Re)2 and/or C1-3 alkyl, which alkyl group is optionally substituted by one or more substituents selected from haio, -ORe or -C(O)2R6, or B1, B2, B5 and B6 may alternatively and independently represent =O.
13. A compound as claimed in any one of the preceding claims, wherein Ra, Rb, Rd, Re and Rf independently represent hydrogen or C1-3 alkyl optionally substituted by one or more halo atoms.
14. A compound as claimed in any one of the preceding claims, wherein Rh represents H or C1-2 alkyl.
15. A compound as claimed in any one of the preceding claims, wherein R3 represents hydrogen, C1-2 alkyl or fluoro.
16. A pharmaceutical formulation including a compound of formula I, as defined in any one of Claims 2 or 3 to 15 (as dependent on Claim 2), or a pharmaceutically acceptable ester, amide, solvate or salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
17. A compound, as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in the treatment of a disease in which inhibition of a PIM family kinase and/or PI3-K is desired and/or required.
18. Use of a compound of formula I, as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of a PIM family kinase and/or PI3-K is desired and/or required.
19. A compound as claimed in Claim 17 or a use as claimed in Claim 18, wherein the disease is cancer, an inflammatory disease, immunosuppression, benign prostate hyperplasia, familial adenomatosis, polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, post-surgical stenosis and restenosis, a viral condition, a parasitic condition or a neurodegenerative disorder.
20. A compound or use as claimed in Claim 19 wherein the disease is cancer.
21. A compound, as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in the treatment of a disease as defined in Claim 19 or Claim 20.
22. A method of treatment of a disease in which inhibition of a PIM family kinase and/or PI3-K is desired and/or required, which method comprises administration of a therapeutically effective amount of a compound of formula I as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof, to a patient suffering from, or susceptible to, such a condition.
23. A combination product comprising:
(A) a compound of formula I as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof; and
(B) another therapeutic agent that is useful in the treatment of in the treatment of cancer and/or a proliferative disease, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
24. A combination product as claimed in Claim 23 which comprises a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof, another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and a pharmaceutically- acceptable adjuvant, diluent or carrier.
25. A combination product as claimed in Claim 23 which comprises a kit of parts comprising components: (a) a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
(b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
26. A process for the preparation of a compound of formula I as defined in Claim 1 , which process comprises:
(i) for compounds of formula I in which X represents a direct bond, and R2 represents optionally substituted C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, or for compounds of formula I in which X represents a C1-8 alkylene linker group and R2 is as defined in Claim 1 , reaction of a corresponding compound of formula II,
Figure imgf000096_0001
wherein L1 represents a suitable leaving group, and Z, M, R1, B and R3 are as defined in Claim 1 , with a compound of formula III,
L2-Xa-R2a III or a compound of formula IV,
L2-Xb-R2 IV respectively, wherein L2 represents -B(OH)2, -B(OR^)2, -Sn(R^)3, in which each Rm independently represents a C1-6 alkyl group, or, in the case of -B(OR^)2, the respective R^ groups may be linked together to form a 4- to 6-membered cyclic group, Xa represents a direct bond, R2a represents C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, all of which are optionally substituted as defined in Claim 1 , Xb represents C1-8 alkylene (optionally substituted as in the definition of X in Claim 1 ), and R2 is as defined in Claim 1 ; (ii) for compounds of formula I in which X represents -O-, -S- or -N(Rd)-, reaction of a compound of formula Il as hereinbefore defined, with a compound of formula V1
HXC-R2 V wherein Xc represents -O-, -S- or -N(Rd)-, and R2 is as defined in Claim 1 ;
(iii) for compounds of formula I in which Z represents -(CH2)π-N(Ra)- or -(CH2)n-O-, M represents a direct bond, and R1 represents optionally substituted C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, reaction of a corresponding compound of formula I in which Z represents -(CH2)n-N(Ra)- or -(CH2)n-O-, M represents a direct bond, and R1 represents H, with a compound of formula Vl,
R1a-L1 Vl wherein L1 is as defined above, and R1a represents C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, all of which are optionally substituted as defined in respect of corresponding R1 substituents in Claim 1 ;
(iv) for compounds of formula I in which Z represents -O-, -S- or -(CH2)n->N(Ra)- in which n represents 0, reaction of a compound of formula VII,
Figure imgf000097_0001
wherein B, X, R2 and R3 are as defined in Claim 1 , and L1 is as defined above, with a compound of formula VIII,
H-Za-M-R1 VIII wherein Za represents -O-, -S- or -N(Ra)-, and Ra, R1 and M are as defined in
Claim 1;
(v) for compounds of formula I in which Z represents a direct bond and M represents C1-8 alkylene optionally substituted as hereinbefore defined, reaction of a compound of formula VIII as hereinbefore defined, with a compound of formula IX,
L1-Ma-R1 IX
wherein Ma represents C1-8 alkylene optionally substituted by one or more substituents selected from halo, -ORb, -SRb and -N(Rb)2, and R1 and L1 are as hereinbefore defined, for example under reaction conditions such as those hereinbefore described in respect of process step (i);
(vi) for compounds of formula I in which B, Z or X represents -S(O)- or -S(O)2, oxidation of a corresponding compound of formula I in which B, Z or X represents -S-;
(vii) for compounds of formula I in which Z represents -NHS(O)2, -NHC(O)- or
-NHC(O)NH-, reaction of a corresponding compound of formula I in which Z represents -N(Ra)-, Ra represents H, M represents a direct bond and R1 represents hydrogen, with a compound of formula X, L1-Q1-M-R1 X wherein L1 is as defined above, Q1 represents -S(O)2-, -C(O)- or -C(O)NH-, and M and R1 are as defined in Claim 1 ;
(viii) for compounds of formula I in which X represents -NH- and R2 represents optionally substituted C1-8 alkyl, reductive amination of a corresponding compound of formula I in which X represents -NH- and R2 represents hydrogen, with a compound of formula Xl,
R2b-CHO Xl wherein R2b represents C1-7 alkyl optionally substituted by one or more substituents selected from A3, in which A3 is defined in Claim 1 ; (ix) for compounds of formula I in which X represents -CH2-NH-, reductive amination of a compound of formula XII,
Figure imgf000098_0001
wherein Z, M, R1, B and R3 are as defined in Claim 1 , with a compound of formula XIII,
R2-NH2 XlII wherein R2 is as defined in Claim 1 ;
(x) for compounds of formula I in which X represents -CH2-N(Rd)- and R2 represents hydrogen or optionally substituted C1-8 alkyl, provided that at least one of R2 and Rd is other than hydrogen (so forming a secondary or tertiary amine), or, for compounds of formula I in which -X-R2 represents -CH2-heterocycloalkyl, in which the heterocycloalkyl group is attached to the relevant -CH2- moiety via a nitrogen atom of the heterocycloalkyl group (so forming a tertiary amino moiety; for example -CH2-[4-morpholinyl]), reaction of a compound of formula XIIIA,
Figure imgf000099_0001
wherein Z, M, R1, B and R3 are as defined in Claim 1 , with formaldehyde and a compound of formula XIIIB,
Xd-R2d XIIIB wherein Xd represents -N(Rd)- and R2d represents hydrogen or C1-8 alkyl (optionally substituted by one or more substituents selected from A3), provided that at least one of Rd and R2d is other than hydrogen (so forming a secondary or tertiary amine), or with a compound of formula XIIIC, hef XIIIC wherein hef represents a heterocycloalkyl group containing a -N(H)- moiety that is integral to the cyclic group; (xi) for compounds of formula I in which X represents -CH2-O- and R2 represents hydrogen, reduction of a corresponding compound of formula XII as defined above;
(xii) for compounds of formula I in which X represents -(CH2)m-C(O)N(Rd)-, reaction of a compound corresponding to a compound of formula I but in which X represents -(CH2)m-C(O)OH with a compound of formula XIV, H(Rd)N-R2 XIV wherein Rd and R2 are as defined in Claim 1 ;
(xiii) for compounds of formula I in which there is a -CH2- group present, reduction of a corresponding compound of formula I in which there is a -C(OH)- group present; (xiv) for compounds of formula I in which X represents methylene substituted by -OH, and R2 represents optionally substituted C1-8 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, reaction of a compound of formula XII as defined above with a compound of formula XV,
R2a-M1 XV wherein M1 represents an appropriate alkali metal group, a -Mg-halide or a zinc- based group, and R2a represents R2 as defined in Claim 1 provided that it does not represent hydrogen, halo or -COOH (i.e. R2a is as defined above); (xv) for compounds of formula I in which there is a -NH2 group present, reduction of a corresponding compound of formula I in which there is a -NO2 group present; (xvi) compounds of formula I in which -X-R2 represents -C(O)OH, may be prepared by oxidation of a corresponding compound of formula XII as defined above;
(xvii) compounds of formula I in which X represents -(CH2)m-S(O)2N(H)- may be prepared by reaction of a compound corresponding to a compound of formula I but in which -X-R2 represents -(CH2)m-S(O)2OH (or an activated derivative thereof), with a compound of formula XIV as defined above but in which Rd represents hydrogen.
27. A process for the preparation of a pharmaceutical formulation as defined in Claim 16, which process comprises bringing into association a compound of formula I, as defined in any one of one of Claims 2 to 15 (as dependent on Claim 2), or a pharmaceutically acceptable ester, amide, solvate or salt thereof with a pharmaceutically-acceptable adjuvant, diluent or carrier.
28. A process for the preparation of a combination product as defined in any one of Claims 23 to 25, which process comprises bringing into association a compound of formula I, as defined in any one of Claims 1 to 15 but without the provisos, or a pharmaceutically acceptable ester, amide, solvate or salt thereof with the other therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
PCT/GB2008/003287 2007-09-27 2008-09-29 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof WO2009040552A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SI200831527T SI2193133T1 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
JP2010526362A JP5410431B2 (en) 2007-09-27 2008-09-29 Use of imidazolothiadiazoles as protein kinase inhibitors
EP08806437.3A EP2193133B1 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
PL08806437T PL2193133T3 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
ES08806437.3T ES2548768T3 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
US12/679,514 US8563550B2 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
DK08806437.3T DK2193133T3 (en) 2007-09-27 2008-09-29 IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
CN200880118104.5A CN101878219B (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
HRP20151128TT HRP20151128T1 (en) 2007-09-27 2015-10-26 Imidazolothiadiazoles for use as protein kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07381066.5 2007-09-27
EP07381066 2007-09-27

Publications (2)

Publication Number Publication Date
WO2009040552A2 true WO2009040552A2 (en) 2009-04-02
WO2009040552A3 WO2009040552A3 (en) 2009-05-22

Family

ID=39092755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003287 WO2009040552A2 (en) 2007-09-27 2008-09-29 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof

Country Status (13)

Country Link
US (1) US8563550B2 (en)
EP (1) EP2193133B1 (en)
JP (1) JP5410431B2 (en)
CN (1) CN101878219B (en)
CY (1) CY1116882T1 (en)
DK (1) DK2193133T3 (en)
ES (1) ES2548768T3 (en)
HR (1) HRP20151128T1 (en)
HU (1) HUE025976T2 (en)
PL (1) PL2193133T3 (en)
PT (1) PT2193133E (en)
SI (1) SI2193133T1 (en)
WO (1) WO2009040552A2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
WO2010112874A1 (en) * 2009-04-02 2010-10-07 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
FR2945289A1 (en) * 2009-05-11 2010-11-12 Sanofi Aventis 2-CYCLOAMINO-5- (PYRIDIN-4-YL) IMIDAZO-2,1-B1 DERIVATIVES 1,3,4! THIADIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011036461A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
WO2011080510A1 (en) 2009-12-31 2011-07-07 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2012156756A2 (en) 2011-05-19 2012-11-22 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US8563550B2 (en) 2007-09-27 2013-10-22 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazolothiadiazoles for use as protein kinase inhibitors
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2021078120A1 (en) * 2019-10-21 2021-04-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN114195736A (en) * 2021-12-30 2022-03-18 浙江闰土染料有限公司 Preparation method of 2-amino-5-bromo-1, 3, 4-thiadiazole
EP3842439A4 (en) * 2018-08-21 2022-04-27 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
RU2798838C2 (en) * 2018-08-21 2023-06-28 Керин Фармасьютикал Ко., Лтд. Bicyclic heteroaromatic ring derivative

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
WO2014015167A2 (en) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
BR112019027717A2 (en) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. methods to treat huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
LT3814357T (en) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP4442692A1 (en) * 2021-11-29 2024-10-09 Ocean University of China Imidazothiazole derivative, preparation method therefor, and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
WO2003051890A1 (en) * 2001-12-14 2003-06-26 Aegera Therapeutics Inc. Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
WO2007118318A1 (en) * 2006-04-13 2007-10-25 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (en) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen IMIDAZOTHIADIAZOLALKENCARBONIC ACID AMIDES, NEW INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
IT1269176B (en) 1994-01-11 1997-03-21 Isagro Srl FUNGICIDE HETEROBYCLES
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
EP1307462A2 (en) 2000-08-09 2003-05-07 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
KR101075812B1 (en) 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 Triazolopyridazines as protein kinases inhibitors
PA8595001A1 (en) 2003-03-04 2004-09-28 Pfizer Prod Inc NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
CA2527906A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides and uses thereof
ES2441178T3 (en) 2005-06-01 2014-02-03 Ucb Pharma, S.A. 2-Oxo-1-pyrrolidine derivatives, procedures to prepare them and their therapeutic use on the central nervous system
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US20070267288A1 (en) 2006-05-21 2007-11-22 Steven Allen Carlson Systems and methods for hydrogen storage and generation
CN101037445A (en) * 2007-04-14 2007-09-19 西北师范大学 Imidazo [2,1-b]-1,3,4-thiadiazole derivatives having potential biological activity and synthesizing method thereof
PE20090215A1 (en) 2007-05-09 2009-03-30 Novartis Ag COMPOUNDS DERIVED FROM IMIDAZOPYRIDAZINE AS KINASE INHIBITORS
EP2162132A4 (en) 2007-05-21 2013-01-16 Sgx Pharmaceuticals Inc Heterocyclic kinase modulators
SI2193133T1 (en) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolothiadiazoles for use as protein kinase inhibitors
ES2470681T3 (en) 2008-07-29 2014-06-24 Merck Patent Gmbh Imidazothiadiazole derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
WO2003051890A1 (en) * 2001-12-14 2003-06-26 Aegera Therapeutics Inc. Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
WO2007118318A1 (en) * 2006-04-13 2007-10-25 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN FRANKFURT-MAIN, DE; BRN 974924 (RN: 57772-06-2) XP002470756 & JOURNAL OF THE CHEMICAL SOCIETY PERKIN TRANS. 2, 1980, pages 421-426, GBCHEMICAL SOCIETY. LETCHWORTH. *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DEHURI, S. ET AL.: "Studies on heterocyclic compounds." XP002470755 retrieved from STN Database accession no. 1983:179345 cited in the application & JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 59, no. 10, 1982, pages 1170-1173, *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US8563550B2 (en) 2007-09-27 2013-10-22 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazolothiadiazoles for use as protein kinase inhibitors
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8389554B2 (en) 2008-07-29 2013-03-05 MERCK Patent Gesellschaft mit beschränkter Haftung Imidazothiadiazole derivatives
JP2011529456A (en) * 2008-07-29 2011-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Imidazothiadiazole derivatives
US20110130396A1 (en) * 2008-07-29 2011-06-02 Guenter Hoelzemann Imidazothiadiazole derivatives
AU2009275544B2 (en) * 2008-07-29 2013-09-12 Merck Patent Gmbh Imidazothiadiazoles derivatives
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
US20120094996A1 (en) * 2009-04-02 2012-04-19 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
AU2010231162B2 (en) * 2009-04-02 2014-12-11 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
WO2010112874A1 (en) * 2009-04-02 2010-10-07 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
EA022753B1 (en) * 2009-04-02 2016-02-29 Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii Imidazothiadiazoles useful as inhibitors of kinases
WO2010130934A3 (en) * 2009-05-11 2011-01-06 Sanofi-Aventis 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazole derivatives, preparation thereof, and therapeutic use thereof
FR2945289A1 (en) * 2009-05-11 2010-11-12 Sanofi Aventis 2-CYCLOAMINO-5- (PYRIDIN-4-YL) IMIDAZO-2,1-B1 DERIVATIVES 1,3,4! THIADIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011036461A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
US9682991B2 (en) 2009-12-31 2017-06-20 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Tricyclic compounds for use as kinase inhibitors
WO2011080510A1 (en) 2009-12-31 2011-07-07 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP4438734A2 (en) 2010-06-14 2024-10-02 The Scripps Research Institute Reprogramming of cells to a new fate
EP3399026A1 (en) 2010-06-14 2018-11-07 The Scripps Research Institute Reprogramming of cells to a new fate
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
US9453007B2 (en) 2010-12-22 2016-09-27 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9567355B2 (en) 2010-12-22 2017-02-14 Abbvie Inc. Hepatitis C inhibitors and uses thereof
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
US9808466B2 (en) 2011-05-19 2017-11-07 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
WO2012156756A2 (en) 2011-05-19 2012-11-22 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
US9284334B2 (en) 2011-05-19 2016-03-15 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US9617281B2 (en) 2012-07-04 2017-04-11 Laboratories Del Dr. Esteve S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
WO2014006130A1 (en) 2012-07-04 2014-01-09 Laboratorios Del Dr. Esteve, S.A. IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
RU2798838C2 (en) * 2018-08-21 2023-06-28 Керин Фармасьютикал Ко., Лтд. Bicyclic heteroaromatic ring derivative
EP3842439A4 (en) * 2018-08-21 2022-04-27 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
TWI811428B (en) * 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 Bicyclic Heteroaromatic Derivatives
US11952387B2 (en) 2018-08-21 2024-04-09 Kyorin Pharmaceutical Co., Ltd Bicyclic heteroaromatic ring derivative
US11597733B2 (en) 2019-10-21 2023-03-07 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2021078120A1 (en) * 2019-10-21 2021-04-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN114195736A (en) * 2021-12-30 2022-03-18 浙江闰土染料有限公司 Preparation method of 2-amino-5-bromo-1, 3, 4-thiadiazole

Also Published As

Publication number Publication date
US8563550B2 (en) 2013-10-22
CN101878219A (en) 2010-11-03
PL2193133T3 (en) 2016-01-29
PT2193133E (en) 2015-10-22
EP2193133B1 (en) 2015-08-19
US20110190289A1 (en) 2011-08-04
ES2548768T3 (en) 2015-10-20
JP5410431B2 (en) 2014-02-05
CN101878219B (en) 2014-04-02
EP2193133A2 (en) 2010-06-09
WO2009040552A3 (en) 2009-05-22
SI2193133T1 (en) 2015-12-31
HUE025976T2 (en) 2016-05-30
JP2010540508A (en) 2010-12-24
CY1116882T1 (en) 2017-04-05
HRP20151128T1 (en) 2015-11-20
DK2193133T3 (en) 2015-10-05

Similar Documents

Publication Publication Date Title
EP2193133B1 (en) Imidazolothiadiazoles for use as protein kinase inhibitors
US20110046127A1 (en) Imidazopyridazines for Use as Protein Kinase Inhibitors
AU2010231162B2 (en) Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
EP2419429A1 (en) Imidazopyrazines for use as kinase inhibitors
CA2786002C (en) Tricyclic compounds for use as kinase inhibitors
WO2012020215A1 (en) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2011101644A1 (en) Triazolo [4, 5 - b] pyridin derivatives
CA2775204A1 (en) Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors
WO2013004984A1 (en) Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2013005041A1 (en) Tricyclic heterocyclic compounds as kinase inhibitors
WO2012020217A1 (en) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118104.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806437

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008806437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2100/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010526362

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12679514

Country of ref document: US